<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables v1.3 20210610//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-archive-oasis-article1-3.dtd?>
<?SourceDTD.Version 1.3?>
<?ConverterInfo.XSLTName jats-oasis2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">mSystems</journal-id>
    <journal-id journal-id-type="iso-abbrev">mSystems</journal-id>
    <journal-id journal-id-type="publisher-id">msystems</journal-id>
    <journal-title-group>
      <journal-title>mSystems</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2379-5077</issn>
    <publisher>
      <publisher-name>American Society for Microbiology</publisher-name>
      <publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10734502</article-id>
    <article-id pub-id-type="pmid">37975659</article-id>
    <article-id pub-id-type="publisher-id">00653-23</article-id>
    <article-id pub-id-type="doi">10.1128/msystems.00653-23</article-id>
    <article-id pub-id-type="publisher-id">msystems.00653-23</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Resource Report</subject>
      </subj-group>
      <subj-group subj-group-type="article-attributes">
        <compound-subject>
          <compound-subject-part content-type="code">editors-pick</compound-subject-part>
          <compound-subject-part content-type="label">Editor’s PickOpen Peer Review</compound-subject-part>
        </compound-subject>
      </subj-group>
      <subj-group subj-group-type="biological-terms">
        <compound-subject>
          <compound-subject-part content-type="code">computational-biology</compound-subject-part>
          <compound-subject-part content-type="label">Computational Biology</compound-subject-part>
        </compound-subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5993-8445</contrib-id>
        <name>
          <surname>Neff</surname>
          <given-names>Samuel L.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0543-402X</contrib-id>
        <name>
          <surname>Hampton</surname>
          <given-names>Thomas H.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1094-0621</contrib-id>
        <name>
          <surname>Koeppen</surname>
          <given-names>Katja</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sarkar</surname>
          <given-names>Sharanya</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Latario</surname>
          <given-names>Casey J.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ross</surname>
          <given-names>Benjamin D.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1661-407X</contrib-id>
        <name>
          <surname>Stanton</surname>
          <given-names>Bruce A.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="cor1" ref-type="corresp"/>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
        <email>bruce.a.stanton@dartmouth.edu</email>
      </contrib>
      <aff id="aff1"><label>1</label><institution-wrap><institution>Department of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College</institution></institution-wrap>, <city>Hanover</city>, <state>New Hampshire</state>, <country>USA</country></aff>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <role>Editor</role>
        <name>
          <surname>Gilbert</surname>
          <given-names>Jack A.</given-names>
        </name>
        <aff><institution-wrap><institution>University of California San Diego</institution></institution-wrap>, <city>La Jolla</city>, <state>California</state>, <country>USA</country></aff>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="cor1">Address correspondence to Bruce A. Stanton, <email xlink:href="mailto:bruce.a.stanton@dartmouth.edu">bruce.a.stanton@dartmouth.edu</email></corresp>
      <fn fn-type="COI-statement">
        <p>The authors declare no conflict of interest.</p>
      </fn>
    </author-notes>
    <pub-date publication-format="electronic" date-type="collection">
      <season>Nov-Dec</season>
      <year>2023</year>
    </pub-date>
    <pub-date date-type="pub" publication-format="electronic">
      <day>17</day>
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>17</day>
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
    <volume>8</volume>
    <issue>6</issue>
    <elocation-id>e00653-23</elocation-id>
    <history>
      <date date-type="received">
        <day>22</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>06</day>
        <month>10</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2023 Neff et al.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>Neff et al.</copyright-holder>
      <ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2023-11-17"/>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="msystems.00653-23.pdf"/>
    <self-uri content-type="reviewer_comments" xlink:href="reviewer-comments.pdf"/>
    <abstract abstract-type="primary">
      <title>ABSTRACT</title>
      <p>Developing software tools that leverage biological data sets to accelerate drug discovery is an important aspect of bioinformatic research. Here, we present a novel example: a web application called Rocket-miR that applies an existing bioinformatic algorithm (IntaRNA) to predict cross-species miRNA-mRNA interactions and identify human miRNAs with potential antimicrobial activity against antibiotic-resistant bacterial infections. Rocket-miR is the logical extension of our prior finding that human miRNA let-7b-5p impairs the ability of the ubiquitous opportunistic pathogen <italic toggle="yes">Pseudomonas aeruginosa</italic> to form biofilms and resist the bactericidal effect of β-lactam antibiotics. Rocket-miR’s point and click interface enables researchers without programming expertise to predict additional human-miRNA-pathogen interactions. Identified miRNAs can be developed into novel antimicrobials effective against the 24 clinically relevant pathogens, implicated in diseases of the lung, gut, and other organs, that are included in the application. The paper incorporates three case studies contributed by microbiologists that study human pathogens to demonstrate the usefulness and usability of the application. Rocket-miR is accessible at the following link: <ext-link xlink:href="http://scangeo.dartmouth.edu/RocketmiR/" ext-link-type="uri">http://scangeo.dartmouth.edu/RocketmiR/</ext-link>.</p>
      <sec>
        <title>IMPORTANCE</title>
        <p>Antimicrobial-resistant infections contribute to millions of deaths worldwide every year. In particular, the group of bacteria collectively known as ESKAPE (<italic toggle="yes">Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,</italic> and <italic toggle="yes">Enterobacter</italic> sp<italic toggle="yes">.</italic>) pathogens are of considerable medical concern due to their virulence and exceptional ability to develop antibiotic resistance. New kinds of antimicrobial therapies are urgently needed to treat patients for whom existing antibiotics are ineffective. The Rocket-miR application predicts targets of human miRNAs in bacterial and fungal pathogens, rapidly identifying candidate miRNA-based antimicrobials. The application’s target audience are microbiologists that have the laboratory resources to test the application’s predictions. The Rocket-miR application currently supports 24 recognized human pathogens that are relevant to numerous diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD), urinary tract infections, and pneumonia. Furthermore, the application code was designed to be easily extendible to other human pathogens that commonly cause hospital-acquired infections.</p>
      </sec>
    </abstract>
    <kwd-group>
      <title>KEYWORDS</title>
      <kwd>cystic fibrosis</kwd>
      <kwd>bioinformatics</kwd>
      <kwd>miRNA</kwd>
      <kwd>CF pathogens</kwd>
      <kwd>antimicrobial agents</kwd>
      <kwd>host-pathogen interactions</kwd>
      <kwd>ESKAPE pathogens</kwd>
    </kwd-group>
    <funding-group specific-use="FundRef">
      <award-group award-type="grant" id="award-1">
        <funding-source>
          <institution-wrap>
            <institution>Cystic Fibrosis Foundation (CFF)</institution>
          </institution-wrap>
        </funding-source>
        <award-id>STANTO19R0</award-id>
        <principal-award-recipient>
          <name>
            <surname>Neff</surname>
            <given-names>Samuel L.</given-names>
          </name>
          <name>
            <surname>Hampton</surname>
            <given-names>Thomas H.</given-names>
          </name>
          <name>
            <surname>Koeppen</surname>
            <given-names>Katja</given-names>
          </name>
          <name>
            <surname>Sarkar</surname>
            <given-names>Sharanya</given-names>
          </name>
          <name>
            <surname>Stanton</surname>
            <given-names>Bruce A.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group award-type="grant" id="award-2">
        <funding-source>
          <institution-wrap>
            <institution>HHS | National Institutes of Health (NIH)</institution>
          </institution-wrap>
        </funding-source>
        <award-id>P30 DK117469, R01 HL151385</award-id>
        <principal-award-recipient>
          <name>
            <surname>Hampton</surname>
            <given-names>Thomas H.</given-names>
          </name>
          <name>
            <surname>Koeppen</surname>
            <given-names>Katja</given-names>
          </name>
          <name>
            <surname>Sarkar</surname>
            <given-names>Sharanya</given-names>
          </name>
          <name>
            <surname>Stanton</surname>
            <given-names>Bruce A.</given-names>
          </name>
          <name>
            <surname>Neff</surname>
            <given-names>Samuel L.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group award-type="grant" id="award-3">
        <funding-source>
          <institution-wrap>
            <institution>HHS | National Institutes of Health (NIH)</institution>
          </institution-wrap>
        </funding-source>
        <award-id>R35 GM142685</award-id>
        <principal-award-recipient>
          <name>
            <surname>Latario</surname>
            <given-names>Casey J.</given-names>
          </name>
          <name>
            <surname>Ross</surname>
            <given-names>Benjamin</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group award-type="grant" id="award-4">
        <funding-source>
          <institution-wrap>
            <institution>The Flatley Foundation</institution>
          </institution-wrap>
        </funding-source>
        <principal-award-recipient>
          <name>
            <surname>Neff</surname>
            <given-names>Samuel L.</given-names>
          </name>
          <name>
            <surname>Hampton</surname>
            <given-names>Thomas H.</given-names>
          </name>
          <name>
            <surname>Koeppen</surname>
            <given-names>Katja</given-names>
          </name>
          <name>
            <surname>Sarkar</surname>
            <given-names>Sharanya</given-names>
          </name>
          <name>
            <surname>Stanton</surname>
            <given-names>Bruce A.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <counts>
      <count count="2" count-type="supplementary-material"/>
      <count count-type="authors" count="7"/>
      <fig-count count="8"/>
      <table-count count="4"/>
      <ref-count count="133"/>
      <page-count count="25"/>
      <word-count count="15082"/>
    </counts>
    <custom-meta-group>
      <custom-meta>
        <meta-name>cover-date</meta-name>
        <meta-value>November/December 2023</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="s1">
    <title>INTRODUCTION</title>
    <p>Antimicrobial resistance (AMR) is a chief global health threat of the 21st century. AMR infections affect more than 2.8 million people and cause 35,000 deaths in the USA per year according to a recent report by the Centers for Disease Control and Prevention (CDC) (<xref rid="B1" ref-type="bibr">1</xref>). A systematic literature review in <italic toggle="yes">The Lancet</italic>, drawing from hospital records and public health surveillance data, attributed over 1.2 million deaths worldwide to bacterial AMR in 2019, the majority of which were caused by lower respiratory tract infections (<xref rid="B2" ref-type="bibr">2</xref>). The Organization for Economic Co-operation and Development further estimated in 2018 that over the next 30 years (2020–2050), managing the complications of AMR will carry a cost of $3.5 billion per year to the global economy (<xref rid="B3" ref-type="bibr">3</xref>). Unfortunately, for a variety of technical and economic reasons, relatively few drug and biotechnology companies are developing new antibiotics (<xref rid="B4" ref-type="bibr">4</xref>). Thus, there is a pressing need for novel therapies to treat AMR.</p>
    <p>The risk of AMR is especially acute for people with chronic diseases, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), that render individuals immune-compromised and prone to chronic antibiotic-resistant infections. The application described in this paper was specifically developed to identify human miRNAs that target AMR genes in CF-related pathogens but is relevant to drug-resistant pathogens in general. Common CF pathogens <italic toggle="yes">Pseudomonas aeruginosa</italic> and <italic toggle="yes">Staphylococcus aureus</italic>, for example, are also listed among the six ESKAPE (<italic toggle="yes">Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,</italic> and <italic toggle="yes">Enterobacter</italic> sp<italic toggle="yes">.</italic>) pathogens, a group of antibiotic-resistant bacteria that are a common cause of hospital-acquired infections and recognized by the WHO as pathogens in urgent need of new antibiotics (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>).</p>
    <p><italic toggle="yes">Pseudomonas aeruginosa</italic> is the most prevalent lung pathogen in people with CF (pwCF), especially adults, and a significant contributor to morbidity and mortality (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). In the CF lungs, mutations in the cystic fibrosis transmembrane conductance regulator (<italic toggle="yes">CFTR</italic>) gene lead to the production of highly viscous, hyper-concentrated mucus (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). The physiological consequences are obstructed breathing, dysregulation of the immune system, and poor airway clearance that enables infection by opportunistic pathogens, notably drug-resistant <italic toggle="yes">P. aeruginosa</italic> (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). A recent study found that the risk of death for pwCF doubled with <italic toggle="yes">P. aeruginosa</italic> lung infection and increased eightfold when the bacteria acquired resistance to antibiotics (<xref rid="B13" ref-type="bibr">13</xref>). Furthermore, a recent meta-analysis involving <italic toggle="yes">P. aeruginosa</italic> isolates treated with common anti-pseudomonal antibiotics determined that for a majority of the 22 antibiotics surveyed, over one-third of clinical isolates are resistant (<xref rid="B14" ref-type="bibr">14</xref>). A range of other pathogens are also known to contribute to CF lung disease, such as <italic toggle="yes">Burkholderia cenocepacia</italic>, <italic toggle="yes">Stenotrophomonas maltophilia</italic>, <italic toggle="yes">S. aureus</italic> (particularly methicillin-resistant strains), <italic toggle="yes">Mycobacterium abscessus</italic>, and the fungal species <italic toggle="yes">Aspergillus fumigatus</italic> and <italic toggle="yes">Candida albicans</italic> (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). For many of these pathogens, researchers have documented increases in the proportion of bacterial strains resistant to common antibiotics over the past several decades (<xref rid="B17" ref-type="bibr">17</xref><xref rid="B18" ref-type="bibr">–</xref><xref rid="B22" ref-type="bibr">22</xref>).</p>
    <p>AMR occurs through a variety of well-known mechanisms. In <italic toggle="yes">P. aeruginosa</italic>, for example, AMR is driven by a range of biological changes, including the transition to a biofilm-forming state, increased activity of drug efflux pumps, and the development of β-lactamase activity (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>). In response to the failure of conventional antibiotics, researchers are turning to more innovative forms of antimicrobial therapy. Yale University recently launched its Center for Phage Biology and Therapy, with certain researchers focused on developing phage therapy for CF pathogens including <italic toggle="yes">P. aeruginosa</italic> (<xref rid="B25" ref-type="bibr">25</xref><xref rid="B26" ref-type="bibr">–</xref><xref rid="B27" ref-type="bibr">27</xref>). Scientists at other institutions are working to develop phage therapy for additional antibiotic-resistant CF pathogens like the non-tuberculosis mycobacteria species, including <italic toggle="yes">M. abscessus</italic>, or the CF pathogen <italic toggle="yes">B. cenocepacia</italic> (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>).</p>
    <p>Another potential strategy for treating AMR infections is to use miRNAs as antimicrobial therapeutics. Most ongoing efforts at miRNA-based drug development have involved modulating the expression of miRNAs to suppress the genes that contribute to cancer (<xref rid="B30" ref-type="bibr">30</xref><xref rid="B31" ref-type="bibr">–</xref><xref rid="B34" ref-type="bibr">34</xref>), though recent studies have involved other diseases including Huntington’s and keloid disease (<xref rid="B35" ref-type="bibr">35</xref><xref rid="B36" ref-type="bibr">–</xref><xref rid="B37" ref-type="bibr">37</xref>). In addition to the use of human miRNAs to target cancer-causing genes in human cells, we have shown that human miRNA let-7b-5p inhibits several genes that contribute to biofilm formation and antibiotic resistance in <italic toggle="yes">P. aeruginosa</italic> (<xref rid="B38" ref-type="bibr">38</xref>).</p>
    <p>The potential for cross-kingdom miRNA targeting interactions has been recognized for well over a decade. Studies since the early 2010s have demonstrated that small RNAs are transferred between crop species and parasitic fungal pathogens—a natural plant defense mechanism that limits fungal growth (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>). Recognizing the biological possibility of this plant-fungal exchange, crop scientists have developed genetic engineering techniques to augment the expression of plant small RNAs as a strategy to limit pathogen growth and preserve crop yield (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). Cross-kingdom interactions have also been observed in the human gut microbiome. Researchers have demonstrated the ability of human miRNA mimics to enter and reduce the growth rates of intestinal pathogens (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>). Conversely, other studies have utilized human and plant-derived miRNAs to enhance the growth or metabolite production of commensal gut bacteria and ameliorate disease symptoms. Furthermore, it is known that bacteria are capable of releasing small RNAs that influence protein expression in other bacteria (<xref rid="B45" ref-type="bibr">45</xref>), human cells (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>), or plant cells (<xref rid="B48" ref-type="bibr">48</xref><xref rid="B49" ref-type="bibr">–</xref><xref rid="B50" ref-type="bibr">50</xref>).</p>
    <p>More recent research has identified cross-kingdom interactions in the lungs, including our own prior work (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>). We have previously shown that human miRNA let-7b-5p is delivered through extracellular vesicles (EVs) secreted by human airway cells to <italic toggle="yes">P. aeruginosa</italic>. Once delivered, let-7b-5p decreases the abundance of proteins essential for biofilm formation. Let-7b-5p also reduces resistance to β-lactam antibiotics by inhibiting the expression of antibiotic efflux pumps (<xref rid="B38" ref-type="bibr">38</xref>). Moreover, other studies have shown that let-7b-5p is associated with reduced inflammation, suggesting additional beneficial effects, especially in pwCF who have a chronic hyperinflammatory response to chronic infection by <italic toggle="yes">P. aeruginosa</italic> and other CF pathogens (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>).</p>
    <p>A notable characteristic of miRNAs is that one miRNA may target hundreds of different genes (<xref rid="B55" ref-type="bibr">55</xref><xref rid="B56" ref-type="bibr">–</xref><xref rid="B57" ref-type="bibr">57</xref>). Thus, although bacteria can rapidly develop antimicrobial resistance by altering the expression of a few genes, miRNA targeting of hundreds of genes make it more challenging for microbes to develop antibiotic resistance. The research on miRNAs, including our work on let-7b-5p, suggests that it is possible to develop and deliver miRNA-based therapeutics, with or without antibiotics, in engineered extracellular vesicles to eliminate antibiotic-resistant infections. This therapeutic approach could theoretically be applied to all microbial pathogens including bacterial and fungal infections.</p>
    <p>The development of Rocket-miR (available online at the following link: <ext-link xlink:href="http://scangeo.dartmouth.edu/RocketmiR/" ext-link-type="uri">http://scangeo.dartmouth.edu/RocketmiR/</ext-link>) described herein enables scientists to target genes and pathways that potentiate antimicrobial resistance by providing miRNA target predictions for 24 clinically relevant pathogens (<xref rid="T1" ref-type="table">Table 1</xref>). The application leverages the popular bioinformatic tool IntaRNA to make miRNA-targeting predictions (described in detail in Materials and Methods) and provides a user-friendly environment to explore this prediction data and arrive at translational insights. Typically, miRNA target prediction requires extensive computational skill, and months of time to process and analyze prediction data. Our application requires no prior computational experience or effort to process and analyze data. The interactive, visual nature of the Rocket-miR application enables researchers to explore the biological potential of human miRNAs targeting genes and whole genetic pathways in human pathogens in a matter of minutes. Furthermore, genes and pathways in the application are represented by descriptive annotations—gene names, protein functions, and pathway identifiers that are recognizable to biologists. To the best of our knowledge there are no other programs that allow the rapid identification of miRNAs to target antimicrobial-resistant genes in microbial pathogens.</p>
    <table-wrap position="float" id="T1">
      <label>TABLE 1</label>
      <caption>
        <p>The 24 clinically relevant human pathogens that can be studied using the Rocket-miR application</p>
      </caption>
      <table frame="hsides" rules="groups">
        <colgroup span="1">
          <col span="1"/>
          <col span="1"/>
          <col span="1"/>
        </colgroup>
        <thead>
          <tr>
            <th align="left" valign="bottom" colspan="1" rowspan="1">Species</th>
            <th align="left" valign="bottom" colspan="1" rowspan="1">Strain</th>
            <th align="left" valign="bottom" colspan="1" rowspan="1">Type</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Achromobacter xylosoxidans</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">A8</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Acinetobacter baumannii</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">AYE</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Aspergillus fumigatus</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Strain 293</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Fungus</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Bacteroides fragilis</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">NCTC 9343</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Burkholderia cenocepacia</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">J2315</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Burkholderia multivorans</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">ATCC 17616 (Tohoku)</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Candida albicans</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">SC5314</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Fungus</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Clostridium difficile</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Strain 630</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Clostridium perfringens</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">ATCC 13124</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Enterobacter cloacae</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">ATCC 13047</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Enterococcus faecium</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">DO</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Escherichia coli</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">K12 (Substr. MG1655)</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Haemophilus influenza</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Strain 477</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Klebsiella pneumoniae</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">MGH 78578</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Mycobacterium abscessus</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">ATCC 19977</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Mycobacterium avium</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Strain 104</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Prevotella melaninogenica</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">ATCC 25845</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Pseudomonas aeruginosa</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">PAO1</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Staphylococcus aureus</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">NCTC 8325</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Stenotrophomonas maltophilia</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">K279a</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Streptococcus parasanguinis</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">ATCC 15912</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Streptococcus pneumoniae</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">R6</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Streptococcus salivarius</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">CCHSS3</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Streptococcus sanguinis</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">SK36</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </sec>
  <sec sec-type="results" id="s2">
    <title>RESULTS</title>
    <sec id="s2-1">
      <title>Application overview</title>
      <p>The Rocket-miR application has five core sections (<xref rid="F1" ref-type="fig">Fig. 1</xref>). The first section is the “Summary View,” which offers a high-level perspective on how well the whole set of 630 human miRNAs incorporated in the application target the genes of a selected microbe. The other four sections—the “miRNA View,” “Pathway View,” “Compare Species” view, and the “Structural Analysis” view—offer a closer look at individual miRNAs, genes, and biological pathways. The “miRNA View” allows researchers to identify Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways that are most likely to be effectively targeted by each human miRNA. Users can follow external links to KEGG pathway images highlighting which genes in that pathway met user-defined targeting thresholds. Whether or not a pathway as a whole is predicted to be “effectively targeted” depends on the proportion of its genes/proteins that meet the targeting cutoffs set up in the application. These cutoffs, in turn, are based on prior published experimental data demonstrating the range of energy scores associated with significant downregulation of bacterial protein expression (the targeting cutoffs are described in more detail in Materials and Methods). The “Pathway View” offers the reverse perspective, showing the user a ranked list of human miRNAs that best target a chosen pathway of interest. The “Compare Species” view allows the user to pick multiple microbes and see how well a chosen human miRNA performs across the different species. Finally, the “Structural Analysis” view allows the user to examine and compare the nucleotide sequences of selected miRNAs.</p>
      <fig position="float" fig-type="figure" id="F1">
        <label>Fig 1</label>
        <caption>
          <p>The Rocket-miR application contains five sections. Enlarged versions of the panels in this figure are available as Fig. S1 to S5. After selecting a pathogen of interest, the user is presented with the Summary View (1), where they can view a summary of the target prediction data for all human miRNAs and all genes of the chosen pathogen. They can then navigate to the other four application views. The miRNA View (2) displays the KEGG pathways best targeted by each individual human miRNA in a chosen pathogen. The Pathway View (3) shows the reverse—the most effective miRNAs for targeting a given pathway. The Compare Species View (4) allows the user to compare the effect of a selected miRNA on different KEGG pathways across species. Finally, the Structural Analysis View (5) allows the user to view and compare the nucleotide structure of all the human miRNAs incorporated in the application.</p>
        </caption>
        <graphic xlink:href="msystems.00653-23.f001" position="float"/>
      </fig>
      <p>To demonstrate the usefulness of the application in a domain-specific context, Results includes three case studies from researchers who study cystic fibrosis pathogens at the Geisel School of Medicine. Prior to the case studies, we discuss how the vast array of prediction data in the application can be narrowed in scope to identify the miRNAs with the greatest antimicrobial potential.</p>
    </sec>
    <sec id="s2-2">
      <title>Identifying miRNAs with antimicrobial potential</title>
      <p>The Rocket-miR application contains a universe of miRNA-targeting predictions which could be validated by laboratories that study AMR pathogens. How are researchers who use the application to decide on the most promising human miRNAs for <italic toggle="yes">in vitro</italic> studies? Surveying and comparing the predicted targets of human miRNAs across all Rocket-miR pathogens illuminate several strategies to identify the most promising miRNAs and species to target. It also helps identify miRNAs with potential broad-spectrum antimicrobial effects that may target multiple species simultaneously. This section supports the case studies that follow and provides helpful guidance for the use of the Rocket-miR application.</p>
      <p>Throughout this and the following sections of the results, readers should keep in mind that the Rocket-miR results are bioinformatic predictions. <italic toggle="yes">In vitro</italic> experiments involving the miRNAs and pathogens included in the application might not yield exactly the results predicted. The miRNA-mRNA target prediction scores in the Rocket-miR application were generated using the target prediction algorithm IntaRNA, which predicts the strength of interaction based on both the free energy of miRNA-mRNA hybridization and the miRNA secondary structure (<xref rid="B58" ref-type="bibr">58</xref>). More negative targeting scores predict stronger miRNA-mRNA interactions. The Rocket-miR application includes three targeting cutoffs (strong: −16.98, medium: −15.35, weak, −13.47), varying from highest to lowest confidence that the miRNA-mRNA interaction will successfully suppress protein expression, based on prior data from our previous let-7b-5p study (<xref rid="B38" ref-type="bibr">38</xref>). The IntaRNA algorithm and choice of targeting cutoffs are explained further in Materials and Methods.</p>
      <p>A comparative analysis of miRNA target prediction data for all species in the application indicates that some species are likely to be more effectively targeted in general by human miRNAs than others. Approximately 5% of all energy score interactions for <italic toggle="yes">A. fumigatus</italic> meet or exceed the medium targeting score cutoff in the application. In contrast, the next best species in terms of overall targeting potential (<italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">A. xylosoxidans</italic>, <italic toggle="yes">S. maltophilia, M. abscessus</italic>) have between 2% and 3% of their interactions meeting the medium targeting cutoff. On the lower end, there are three species (<italic toggle="yes">C. perfringens</italic>, <italic toggle="yes">C. difficile</italic>, and <italic toggle="yes">S. aureus</italic>) with less than 1% of interactions meeting the cutoff (<xref rid="F2" ref-type="fig">Fig. 2</xref>).</p>
      <fig position="float" fig-type="figure" id="F2">
        <label>Fig 2</label>
        <caption>
          <p>The overall percentage of miRNA-targeting interactions for each species that meet or exceed the medium targeting cutoff (−15.35) varies between species. Each targeting interaction represents the likelihood of stable interaction between a human miRNA and a particular gene in each human pathogen.. The numbers inside of the bars represent the total number of miRNA-gene interactions that meet the cutoff for each species, whereas the y-axis represents the percentage of interactions meeting the cutoff out of the total number of interactions for each species. Species names are abbreviated as follows: AF, <italic toggle="yes">A. fumigatus</italic>; PA, <italic toggle="yes">P. aeruginosa</italic>; AX, <italic toggle="yes">A. xylosoxidans</italic>; SM, <italic toggle="yes">S. maltophilia</italic>; MAb, <italic toggle="yes">M. abscessus</italic>; MAv, <italic toggle="yes">M. avium</italic>; KP, <italic toggle="yes">K. pneumoniae</italic>; ECl, <italic toggle="yes">E. cloacae</italic>; CA, <italic toggle="yes">C. albicans</italic>; BF, <italic toggle="yes">B. fragilis</italic>; SSan, <italic toggle="yes">S. sanguinis</italic>; ECo, <italic toggle="yes">E. coli</italic>; PM, <italic toggle="yes">P. melaninogenica</italic>; BC, <italic toggle="yes">B. cenocepacia</italic>; SPa, <italic toggle="yes">S. parasanguinis</italic>; BM, <italic toggle="yes">B. multivorans</italic>; SPn, <italic toggle="yes">S. pneumoniae</italic>; SSal, <italic toggle="yes">S. salivarius</italic>; AB, <italic toggle="yes">A. baumannii</italic>; HI, <italic toggle="yes">H. influenza</italic>; EF, <italic toggle="yes">E. faecium</italic>; CP, <italic toggle="yes">C. perfringens</italic>; CD, <italic toggle="yes">C. difficile</italic>; SA, <italic toggle="yes">S. aureus</italic>.</p>
        </caption>
        <graphic xlink:href="msystems.00653-23.f002" position="float"/>
      </fig>
      <p>From <xref rid="F2" ref-type="fig">Fig. 2</xref>, one might conclude that only a small percentage of genes in human pathogens can be effectively targeted by human miRNAs. However, although most human miRNAs are not predicted to target very many human genes, a small number of human miRNAs are predicted to target many genes across multiple human pathogens. This small set of miRNAs therefore has great potential as possible antimicrobial agents. From a single-species perspective, our application identified 92 human miRNAs that are predicted to effectively target 10% or more of all genes in <italic toggle="yes">A. fumigatus</italic> (again at the medium targeting cutoff of −15.35). There are five additional species with 40 or more miRNAs that effectively target 10% or more genes (<italic toggle="yes">M. abscessus</italic>, <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">A. xylosoxidans</italic>, <italic toggle="yes">M. avium</italic>, and <italic toggle="yes">S. maltophilia</italic>) at the same cutoff. All but one species (<italic toggle="yes">S. aureus</italic>) has at least a single human miRNA that targets 10% or more of its genes (<xref rid="F3" ref-type="fig">Fig. 3A</xref>).</p>
      <fig position="float" fig-type="figure" id="F3">
        <label>Fig 3</label>
        <caption>
          <p>Identification of broadly effective miRNAs. (<bold>A</bold>) The number of human miRNAs that target 10% or more genes at or above the medium targeting cutoff (−15.35) varies between species. The height of the bars (and the numbers above the bars) represent the number of miRNAs that meet this criterion for each species. The cutoff of 10% was chosen as a simple measure to predict overall effectiveness of human miRNAs in different species. The Rocket-miR application can be used to predict how effectively individual miRNAs might target specific genes and pathways in each species. (<bold>B</bold>) Some miRNAs target 10% or more genes at or above the medium targeting cutoff (−15.35) in many different species. The word cloud provides a visual indication of which miRNAs have the best broad-spectrum effects—with miRNAs of a larger text size targeting 10% or more genes at the medium cutoff in a greater number of species. Species abbreviations in the upper panel are the same as <xref rid="F2" ref-type="fig">Fig. 2</xref>.</p>
        </caption>
        <graphic xlink:href="msystems.00653-23.f003" position="float"/>
      </fig>
      <p>Building on this single-species analysis, we considered whether some human miRNAs are predicted to target multiple pathogenic species simultaneously. <xref rid="F3" ref-type="fig">Figure 3B</xref> identifies the miRNAs most likely to be effective in multiple pathogens. These broadly effective miRNAs include let-7b-5p, miR-877–5p, miR-3127–5p, miR-3138–3p, miR-320-P1-3p, and miR-320-P3-3p. Each of these six human miRNAs are predicted to target 10% or more of genes in at least 20 of the 24 pathogens included in the Rocket-miR application (at the medium cutoff). <xref rid="T2" ref-type="table">Table 2</xref> further demonstrates, for each of the six broad-spectrum miRNAs, what proportion of all genes are targeted in each of the application’s 24 different species.</p>
      <table-wrap position="float" id="T2">
        <label>TABLE 2</label>
        <caption>
          <p>Six miRNAs that target 10% or more genes at the medium targeting cutoff in a combined 24 different CF pathogens<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" valign="bottom" colspan="1" rowspan="1">Species</th>
              <th align="left" valign="bottom" colspan="1" rowspan="1">let-7b-5p</th>
              <th align="left" valign="bottom" colspan="1" rowspan="1">877-5p</th>
              <th align="left" valign="bottom" colspan="1" rowspan="1">3127-5p</th>
              <th align="left" valign="bottom" colspan="1" rowspan="1">3138-3p</th>
              <th align="left" valign="bottom" colspan="1" rowspan="1">320-P1-3p</th>
              <th align="left" valign="bottom" colspan="1" rowspan="1">320-P3-3p</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Achromobacter xylosoxidans</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.31</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.51</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.26</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.16</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.23</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Acinetobacter baumannii</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.24</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.12</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.11</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Aspergillus fumigatus</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.53</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.78</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.45</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.56</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.51</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.52</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Bacteroides fragilis</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.33</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.10</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Burkholderia cenocepacia</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.26</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.30</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.12</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.11</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.10</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Burkholderia multivorans</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.22</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.30</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.12</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.11</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.12</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.09</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Candida albicans</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.35</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.32</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.11</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.17</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Clostridium difficile</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.06</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.04</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.02</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.03</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.01</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.03</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Clostridium perfringens</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.05</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.04</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.02</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.03</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.01</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.02</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Enterobacter cloacae</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.24</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.45</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Enterococcus faecium</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.10</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.17</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.06</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.11</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.05</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.08</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Escherichia coli</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.40</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.13</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.17</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.16</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Haemophilus influenza</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.12</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.10</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.12</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Klebsiella pneumoniae</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.24</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.49</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.22</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.22</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Mycobacterium abscessus</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.25</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.39</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.17</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.16</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.16</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Mycobacterium avium</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.29</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.35</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.17</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.13</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Prevotella melaninogenica</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.25</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.36</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.13</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.25</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.13</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Pseudomonas aeruginosa</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.41</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.61</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.27</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.27</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.35</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.29</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Staphylococcus aureus</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.09</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.06</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.04</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.04</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.02</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.03</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Stenotrophomonas maltophilia</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.32</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.44</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.23</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Streptococcus parasanguinis</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.34</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.16</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Streptococcus pneumoniae</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.30</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.13</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.17</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Streptococcus salivarius</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.30</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.13</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Streptococcus sanguinis</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.37</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T2_FN1">
            <label>
              <sup>
                <italic toggle="yes">a</italic>
              </sup>
            </label>
            <p>The exact percentage of genes targeted in each pathogen is listed for each of the five miRNAs.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Drawing on the combined information from <xref rid="F2 F3" ref-type="fig">Fig. 2 and 3</xref> ; <xref rid="T2" ref-type="table">Table 2</xref>, a researcher might make an educated decision about whether targeting a given species with human miRNAs is an endeavor worthy of laboratory resources, and if so, what miRNAs would be most promising to consider as antimicrobial candidates. Though predicted targeting of a large portion of genes in the genome is not a guarantee that a miRNA will effectively interfere with the growth and/or virulence capabilities of a given pathogen, it does increase the likelihood that the miRNA will have a potent effect.</p>
    </sec>
    <sec id="s2-3">
      <title>Experimental validation of Rocket-miR predictions</title>
      <p>To validate Rocket-miR predictions with <italic toggle="yes">in vitro</italic> experiments, the effect of let-7b-5p expression on the planktonic growth and biofilm formation of <italic toggle="yes">P. aeruginosa</italic> was performed using biofilm inoculator (peg lid) plates to measure colony forming units (CFUs; as described elsewhere) (<xref rid="B59" ref-type="bibr">59</xref>). An expression vector containing the let-7b-5p sequence was electroporated into <italic toggle="yes">P. aeruginosa</italic> to induce let-7b-5p expression, as described in Materials and Methods. As shown in <xref rid="F4" ref-type="fig">Fig. 4A</xref>, let-7b-5p expression reduced planktonic growth of <italic toggle="yes">P. aeruginosa</italic> in the presence and absence of aztreonam (1/2 the minimum inhibitory concentration), an antibiotic commonly used to treat people with CF, compared to empty vector control with and without aztreonam (<xref rid="B60" ref-type="bibr">60</xref>). <xref rid="F4" ref-type="fig">Figure 4B</xref> demonstrates that let-7b-5p inhibited biofilm formation of <italic toggle="yes">P. aeruginosa</italic> in the presence of aztreonam compared to empty vector control plus aztreonam (<xref rid="F4" ref-type="fig">Fig. 4B</xref>).</p>
      <fig position="float" fig-type="figure" id="F4">
        <label>Fig 4</label>
        <caption>
          <p>Let-7b-5p reduced planktonic growth and biofilm formation of <italic toggle="yes">P. aeruginosa</italic> as predicted by Rocket-miR. (<bold>A</bold>) <italic toggle="yes">P. aeruginosa</italic> transfected with let-7b-5p exhibited less planktonic growth compared to <italic toggle="yes">P. aeruginosa</italic> transfected with the empty plasmid in the presence and absence of aztreonam. (<bold>B</bold>) Let-7b-5p also significantly reduced biofilm formation by <italic toggle="yes">P. aeruginosa</italic> in the presence of aztreonam compared to empty vector in the presence of aztreonam. ***<italic toggle="yes">P</italic> &lt; 0.0001. Experiments were repeated four times.</p>
        </caption>
        <graphic xlink:href="msystems.00653-23.f004" position="float"/>
      </fig>
      <p>These new results are in line with previous experiments. In a prior study, we had demonstrated, using a crystal violet assay, that addition of aztreonam (1/2 the minimum inhibitory concentration) and expression of let-7b-5p in <italic toggle="yes">P. aeruginosa</italic> had an additive effect to reduce biofilm formation (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B61" ref-type="bibr">61</xref>). The additive effect of let-7b-5p and aztreonam is predicted based on the observation that let-7b-5p inhibits numerous genes in the biofilm formation pathways and inhibits aztreonam efflux pumps in <italic toggle="yes">P. aeruginosa</italic> (<xref rid="B38" ref-type="bibr">38</xref>).</p>
      <p>These experimental results confirm the Rocket-miR prediction that let-7b-5p effectively targets <italic toggle="yes">P. aeruginosa</italic>, with significant impacts on growth (planktonic and biofilm) and antibiotic sensitivity. They also demonstrate a simple approach for assessing the effects of human miRNAs on microbial cells that can be leveraged in future studies with different miRNAs, microorganisms, and antibiotics. To provide additional inspiration for future studies, the following three case studies explore how the Rocket-miR application can be used to predict the effects of human miRNAs on the level of individual genes and biological pathways in selected bacteria. The case studies cover several clinically relevant human pathogens.</p>
    </sec>
    <sec id="s2-4">
      <title>Case study #1: identifying antimicrobial miRNAs to target β-lactam resistance in <italic toggle="yes">Pseudomonas aeruginosa</italic></title>
      <sec id="s2-4-1">
        <title>Sharanya Sarkar, Ph.D. candidate, Stanton Lab, Geisel School of Medicine</title>
        <p>Although the CF lung is characterized by polymicrobial infections involving a wide variety of species such as <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Haemophilus influenzae</italic>, and <italic toggle="yes">Burkholderia cenocepacia</italic>, 50% of adult pwCF are colonized by <italic toggle="yes">Pseudomonas aeruginosa</italic> (<italic toggle="yes">P.a</italic>.) (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>). Prolonged colonization by <italic toggle="yes">P.a</italic>. is linked with worse lung function and enhanced mortality rates in pwCF (<xref rid="B64" ref-type="bibr">64</xref>). In the chronic state, <italic toggle="yes">P.a</italic>. escapes immune clearance and resists conventional antibiotics via mechanisms such as the production of β-lactamases to degrade antibiotics and efflux pumps to export antibiotics from <italic toggle="yes">Pseudomonas</italic> cells, reduced expression of porin channels to prevent antibiotic intake, and adopting a biofilm community structure that is less susceptible to antibiotic treatment (<xref rid="B65" ref-type="bibr">65</xref>). Thus, new treatments are required to reduce the <italic toggle="yes">P.a</italic>. burden in the CF lung by targeting pathways such as antibiotic resistance and biofilm formation. Accordingly, the Stanton lab is developing miRNA-based antimicrobial therapies to eliminate <italic toggle="yes">P.a</italic>. and other pathogens in the CF lung.</p>
        <p>Leveraging the analysis capabilities of this application, we were particularly interested in identifying novel therapeutic miRNAs that could target antibiotic resistance and biofilm formation pathways in <italic toggle="yes">P.a</italic>. After selecting <italic toggle="yes">Pseudomonas aeruginosa</italic> from the “Species Selection” tab in the sidebar, the “Summary View” arranged the human miRNAs in the order of how effectively they targeted genes in <italic toggle="yes">P.a</italic>. We found that miR-877–5p had the best median energy score—indicating that it was predicted to effectively target more genes in <italic toggle="yes">P. aeruginosa</italic> than any other human miRNA. From the “miRNA View” section of the application, we downloaded an excel file with the complete list of <italic toggle="yes">P.a</italic>. KEGG pathways and the corresponding percentage of genes targeted by miR-877-5p. Since we were most interested in virulence pathways such as biofilm formation and antibiotic resistance, we examined pathways associated with these terms and found that 46.0% of genes in the biofilm formation pathway and 54.8% of genes in the β-lactam resistance pathway were predicted to be effectively targeted by miR-877-5p. These values were obtained by selecting a “Strong” targeting cutoff, thereby giving us the maximum confidence in the likelihood of protein targeting by this miRNA. To understand exactly what genes in the two pathways were predicted to be targeted by miR-877-5p, we clicked on the hyperlinked pathway terms in the miRNA View. These hyperlinks opened two new windows on the browser depicting the targeted genes on a KEGG pathway diagram (<xref rid="F5" ref-type="fig">Fig. 5A and B</xref>). To further establish the targeting power of miRNA-877-5p vs other human miRNAs, we used the “Pathway View” section of the application and selected biofilm formation and β-lactam resistance as our chosen pathways. The Pathway View indicated that miRNA-877-5p was indeed the human miRNA predicted to target these two pathways most effectively, with the second most effective miRNA targeting as much as 15% fewer genes in both cases.</p>
        <fig position="float" fig-type="figure" id="F5">
          <label>Fig 5</label>
          <caption>
            <p>Key genes targeted by human 877-5p in (i) the biofilm formation pathway and (ii) the β-lactam resistance pathway in <italic toggle="yes">Pseudomonas aeruginosa</italic> are highlighted in blue. Highlighted genes meet the application’s strong targeting cutoff, with a predicted energy score less than or equal to −16.98 (a more negative energy score being indicative of stronger predicted targeting). Green genes are present in the <italic toggle="yes">P. aeruginosa</italic> genome but not strongly targeted. The rationale for the values of the targeting cutoffs is described further in Materials and Methods.</p>
          </caption>
          <graphic xlink:href="msystems.00653-23.f005" position="float"/>
        </fig>
        <p>Since much of our prior work in the lab has focused on let-7b-5p, we wanted to run an analysis to compare the predicted effects of miR-877-5p and let-7b-5p and consider miR-877-5p as a new candidate for future therapeutic developments. We performed the same analysis as outlined above in this case study for let-7b-5p and summarized our findings (<xref rid="T3" ref-type="table">Table 3</xref>). While let-7b-5p had a weaker performance as compared to miR-877-5p on most of the key parameters, the two miRNAs targeted complementary genes in some sub-pathways such as the chemosensory system, <italic toggle="yes">Pseudomonas</italic> quinolone signal(PQS) system, and β-lactamase classes. For instance, while let-7b-5p showed predicted targeting for the class C β-lactamase, miR-877-5p showed predicted targeting for the class D β-lactamase.</p>
        <table-wrap position="float" id="T3">
          <label>TABLE 3</label>
          <caption>
            <p>Comparative analyses of key parameters between miRNAs let-7b-5p and miR-877-5p</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col span="1"/>
              <col span="1"/>
              <col span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" valign="top" rowspan="2" colspan="1">Key parameters</th>
                <th align="center" valign="top" colspan="2" rowspan="1">microRNA</th>
              </tr>
              <tr>
                <th align="left" valign="top" colspan="1" rowspan="1">let-7b-5p</th>
                <th align="left" valign="top" colspan="1" rowspan="1">miR-877-5p</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">Median interaction energy score for <italic toggle="yes">P.a</italic>.</td>
                <td align="left" valign="top" colspan="1" rowspan="1">14.67</td>
                <td align="left" valign="top" colspan="1" rowspan="1">16.33</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">% Genes targeted in biofilm formation pathway</td>
                <td align="left" valign="top" colspan="1" rowspan="1">31.0%</td>
                <td align="left" valign="top" colspan="1" rowspan="1">46.0%</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">% Genes targeted in β-lactam resistance pathway</td>
                <td align="left" valign="top" colspan="1" rowspan="1">29.0%</td>
                <td align="left" valign="top" colspan="1" rowspan="1">54.8%</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">Proteins targeted in biofilm formation pathway</td>
                <td align="left" valign="top" colspan="1" rowspan="1">PilJ, ChPa., CyaB, FleQ, PqsE, PA1611, PA1976, GacS, RetS, HSI-I, TpbB, RoeA, MucR, BifA, FleQ, Psl, FunX, FunW</td>
                <td align="left" valign="top" colspan="1" rowspan="1">PilI, ChPa, PilG, CyaB, CpdA, FleQ, ExsA, PqsA, MvtR, RhlR, RhlC, LecB, LasI, SagS, PA1976, HsbR, HsbA, LadS, RetS, HSI-I, WspB/D, Wsp-F, TpbB, RoeA, MucR, BifA, FleQ, Psl, PelB, PelD, PelE, PelF, PelG, FunX, FunW</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">Proteins targeted in β-lactam resistance pathway</td>
                <td align="left" valign="top" colspan="1" rowspan="1">OPaD, RND, Class C β-lactamase, AmpG, FtsI, NalC, AmpR, OprD, MexB/AcrB</td>
                <td align="left" valign="top" colspan="1" rowspan="1">OPaD, OMP, RND, MFP, Class D β-lactamase, AmpG, ParS, ParR, OprD, FtsI, NalC, MexZ, MexX, MexY, MexR, NalD, MexB/AcrB</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>This case study led to the development of the hypothesis that human microRNA 877-5p can be used as a potent antimicrobial candidate, specifically against the notorious CF pathogen <italic toggle="yes">Pseudomonas aeruginosa</italic>. This hypothesis can be easily translated to wet bench experiments, which in turn, will play an important role in understanding host-pathogen interactions in the context of eukaryotic miRNA regulation. For instance, naturally occurring EVs or synthetic polymeric nanoparticles, loaded with miR-877-5p, could be administered in CF mice models to test their efficacy in abating <italic toggle="yes">P.a</italic>. infection and inflammation. There is prior precedent for the study of miR-877-5p as a therapeutic agent. For example, miR-877-5p has been shown by several research groups to inhibit hepatocellular, prostate, lung, and gastric cancers (<xref rid="B66" ref-type="bibr">66</xref><xref rid="B67" ref-type="bibr">–</xref><xref rid="B69" ref-type="bibr">69</xref>). Furthermore, miR-877-5p has also been demonstrated to alleviate acute respiratory distress syndrome both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> (<xref rid="B70" ref-type="bibr">70</xref>). Therefore, utilizing this miRNA in the context of CF pathology would be a logical step. To achieve even better results, one might combine let-7b-5p with miR-877-5p in EVs or nanoparticles to achieve complementary gene targeting in multiple pathways. One might also co-load vesicles with a β-lactam antibiotic and miRNA-877-5p to improve the efficacy of the antibiotic while the β-lactam resistance pathway is rendered ineffective by the miRNA. The total analysis in this application took around 30 min, and outstanding features such as typing in direct terms in the search boxes (rather than scrolling through a long list) made the process even faster. Overall, Rocket-miR was a fast and user-friendly experience, and helped us to develop a testable hypothesis with results that could advance miRNA-based interventions as a therapeutic strategy for CF.</p>
      </sec>
    </sec>
    <sec id="s2-5">
      <title>Case study #2: targeting a polymicrobial community of CF pathogens</title>
      <sec id="s2-5-1">
        <title>Sharanya Sarkar, Ph.D. candidate, Stanton Lab, Geisel School of Medicine</title>
        <p>Building on the first case study, we wanted to explore the potential use of miR-877-5p to target four key CF pathogens simultaneously, namely, <italic toggle="yes">Prevotella melaninogenica</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, <italic toggle="yes">Staphylococcus aureus</italic>, and <italic toggle="yes">Streptococcus sanguinis</italic> (<xref rid="F6" ref-type="fig">Fig. 6</xref>). These four pathogens constitute a familiar CF “pulmotype” based on factors from prior research such as prevalence/abundance, co-occurrence, physical/spatial proximity, metabolic cross-feeding, and capacity to dictate health outcomes in pwCF (<xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B72" ref-type="bibr">72</xref>). <italic toggle="yes">P.a</italic>. has been shown to significantly influence the inflammatory responses, independent of <italic toggle="yes">S. aureus</italic> in chronic infection models, and also double the risk of death in adult pwCF (<xref rid="B73" ref-type="bibr">73</xref>). <italic toggle="yes">S. aureus</italic>, on the contrary, is usually more prevalent in younger, healthier CF patients (<xref rid="B74" ref-type="bibr">74</xref>). <italic toggle="yes">Prevotella</italic> is a common anaerobe found in the CF lung, and a study has reported that anaerobes like <italic toggle="yes">Prevotella</italic> detected in the sputum during periods of clinical pulmonary exacerbation were linked with lessened inflammation and better lung function, with respect to sputum samples containing <italic toggle="yes">P.a</italic>. (<xref rid="B75" ref-type="bibr">75</xref>). Therefore, reducing <italic toggle="yes">P.a</italic>. abundance relative to <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">P. melaninogenica</italic> may improve clinical outcomes.</p>
        <fig position="float" fig-type="figure" id="F6">
          <label>Fig 6</label>
          <caption>
            <p>Community health bar graph demonstrating the β-lactam resistance pathway targeting of miRNA 877-5p in four key CF species<italic toggle="yes">—Prevotella melaninogenica, Pseudomonas aeruginosa, Staphylococcus aureus,</italic> and <italic toggle="yes">Streptococcus sanguinis</italic>. In this figure, downloaded directly from the Rocket-miR application, 100% protein targeting would indicate that all genes on the β-lactam resistance pathway are effectively targeted by a given miRNA. β-Lactam resistance is targeted most effectively by miRNA 877-5p in <italic toggle="yes">P.a</italic>. (54.8% of genes targeted) and least in <italic toggle="yes">S. aureus</italic> (11.1% of genes targeted).</p>
          </caption>
          <graphic xlink:href="msystems.00653-23.f006" position="float"/>
        </fig>
        <p>Expanding on these results, it may be possible to target the β-lactam resistance pathway in this community of species more effectively by leveraging multiple human miRNAs simultaneously. <xref rid="F7" ref-type="fig">Figure 7</xref> demonstrates the combined effect of the five broad-spectrum miRNAs identified in <xref rid="T2" ref-type="table">Table 2</xref> against the β-lactam resistance pathway for the four-species community as an example of how miRNAs may be combined. More genes on the β-lactam resistance pathway are effectively targeted when the six miRNAs are used together than when miR-877-5p is used alone—with one-third of the <italic toggle="yes">S. aureus</italic> genes on the β-lactam resistance pathway and more than 50% of the <italic toggle="yes">S. sanguinis</italic> genes on the pathway predicted to be targeted (compared to ~10% and ~25% for miR-877-5p alone). Targeting of <italic toggle="yes">P. melaninogenica</italic> and <italic toggle="yes">P. aeruginosa</italic> is also predicted to improve, with approximately 75% and 80% of genes targeted, respectively (compared to ~45% and ~55%, respectively).</p>
        <fig position="float" fig-type="figure" id="F7">
          <label>Fig 7</label>
          <caption>
            <p>The combined predicted effect of the six broad-spectrum human miRNAs shown in <xref rid="T3" ref-type="table">Table 3</xref> (let-7b-5p, 3127-5p, 3138-3p, 320-P1-3p, 320-P3-3p, 877-5p) on β-lactam resistance in this CF-relevant four-species microbial community is greater than the effect of the individual miRNAs 877-5p or let-7b-5p administered alone (<xref rid="F3" ref-type="fig">Fig. 3</xref>; <xref rid="T2" ref-type="table">Table 2</xref>). As in <xref rid="F3" ref-type="fig">Fig. 3</xref>, the most stringent cutoff in the application (−16.98) was used to determine which genes on the β-lactam resistance KEGG pathway were targeted effectively in each species. The height of the bars (and values inside the bars) represents the proportion of total genes in the β-lactam resistance KEGG pathway where at least one of the six miRNAs meet or exceed the targeting cutoff.</p>
          </caption>
          <graphic xlink:href="msystems.00653-23.f007" position="float"/>
        </fig>
      </sec>
    </sec>
    <sec id="s2-6">
      <title>Case study #3: human miRNAs target the <italic toggle="yes">Bacteroides fragilis</italic> type VI secretion system (T6SS)</title>
      <sec id="s2-6-1">
        <title>Casey Latario, Ph.D. candidate, Ross Lab, Geisel School of Medicine</title>
        <p>In this final case study, we sought to gain insight into the potential for host-microbe interactions mediated by miRNA targeting of a bacterium inhabiting a different site in the body, the colonic symbiont <italic toggle="yes">Bacteroides fragilis. B. fragilis</italic> is present exclusively in mammals and is both prevalent and relatively abundant in the healthy human gastrointestinal microbiome (<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>). <italic toggle="yes">B. fragilis</italic> is generally considered to be a beneficial organism, though enterotoxigenic strains can be associated with inflammatory intestinal disease and colonic tumorigenesis (<xref rid="B78" ref-type="bibr">78</xref>). In pwCF, <italic toggle="yes">Bacteroides</italic> species including <italic toggle="yes">B. fragilis</italic> are diminished in abundance compared to healthy controls and there is great interest in identifying avenues for the restoration of these populations back to healthy levels to alleviate gastrointestinal symptoms in CF (<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>).</p>
        <p>We used Rocket-miR to identify miRNA targets in the genome of the reference strain of <italic toggle="yes">B. fragilis</italic> NCTC 9343. The top hit predicted by Rocket-miR was 1913_3p, which targets <italic toggle="yes">tssG</italic> mRNA with an energy score of −30.97 (<xref rid="T4" ref-type="table">Table 4</xref>). TssG is an integral part of the T6SS, a nanomachine first discovered in <italic toggle="yes">Vibrio cholerae</italic> and <italic toggle="yes">Pseudomonas aeruginosa,</italic> but later found to be broadly distributed throughout Gram-negative bacteria (<xref rid="B81" ref-type="bibr">81</xref><xref rid="B82" ref-type="bibr">–</xref><xref rid="B83" ref-type="bibr">83</xref>). The T6SS functions to translocate toxic effector proteins in a contact-dependent manner to a recipient target cell (<xref rid="B84" ref-type="bibr">84</xref>). Since translocated effector proteins often possess endonuclease, protease, phospholipase, or other activities, their concerted action typically results in bacteriostasis or bacteriolysis of targeted cells, thereby providing a fitness advantage to the producing bacterium (<xref rid="B85" ref-type="bibr">85</xref>). The T6SS is composed of three subcomplexes: the membrane complex (MC), baseplate (BP), and tail-tube complex (TTC) (<xref rid="B86" ref-type="bibr">86</xref>). As yet only functionally characterized in Proteobacteria, TssG is an essential conserved component of the baseplate subcomplex, which is composed of six heterotetrameric “wedges” (<xref rid="B87" ref-type="bibr">87</xref>). TssG forms the core of each wedge (<xref rid="F8" ref-type="fig">Fig. 8</xref>). Deletion of <italic toggle="yes">tssG</italic> inhibits assembly of the baseplate and thus ablates T6SS activity. We predict that the outcome of miR-1913_3p inhibition of <italic toggle="yes">tssG</italic> would be the reduction of <italic toggle="yes">B. fragilis</italic> T6SS activity in the gut.</p>
        <table-wrap position="float" id="T4">
          <label>TABLE 4</label>
          <caption>
            <p>Sixteen <italic toggle="yes">B. fragilis</italic> T6SS genes and their predicted targeting by human miRNAs<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col span="1"/>
              <col span="1"/>
              <col span="1"/>
              <col span="1"/>
              <col span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" valign="top" colspan="1" rowspan="1">Locus tag</th>
                <th align="left" valign="top" colspan="1" rowspan="1">T6SS nomenclature</th>
                <th align="left" valign="top" colspan="1" rowspan="1">Subcomplex</th>
                <th align="left" valign="top" colspan="1" rowspan="1">miRNA</th>
                <th align="left" valign="top" colspan="1" rowspan="1">Energy score</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09380/BF9343_1923</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TssG</td>
                <td align="left" valign="top" colspan="1" rowspan="1">BP</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.1913_3p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−30.9755</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09390/BF9343_1925</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TssN</td>
                <td align="left" valign="top" colspan="1" rowspan="1">MC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.3138_3p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−23.7509</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09415/BF9343_1930</td>
                <td align="left" valign="top" colspan="1" rowspan="1">VgrG</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TTC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.504.v2_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−22.4218</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09360/BF9343_1919</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TssR</td>
                <td align="left" valign="top" colspan="1" rowspan="1">MC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.877_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−21.4969</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09410/BF9343_1929</td>
                <td align="left" valign="top" colspan="1" rowspan="1">PAAR</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TTC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.3944_3p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−21.2825</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09465/BF9343_1940</td>
                <td align="left" valign="top" colspan="1" rowspan="1">ClpV</td>
                <td align="left" valign="top" colspan="1" rowspan="1">ATPase</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.185_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−21.2479</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09385/BF9343_1924</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TssK</td>
                <td align="left" valign="top" colspan="1" rowspan="1">BP</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.3138_3p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−20.2922</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09420/BF9343_1931</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TssF</td>
                <td align="left" valign="top" colspan="1" rowspan="1">BP</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.877_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−20.0846</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09430/BF9343_1933</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TagC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Unknown</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.4664_3p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−19.5252</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09405/BF9343_1928</td>
                <td align="left" valign="top" colspan="1" rowspan="1">bte2</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Effector</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.877_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−19.2061</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09400/BF9343_1927</td>
                <td align="left" valign="top" colspan="1" rowspan="1">bti2a</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Immunity</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Let.7.P1b_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−18.5971</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09485/BF9343_1944</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TetR</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Unknown</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Has.Mir.130.P4a_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−18.2097</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09365/BF9343_1920</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TssP</td>
                <td align="left" valign="top" colspan="1" rowspan="1">MC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.204.P1_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−18.1975</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09450/BF9343_1937</td>
                <td align="left" valign="top" colspan="1" rowspan="1">bte1</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Effector</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.139_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−18.1686</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09460/BF9343_1939</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hcp</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TTC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.432_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−17.4228</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09395/BF9343_1926</td>
                <td align="left" valign="top" colspan="1" rowspan="1">bti2b</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Immunity</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.430.P24_3p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−16.8882</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="T4_FN1">
              <label>
                <sup>
                  <italic toggle="yes">a</italic>
                </sup>
              </label>
              <p>The <italic toggle="yes">B. fragilis</italic> NCTC 9343 strain locus tags are indicated for each gene, alongside the T6SS gene designation, the subcomplex to which each corresponds, and the Rocket-miR energy score for the human miRNA predicted to target the gene most effectively. A more negative energy score corresponds to a stronger interaction.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <fig position="float" fig-type="figure" id="F8">
          <label>Fig 8</label>
          <caption>
            <p>Rocket-miR identified the type VI secretion system gene <italic toggle="yes">tssG</italic> harbored by <italic toggle="yes">Bacteroides fragilis</italic> as the top predicted gene targeted by human miRNA. The schematic depicts a T6SS, composed of three distinct subcomplexes: the MC, BP, and TTC. The T6SS BP is formed by units of TssEFGK wedges (inset), with TssG as the central protein (indicated in dark blue). Below the T6SS is a <italic toggle="yes">B. fragilis</italic> T6SS locus, with the <italic toggle="yes">tssG</italic> gene shown in dark blue. The transcribed <italic toggle="yes">tssG</italic> (blue mRNA) is shown interacting with a potential inhibitory miRNA, 1913_3p (red miRNA). MC proteins and genes are indicated in red, TTC in purple.</p>
          </caption>
          <graphic xlink:href="msystems.00653-23.f008" position="float"/>
        </fig>
        <p>Notably, in addition to <italic toggle="yes">tssG</italic>, we found that many other <italic toggle="yes">B. fragilis</italic> T6SS genes were predicted by Rocket-miR to be the targets of human-encoded miRNAs with strong predicted energy scores. These genes included two other BP genes in addition to TssG, three MC genes, two TTC genes, the T6SS-associated ClpV ATPase, and two effector immunity gene pairs (<xref rid="T4" ref-type="table">Table 4</xref>). Inactivation of any of these genes could be inferred to impair or inactivate the T6SS. In sum, 16/26 (61.5%) <italic toggle="yes">B. fragilis</italic> T6SS genes are predicted to be effective targets for human miRNAs.</p>
        <p>Considering these data, we predict that exposure of <italic toggle="yes">B. fragilis</italic> cells to EVs released by colonic cells containing miR-1913_3p or other miRNAs listed in <xref rid="T4" ref-type="table">Table 4</xref> would result in reduced T6SS expression and subsequent diminishment of interbacterial antagonism. In addition, engineered extracellular vesicles or nanoparticles containing these miRNAs could be developed to reduce T6SS and therefore reduce the pathogenicity of <italic toggle="yes">B. fragilis</italic>. Since EVs secreted by colon cells are likely to exist in a gradient extending luminally from the epithelial layer, one potential function of this mechanism could be the dampening of T6SS-dependent bacterial lysis near the epithelium to prevent unwanted inflammatory responses to bacterial-derived cellular products. This dampening would also be predicted to lower <italic toggle="yes">B. fragilis</italic> fitness during interactions with other Gram-negative bacterial competitors, but may promote co-existence especially with other <italic toggle="yes">Bacteroides</italic> species (<xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B89" ref-type="bibr">89</xref>). While the mucosal layer acts to buffer the epithelium from the bulk of the gut microbiota, <italic toggle="yes">B. fragilis</italic> can colonize colonic crypts and even form polymicrobial biofilms at sites of colonic polyp formation (<xref rid="B90" ref-type="bibr">90</xref>, <xref rid="B91" ref-type="bibr">91</xref>) . How or if <italic toggle="yes">B. fragilis</italic> biogeography and interbacterial interactions are impacted in CF is currently unknown. Further mechanistic investigation of the impact of miRNAs on <italic toggle="yes">B. fragilis</italic> T6SS in both healthy individuals and in the context of CF will be important to lend experimental credence to our observations and illuminate potential therapeutic avenues.</p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s3">
    <title>DISCUSSION</title>
    <p>By designing Rocket-miR as an accessible, point-and-click web application, we have made the results of miRNA target prediction accessible to a broad audience of researchers. Researchers at any level of computational experience can access target prediction data in Rocket-miR within a few minutes. Without such an application, it would take weeks for an experienced bioinformatician with access to high performance computing resources to gather and analyze the same target prediction data for just a single pathogen. While miRNA target prediction databases do exist (<xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B93" ref-type="bibr">93</xref>), they are limited to model organisms and other commonly studied species—not most microbial pathogens such as those that infect people with CF and other diseases. To our knowledge, Rocket-miR is the only data mining tool of its kind that exists for the microbiology community. The Rocket-miR application provides this research community a starting point to develop a new class of miRNA-based antimicrobial therapeutics. Drawing on public genomic sequencing data in bacteria, it aims to encourage new wet bench experiments that will expand the range of treatment options for drug-resistant pathogens. These experiments will also enhance biological understanding of host pathogen miRNA-mRNA interactions.</p>
    <p>As our case studies demonstrate, scientists may use human miRNAs to target individual genes and biological pathways composed of multiple functionally related genes. Targeting KEGG pathways related to antibiotic resistance, biofilm formation, or other virulence traits could help treat drug-resistant infections. Furthermore, while small molecule drugs are traditionally designed to target individual proteins, miRNA-based therapeutics would likely have a much broader effect, disrupting the function of many genes simultaneously. While a bacterium may evolve resistance to a small molecule that targets an individual protein, it is much less likely that this bacterium could evolve to resist an miRNA that is targeting many genes at once (<xref rid="B55" ref-type="bibr">55</xref><xref rid="B56" ref-type="bibr">–</xref><xref rid="B57" ref-type="bibr">57</xref>). An effective therapeutic regimen could even combine miRNA-based drugs with more precise small molecule drugs or traditional antibiotics. As a similar example, engineered vesicles or nanoparticles have been designed for cancer treatment that include both small RNAs or small RNA antagonists and chemotherapeutic agents. In addition to the synergistic effects they enable, these delivery vehicles also make the small RNAs more effective by protecting them from ribonucleases (<xref rid="B94" ref-type="bibr">94</xref><xref rid="B95" ref-type="bibr">–</xref><xref rid="B96" ref-type="bibr">96</xref>).</p>
    <p>The Rocket-miR application encourages researchers to consider not only the possibility of targeting individual pathogens, but also targeting multiple pathogens simultaneously. We have identified a set of miRNAs with predicted broad-spectrum effects across multiple CF pathogens. This includes let-7b-5p, which we have found in previous research to effectively target virulence pathways in <italic toggle="yes">Pseudomonas aeruginosa</italic>. We have further predicted that let-7b-5p will be effective against a community of species including <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">P. melaninogenica</italic>, <italic toggle="yes">S. aureus</italic>, and <italic toggle="yes">S. sanguinis</italic>.</p>
    <p>This analysis extends our understanding of human miRNA-pathogen mRNA interactions. Of the 24 CF pathogens included in the Rocket-miR application, we predict that the fungal species <italic toggle="yes">A. fumigatus</italic> would be most effectively targeted by human miRNAs—with approximately twice as many targeting interactions meeting the application’s medium targeting cutoff than the next best targeted species. An interesting topic of further study would be to explore the underlying reasons for the differences in predicted targeting across species shown in <xref rid="F2 F3" ref-type="fig">Fig. 2 and 3</xref>. Making and testing target predictions for additional species and/or strains of a bacterium may uncover the factors that underlie a pathogen’s susceptibility to targeting by human miRNAs. For example, it may be that the relative evolutionary closeness of <italic toggle="yes">Aspergillus</italic> and other fungal species to humans (i.e., both are eukaryotes) renders them more susceptible to targeting by human miRNAs in general than bacterial species. It is also possible that genomic features like GC content make a given pathogen more or less susceptible to targeting by human miRNAs.</p>
    <p>The pathogen that is predicted to be least effectively targeted by human miRNAs is the common Gram-positive bacterium <italic toggle="yes">S. aureus</italic>, with no human miRNAs predicted to target more than 10% of its genes (<xref rid="F3" ref-type="fig">Fig. 3A</xref>). However, it may be possible to treat less susceptible pathogens like <italic toggle="yes">S. aureus</italic> with a combination of human miRNAs to increase the total number of genes (and biological pathways) that can be effectively targeted (<xref rid="F7" ref-type="fig">Fig. 7</xref>). Investigations along these lines would be worthwhile, as antibiotic-resistant <italic toggle="yes">S. aureus</italic> infections are common in people with CF as well as in hospital-acquired infections (<xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B98" ref-type="bibr">98</xref>). Alternatively, as another way to target <italic toggle="yes">S. aureus</italic> and other CF pathogens as well, it may be possible to design miRNA mimics that are based on human miRNAs but altered in sequence to improve targeting success (<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B100" ref-type="bibr">100</xref>). Researchers could combine IntaRNA target predictions with Rocket-miR’s visualization to compare the predicted effects of their own designed miRNA mimics on <italic toggle="yes">S. aureus</italic> or other human pathogens.</p>
    <p>Though a demonstrably useful tool, the Rocket-miR application does have limitations. One drawback is that the application includes data on only one strain of each human pathogen, as we chose to prioritize including a diverse range of different pathogens rather than multiple strains of a smaller set of pathogens. Two strains of the same species are likely to have a large degree of genetic homology and consequently similar miRNA-targeting prediction data. In support for this assumption, several pairs of species from the same genus (e.g., <italic toggle="yes">B. cenocepacia</italic> and <italic toggle="yes">B. multivorans; C. difficile</italic> and <italic toggle="yes">C. perfringens</italic>) are included in the application and have very similar miRNA-targeting profiles. However, when comparing two strains, one may possess genes that the other lacks, and the sequence homology for a given gene will not be perfect, causing target predictions to differ. Future investigations of strain-specific miRNA targeting would be worthwhile.</p>
    <p>Another concern is challenges related to miRNA-based drug development, including side effects and delivery. As noted in the Introduction, a range of “miRNA mimics” (synthetic compounds that mimic the structure of miRNAs with known therapeutic properties) have been designed and tested in clinical trials for various human cancers, as well as several other diseases (<xref rid="B30" ref-type="bibr">30</xref><xref rid="B31" ref-type="bibr">–</xref><xref rid="B37" ref-type="bibr">37</xref>). However, in 2016, a liver cancer trial for a miR-34a-5p mimic reported serious immune system-related adverse events and the death of four patients (<xref rid="B101" ref-type="bibr">101</xref>). Since 2016, researchers have investigated the causes of the adverse events in this trial, and new approaches are being explored to deliver miRNA-based therapies that would limit dangerous side effects in the future. In the cancer context, this includes encapsulating miRNA mimics in nanoparticles that are designed to delay release of the miRNA until they reach the tumor environment (<xref rid="B102" ref-type="bibr">102</xref>). Research is also ongoing to identify miRNA sequence modifications and new encapsulation methods that would enhance cellular uptake and effectiveness of miRNA mimics inside of cells: curtailing degradation by nucleases in the systemic circulation and degradation within the endosomal compartment (<xref rid="B103" ref-type="bibr">103</xref>).</p>
    <p>To target microbial infections in the lung or gut, delivery of miRNA mimics faces the additional challenge of permeating mucus to reach colonizing microbes. The challenge is especially acute in a disease like CF where mucus is hyper-viscous. Nanoparticles engineered to breach the mucus barrier might overcome this problem (<xref rid="B104" ref-type="bibr">104</xref><xref rid="B105" ref-type="bibr">–</xref><xref rid="B106" ref-type="bibr">106</xref>). Also, to limit the likelihood of off-target side effects, delivery vehicles should be designed to target bacterial cells specifically (<xref rid="B107" ref-type="bibr">107</xref>), just as miRNA-based cancer therapeutics are being designed for selective release in the tumor environment.</p>
    <p>The Rocket-miR application adds to our suite of existing community-oriented bioinformatic tools—including three other R shiny applications (<ext-link xlink:href="http://scangeo.dartmouth.edu/ScanGEO/" ext-link-type="uri">ScanGEO</ext-link>,<ext-link xlink:href="https://iamsoshiny.shinyapps.io/gape/" ext-link-type="uri"> GAPE</ext-link>,<ext-link xlink:href="http://scangeo.dartmouth.edu/CFSeq/" ext-link-type="uri"> CF-Seq</ext-link>) that make insights from public transcriptomic data on human pathogens more accessible to non-computational scientists, and a fourth (<ext-link xlink:href="http://scangeo.dartmouth.edu/ESKAPE/" ext-link-type="uri">ESKAPE Act Plus</ext-link>) that enables researchers without computational experience to perform pathway activation analysis for ESKAPE pathogens (<xref rid="B108" ref-type="bibr">108</xref><xref rid="B109" ref-type="bibr">–</xref><xref rid="B111" ref-type="bibr">111</xref>). We envision Rocket-miR and these other applications as ongoing projects—tools that researchers studying any microbial pathogen can use and extend, to the ultimate benefit of patients with drug-resistant infections. Currently, the Rocket-miR application includes target prediction data for 24 CF pathogens and the so-called ESKAPE pathogens, renowned for their antibiotic resistance and tendency to cause hospital-acquired infections (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). For other human pathogens of interest, researchers can follow the methods outlined in this paper, and the instructions in the Github repository, to build their own version of the application: <ext-link xlink:href="https://github.com/samlo777/Rocket-miR" ext-link-type="uri">https://github.com/samlo777/Rocket-miR</ext-link></p>
  </sec>
  <sec sec-type="materials|methods" id="s4">
    <title>MATERIALS AND METHODS</title>
    <sec id="s4-1">
      <title>Acquiring public sequence data</title>
      <p>The Rocket-miR application includes target prediction data for 24 human pathogens. Making these target predictions required downloading public data from the National Center for Biotechnology Information (NCBI) Assembly database. For each species and particular strain of interest, the genomic coding sequence (CDS) file was downloaded. The coding sequence is the string of nucleotides in an mRNA transcript that corresponds directly to the string of amino acids in the associated protein. Thus, it reflects the state of the transcript after non-coding sequences have been removed by RNA processing (<xref rid="B112" ref-type="bibr">112</xref>, <xref rid="B113" ref-type="bibr">113</xref>).</p>
      <p>Although researchers have traditionally operated on the assumption that human miRNAs target the 3´ untranslated region of human transcripts, more recent research suggests that miRNAs can target other elements of the transcript such as the coding region (<xref rid="B114" ref-type="bibr">114</xref>, <xref rid="B115" ref-type="bibr">115</xref>). Furthermore, IntaRNA target prediction data from our prior study on let-7b-5p targeting of <italic toggle="yes">P. aeruginosa</italic> suggest that in <italic toggle="yes">P. aeruginosa</italic>, human miRNAs are far more likely to interact with the coding region than the untranslated region of the transcript (<xref rid="B38" ref-type="bibr">38</xref>). Thus, the prediction data in the Rocket-miR application are based on coding sequences in CF pathogens (though future efforts to repurpose the application could assess the predicted targeting of non-coding regions as well).</p>
      <p>The CDS file contains the nucleotide sequence of all known protein-encoding genes for a given pathogen strain. It also contains gene identifier metadata that enables the genes to be mapped to KEGG biological pathways. For each of the species in the application, we chose strains that have annotations in the KEGG database, enabling us to make predictions about how specific miRNAs target KEGG pathways.</p>
      <p>The human miRNA sequence data were downloaded from the database MiRGeneDB, which recognizes 630 different human miRNAs as mature miRNA sequences. All the human miRNAs in MiRGeneDB were manually curated by the creators of the database. The creators of MiRGeneDB have noted that other miRNA databases, which encourage community submission of miRNA sequences and include several thousand putative human miRNAs, contain many false positives. Certain sequences labeled as miRNAs may belong to other classes of small RNAs. For this reason, we have chosen the 630 miRNAs in miRGeneDB as the gold standard for human miRNA sequences (<xref rid="B116" ref-type="bibr">116</xref>). That said, researchers may be interested in repurposing the application to predict targets of other small miRNAs. Researchers may also design new miRNA sequences (miRNA mimics) in an attempt to improve on the natural targeting capacity of human miRNAs. In both cases, IntaRNA can be used to make target predictions, which can then be visualized with the Rocket-miR application.</p>
    </sec>
    <sec id="s4-2">
      <title>Predicting miRNA targets</title>
      <p>The IntaRNA target prediction algorithm, designed by the Backofen Lab at the University of Freiburg, predicts hybridization between two RNAs, including miRNA and mRNA (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B117" ref-type="bibr">117</xref>). It considers not only the propensity for nucleotides in the two interacting RNAs to associate, but also the secondary structure of each individual RNA. Before two RNAs can interact, each must adopt an “open,” linearized conformation so that nucleotides in the two molecules are exposed to one another for interaction. If a given RNA has a higher tendency to fold up on itself and form interactions between its own nucleotides, it is less likely to interact with other RNAs, and therefore its predicted interaction score is less favorable.</p>
      <p>IntaRNA was selected as a target prediction algorithm for several reasons. First, databases that provide ready prediction data to the public are limited in scope. The database miRDB, for example, presents millions of predicted targets of miRNAs across five species (human, mouse, rat, dog, and chicken) (<xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B93" ref-type="bibr">93</xref>). However, databases like miRDB are limited to model organisms and other popular species—not microbial pathogens such as those that infect people with CF and other diseases. Though other prediction algorithms like IntaRNA exist that can predict interactions between different RNAs for any species, IntaRNA was chosen because it considers both the nucleotide sequence of pairing miRNAs and the intramolecular interactions of those miRNAs as outlined in the previous paragraph. Other available algorithms—RNAhybrid and RNAplex, for example—tend to focus on nucleotide pairing alone (<xref rid="B118" ref-type="bibr">118</xref>, <xref rid="B119" ref-type="bibr">119</xref>). Finally, the use of IntaRNA is supported by our own prior experience. We have used the algorithm in prior studies to predict miRNA targeting, and these predictions were born out by the results of wet bench experiments (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B52" ref-type="bibr">52</xref>). This gives us confidence in the algorithm’s predictive capacity for human pathogens.</p>
      <p>For each RNA-RNA interaction, IntaRNA calculates an energy score. This energy score is more negative when the interaction between the miRNA and mRNA is stronger. For example, an interaction between a miRNA and mRNA that has an energy score of −15 is predicted to be a stronger interaction than a miRNA-mRNA pair with an energy score of −8. Only negative energy scores are possible. Although RNA molecules possess the nucleotide uracil (U) instead of thymine (T), some RNA sequences in public databases (including those featured in the application) contain Ts in the place of Us. The IntaRNA algorithm recognizes this possibility and automatically converts all thymine nucleotides to uracil in order to predict RNA interactions (see note in the IntaRNA Github Repository:<ext-link xlink:href="https://github.com/BackofenLab/IntaRNA" ext-link-type="uri">
</ext-link><ext-link xlink:href="https://github.com/BackofenLab/IntaRNA" ext-link-type="uri">https://github.com/BackofenLab/IntaRNA</ext-link>).</p>
      <p>The energy cutoffs (strong: −16.98, medium: −15.35, weak, −13.47) in the application are set based on data from our prior work, in which we determined that <italic toggle="yes">Pseudomonas aeruginosa</italic> cells over-expressing let-7b-5p significantly downregulated a set of 48 proteins, with the targeted proteins having a distribution of predicted IntaRNA energy scores [Appendix, pg. 18 (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B38" ref-type="bibr">38</xref>)]. The most stringent cutoff in the application corresponds to the first quartile value in this distribution, the medium targeting cutoff to the median, and the least stringent cutoff to the third quartile value. It is important to note that we chose to limit our analysis to proteins with predicted energy scores less than the least stringent cutoff to be downregulated significantly. Using more stringent cutoffs would increase confidence in the likelihood of targeting but identify fewer candidate miRNAS, a tradeoff that might be suboptimal for species that are less effectively targeted by human miRNAs.</p>
      <p>The IntaRNA program is typically run in a terminal window. When calling the program, a set of query sequences and a set of target sequences are specified in a text-based file. In the context of this study, the query sequence was always set up to contain the set of 630 human miRNA sequences, and the target file contained coding sequences from the different microbial pathogens included in the Rocket-miR application. This computational task was performed on a high-performance computing server. To make the computation more feasible (screening all 630 human miRNAs against 1,000 of mRNA transcripts at once would take up an excessive amount of memory on the server), each CDS file was divided into many small files of 250 mRNA transcripts a piece. Then, the 630 miRNAs were screened against each set of 250 transcripts individually—each with a single call of the IntaRNA algorithm. Using this approach, a microbial pathogen with 4,000 genes requires the IntaRNA algorithm to be applied 16 separate times. Ultimately, the 250-transcript files were stitched back together in a single “Energy Table” for inclusion in the application. All codes used in the command line to run IntaRNA on pathogens of interest, as well as the R script used to consolidate the 250-transcript files into Energy Tables, and data files including the energy tables themselves are available in our GitHub repository:<ext-link xlink:href="https://github.com/samlo777/Rocket-miR" ext-link-type="uri">
</ext-link><ext-link xlink:href="https://github.com/samlo777/Rocket-miR" ext-link-type="uri">https://github.com/samlo777/Rocket-miR</ext-link></p>
    </sec>
    <sec id="s4-3">
      <title>Gathering gene and pathway annotations</title>
      <p>As mentioned above, the microbial strains featured in the application were chosen because they had associated KEGG pathway annotations. This enables users to visualize pathway targeting for their pathogens of interest in addition to the targeting of individual genes. Once the target prediction data were generated for a particular pathogen using IntaRNA, and the “Energy Table” was consolidated, the gene IDs were extracted from that energy table using regex functions from the “stringr” package in R (<xref rid="B120" ref-type="bibr">120</xref>). There are multiple gene IDs housed in the CDS files, though the kinds of IDs present can differ between species. When available, the NCBI Gene ID was extracted. If not, the RefSeq protein ID was extracted.</p>
      <p>Using the ID Mapping feature on the Uniprot website (<ext-link xlink:href="https://www.uniprot.org/id-mapping" ext-link-type="uri">https://www.uniprot.org/id-mapping</ext-link>), NCBI Gene IDs or RefSeq protein IDs were mapped first to Uniprot IDs, and then to KEGG gene IDs in a multistep process (<xref rid="B121" ref-type="bibr">121</xref>). This ID mapping was performed for all the species. In addition, the R “EnrichmentBrowser” package was used to identify the genes on each KEGG pathway (each pathway has its own pathway identifier) (<xref rid="B122" ref-type="bibr">122</xref>). Ultimately, the KEGG gene IDs and KEGG pathway identifiers were all merged into a single table. All gene annotation files are available in the Github repository.</p>
    </sec>
    <sec id="s4-4">
      <title>Application development</title>
      <p>The Rocket-miR application was developed in multiple stages. The first, outlined in the sections above, involved gathering the target prediction and annotation data together in the right format. Once the data were prepared for several pathogens, the various sections of the application were prototyped. The application was carefully designed so that when the time came for new prediction data to be added, it could be seamlessly integrated without changing any of the application code.</p>
      <p>The Rocket-miR application, like all R shiny applications, requires a specific code architecture—a single file labeled app.R with a section for user interface (UI) code (defining the appearance of the application) and a subsequent section for server code (defining the functional code of the application). In addition to the app.R file, a “Data Processing” script was prepared to generate the energy tables for inclusion in the application, and a “Data Setup” script to combine the energy tables with gene annotations. The “Data Setup” file also performed some preliminary calculations on the energy table data so that users of the application could run the application and visualize data more quickly instead of waiting for those calculations to run. All these code files are available in the Github repository.</p>
      <p>The application, developed in R using the RStudio IDE, employs a number of publicly available, open-source R packages (<xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B124" ref-type="bibr">124</xref>). In addition to the “shiny” package, which is required for all shiny applications, the Rocket-miR application makes use of the “shinydashboard” package for its application layout (<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B126" ref-type="bibr">126</xref>). The “shinyjs” package was used to enable users to switch between different modules in the application (<xref rid="B127" ref-type="bibr">127</xref>). The “shinyBS” package was used to create custom buttons (<xref rid="B128" ref-type="bibr">128</xref>). The “DT” package was used to generate data tables that are filterable and searchable (<xref rid="B129" ref-type="bibr">129</xref>). The “stringr” package was used to simplify the text in these tables (e.g., from long gene annotations to a simple gene name) (<xref rid="B120" ref-type="bibr">120</xref>). The “shinycssloaders” package enabled loading animations (<xref rid="B130" ref-type="bibr">130</xref>). Finally, for data analysis and visualization, the “plotly” package was used to create interactive figures, and the “kmer” package was utilized to analyze the structure of miRNA sequences (<xref rid="B131" ref-type="bibr">131</xref>, <xref rid="B132" ref-type="bibr">132</xref>).</p>
    </sec>
    <sec id="s4-5">
      <title><italic toggle="yes">In vitro</italic> validation experiment</title>
      <p>PA14 was electroporated to introduce a pMQ70 expression vector (with arabinose-inducible promoter and carbenicillin resistance as selectable marker) containing either the mature let-7b-5p sequence as an insert (PA14-let-7b-5p) or no insert (PA14-Empty vector), as described previously (<xref rid="B38" ref-type="bibr">38</xref>). The glycerol stocks of these two strains were first streaked out on two different Luria broth (LB) agar plates containing 300 µg/mL carbenicillin. The colonies from the plates were then inoculated in LB broth containing 150 µg/mL carbenicillin for two overnight grow-ups. Twenty-five thousand CFU per mL of the control strain or PA14-let-7b-5p was then plated in MBEC Assay Biofilm Inoculator Plates (Innovotech) with 100 µM arabinose to induce the expression from the promoters and with or without 1.2 µg/mL aztreonam. The plate was placed on a shaker at 110 rpm and 37°C. Twenty-four hours later, the coverlid, composed of the pegs, was washed twice with PBS++ (ThermoFisher DPBS with added calcium and magnesium). The coverlid was then placed into a new 96-well plate containing 200 µL fresh LB/well and sonicated for 10 min in a water-bath sonicator (VWR Symphony model). The LB from the wells was serially diluted, plated on LB agar plates, and incubated overnight at 37°C. CFU were counted and final counts were adjusted by multiplying the dilution factor. Data were analyzed using GraphPad Prism (version 9.1.2; San Diego, CA) and the R software environment for statistical computing and graphics version 4.1.0 (<xref rid="B123" ref-type="bibr">123</xref>). The R package MASS was used to calculate <italic toggle="yes">P</italic>-values from the binomial generalized linear models (<xref rid="B133" ref-type="bibr">133</xref>).</p>
    </sec>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="d96e291">
      <caption>
        <title>Reviewer comments</title>
      </caption>
      <media xlink:href="reviewer-comments.pdf"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <title>ACKNOWLEDGMENTS</title>
    <p>Support for these studies was provided by the Cystic Fibrosis Foundation (STANTO19R0–CFF), the NIH (grants P30 DK117469, R01 HL151385, R35 GM142685), and The Flatley Foundation.</p>
    <p>S.L.N. developed the Rocket-miR application and wrote the manuscript apart from the case studies. T.H.H. and K.K. helped guide the initial formulation of the project. T.H.H. provided helpful feedback on the application and manuscript throughout their development. K.K. contributed code enabling the miRNA target predictions that form the basis of the application. S.S. contributed the first two case studies, while C.J.L. and B.D.R. contributed the third. T.H.H., K.K., S.S., C.J.L., B.D.R., and B.A.S. all provided input on the development of the application and contributed to manuscript preparation for submission.</p>
  </ack>
  <sec sec-type="data-availability" id="s5-1">
    <title>DATA AVAILABILITY</title>
    <p>The source code for the Rocket-miR application was written in R, using the R Studio integrated development environment. The application is accessible online at the following address:<ext-link xlink:href="http://scangeo.dartmouth.edu/RocketmiR/" ext-link-type="uri">
</ext-link><ext-link xlink:href="http://scangeo.dartmouth.edu/RocketmiR/" ext-link-type="uri">http://scangeo.dartmouth.edu/RocketmiR/</ext-link>. The source code and application data are accessible in our Github Repository and can be run independently using RStudio on a personal device by following the instructions in the repository’s README file:<ext-link xlink:href="https://github.com/samlo777/Rocket-miR" ext-link-type="uri">
</ext-link><ext-link xlink:href="https://github.com/samlo777/Rocket-miR" ext-link-type="uri">https://github.com/samlo777/Rocket-miR</ext-link>.</p>
  </sec>
  <sec sec-type="supplementary-material" id="s5-2">
    <title>SUPPLEMENTAL MATERIAL</title>
    <p specific-use="print-only">The following material is available online at <ext-link xlink:href="https://doi.org/10.1128/msystems.00653-23" ext-link-type="uri">https://doi.org/10.1128/msystems.00653-23</ext-link>.</p>
    <supplementary-material id="SuF1" position="float" content-type="local-data">
      <object-id pub-id-type="doi">10.1128/msystems.00653-23.SuF1</object-id>
      <label>Supplemental figures</label>
      <caption>
        <title>msystems.00653-23-s0001.pdf</title>
        <p>Fig. S1 to S5.</p>
      </caption>
      <media xlink:href="msystems.00653-23-s0001.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="SuF2" position="float" content-type="local-data">
      <object-id pub-id-type="doi">10.1128/msystems.00653-23.SuF2</object-id>
      <label>OPEN PEER REVIEW</label>
      <caption>
        <title>reviewer-comments.pdf</title>
      </caption>
      <media xlink:href="reviewer-comments.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <p specific-use="online-only">ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse. </p>
  </sec>
  <ref-list>
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1</label>
      <mixed-citation publication-type="journal">. <person-group person-group-type="author"><collab>CDC</collab></person-group>. <year>2022</year>. <article-title>What Exactly is Antibiotic Resistance?</article-title>
<source>Centers for Disease Control and Prevention</source>. <ext-link xlink:href="https://www.cdc.gov/drugresistance/about.html" ext-link-type="uri">https://www.cdc.gov/drugresistance/about.html</ext-link>. <date-in-citation>13 April 2023</date-in-citation>.</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Murray</surname><given-names>CJL</given-names></string-name>, <string-name><surname>Ikuta</surname><given-names>KS</given-names></string-name>, <string-name><surname>Sharara</surname><given-names>F</given-names></string-name>, <string-name><surname>Swetschinski</surname><given-names>L</given-names></string-name>, <string-name><surname>Robles Aguilar</surname><given-names>G</given-names></string-name>, <string-name><surname>Gray</surname><given-names>A</given-names></string-name>, <string-name><surname>Han</surname><given-names>C</given-names></string-name>, <string-name><surname>Bisignano</surname><given-names>C</given-names></string-name>, <string-name><surname>Rao</surname><given-names>P</given-names></string-name>, <string-name><surname>Wool</surname><given-names>E</given-names></string-name>, <etal>et al.</etal></person-group>. <year>2022</year>. <article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title>. <source>The Lancet</source><volume>399</volume>:<fpage>629</fpage>–<lpage>655</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3</label>
      <mixed-citation publication-type="webpage"><article-title>Stemming the Superbug tide: Just A few dollars more | en | OECD</article-title>. <year>2022</year>. <comment>Available from</comment>: <ext-link xlink:href="https://www.oecd.org/health/stemming-the-superbug-tide-9789264307599-en.htm" ext-link-type="uri">https://www.oecd.org/health/stemming-the-superbug-tide-9789264307599-en.htm</ext-link></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4</label>
      <mixed-citation publication-type="webpage"><article-title>Lack of innovation set to undermine antibiotic performance and health gains</article-title>. <year>2023</year>. <comment>Available from</comment>: <ext-link xlink:href="https://www.who.int/news/item/22-06-2022-22-06-2022-lack-of-innovation-set-to-undermine-antibiotic-performance-and-health-gains" ext-link-type="uri">https://www.who.int/news/item/22-06-2022-22-06-2022-lack-of-innovation-set-to-undermine-antibiotic-performance-and-health-gains</ext-link></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mulani</surname><given-names>MS</given-names></string-name>, <string-name><surname>Kamble</surname><given-names>EE</given-names></string-name>, <string-name><surname>Kumkar</surname><given-names>SN</given-names></string-name>, <string-name><surname>Tawre</surname><given-names>MS</given-names></string-name>, <string-name><surname>Pardesi</surname><given-names>KR</given-names></string-name></person-group>. <year>2019</year>. <article-title>Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review</article-title>. <source>Front Microbiol</source><volume>10</volume>:<elocation-id>539</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2019.00539</pub-id>doi:<ext-link xlink:href="30988669" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30988669</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6</label>
      <mixed-citation publication-type="webpage"><article-title>WHO publishes list of bacteria for which new antibiotics are urgently needed</article-title>. <year>2022</year>. <comment>Available from</comment>: <ext-link xlink:href="https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed" ext-link-type="uri">https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed</ext-link></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parkins</surname><given-names>MD</given-names></string-name>, <string-name><surname>Somayaji</surname><given-names>R</given-names></string-name>, <string-name><surname>Waters</surname><given-names>VJ</given-names></string-name></person-group>. <year>2018</year>. <article-title>Epidemiology, biology, and impact of clonal Pseudomonas aeruginosa infections in cystic fibrosis</article-title>. <source>Clin Microbiol Rev</source><volume>31</volume>:<elocation-id>e00019-18</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/CMR.00019-18</pub-id>doi:<ext-link xlink:href="30158299" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30158299</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>LiPuma</surname><given-names>JJ</given-names></string-name></person-group>. <year>2010</year>. <article-title>The changing microbial epidemiology in cystic fibrosis</article-title>. <source>Clin Microbiol Rev</source><volume>23</volume>:<fpage>299</fpage>–<lpage>323</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CMR.00068-09</pub-id>doi:<ext-link xlink:href="20375354" ext-link-type="pmid"/><pub-id pub-id-type="pmid">20375354</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kreda</surname><given-names>SM</given-names></string-name>, <string-name><surname>Davis</surname><given-names>CW</given-names></string-name>, <string-name><surname>Rose</surname><given-names>MC</given-names></string-name></person-group>. <year>2012</year>. <article-title>CFTR, mucins, and mucus obstruction in cystic fibrosis</article-title>. <source>Cold Spring Harb Perspect Med</source><volume>2</volume>:<elocation-id>a009589</elocation-id>. doi:<pub-id pub-id-type="doi">10.1101/cshperspect.a009589</pub-id>doi:<ext-link xlink:href="22951447" ext-link-type="pmid"/><pub-id pub-id-type="pmid">22951447</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rubin</surname><given-names>BK</given-names></string-name></person-group>. <year>2007</year>. <article-title>Mucus structure and properties in cystic fibrosis</article-title>. <source>Paediatr Respir Rev</source><volume>8</volume>:<fpage>4</fpage>–<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.prrv.2007.02.004</pub-id>doi:<ext-link xlink:href="17419972" ext-link-type="pmid"/><pub-id pub-id-type="pmid">17419972</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Livraghi</surname><given-names>A</given-names></string-name>, <string-name><surname>Randell</surname><given-names>SH</given-names></string-name></person-group>. <year>2007</year>. <article-title>Cystic fibrosis and other respiratory diseases of impaired mucus clearance</article-title>. <source>Toxicol pathol</source><volume>35</volume>:<fpage>116</fpage>–<lpage>129</lpage>. doi:<pub-id pub-id-type="doi">10.1080/01926230601060025</pub-id>doi:<ext-link xlink:href="17325980" ext-link-type="pmid"/><pub-id pub-id-type="pmid">17325980</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Esther</surname><given-names>CR</given-names></string-name>, <string-name><surname>Muhlebach</surname><given-names>MS</given-names></string-name>, <string-name><surname>Ehre</surname><given-names>C</given-names></string-name>, <string-name><surname>Hill</surname><given-names>DB</given-names></string-name>, <string-name><surname>Wolfgang</surname><given-names>MC</given-names></string-name>, <string-name><surname>Kesimer</surname><given-names>M</given-names></string-name>, <string-name><surname>Ramsey</surname><given-names>KA</given-names></string-name>, <string-name><surname>Markovetz</surname><given-names>MR</given-names></string-name>, <string-name><surname>Garbarine</surname><given-names>IC</given-names></string-name>, <string-name><surname>Forest</surname><given-names>MG</given-names></string-name>, <string-name><surname>Seim</surname><given-names>I</given-names></string-name>, <string-name><surname>Zorn</surname><given-names>B</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>CB</given-names></string-name>, <string-name><surname>Delion</surname><given-names>MF</given-names></string-name>, <string-name><surname>Thelin</surname><given-names>WR</given-names></string-name>, <string-name><surname>Villalon</surname><given-names>D</given-names></string-name>, <string-name><surname>Sabater</surname><given-names>JR</given-names></string-name>, <string-name><surname>Turkovic</surname><given-names>L</given-names></string-name>, <string-name><surname>Ranganathan</surname><given-names>S</given-names></string-name>, <string-name><surname>Stick</surname><given-names>SM</given-names></string-name>, <string-name><surname>Boucher</surname><given-names>RC</given-names></string-name></person-group>. <year>2019</year>. <article-title>Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis</article-title>. <source>Sci Transl Med</source><volume>11</volume>:<elocation-id>eaav3488</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.aav3488</pub-id>doi:<ext-link xlink:href="30944166" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30944166</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Durda-Masny</surname><given-names>M</given-names></string-name>, <string-name><surname>Goździk-Spychalska</surname><given-names>J</given-names></string-name>, <string-name><surname>John</surname><given-names>A</given-names></string-name>, <string-name><surname>Czaiński</surname><given-names>W</given-names></string-name>, <string-name><surname>Stróżewska</surname><given-names>W</given-names></string-name>, <string-name><surname>Pawłowska</surname><given-names>N</given-names></string-name>, <string-name><surname>Wlizło</surname><given-names>J</given-names></string-name>, <string-name><surname>Batura-Gabryel</surname><given-names>H</given-names></string-name>, <string-name><surname>Szwed</surname><given-names>A</given-names></string-name></person-group>. <year>2021</year>. <article-title>The determinants of survival among adults with cystic fibrosis-a cohort study</article-title>. <source>J Physiol Anthropol</source><volume>40</volume>:<fpage>19</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40101-021-00269-7</pub-id>doi:<ext-link xlink:href="34749804" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34749804</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bonyadi</surname><given-names>P</given-names></string-name>, <string-name><surname>Saleh</surname><given-names>NT</given-names></string-name>, <string-name><surname>Dehghani</surname><given-names>M</given-names></string-name>, <string-name><surname>Yamini</surname><given-names>M</given-names></string-name>, <string-name><surname>Amini</surname><given-names>K</given-names></string-name></person-group>. <year>2022</year>. <article-title>Prevalence of antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis infection: a systematic review and meta-analysis</article-title>. <source>Microb Pathog</source><volume>165</volume>:<fpage>105461</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.micpath.2022.105461</pub-id>doi:<ext-link xlink:href="35240288" ext-link-type="pmid"/><pub-id pub-id-type="pmid">35240288</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blanchard</surname><given-names>AC</given-names></string-name>, <string-name><surname>Waters</surname><given-names>VJ</given-names></string-name></person-group>. <year>2022</year>. <article-title>Opportunistic pathogens in cystic fibrosis: epidemiology and pathogenesis of lung infection</article-title>. <source>J Pediatric Infect Dis Soc</source><volume>11</volume>:<fpage>S3</fpage>–<lpage>S12</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jpids/piac052</pub-id>doi:<ext-link xlink:href="36069904" ext-link-type="pmid"/><pub-id pub-id-type="pmid">36069904</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gilpin</surname><given-names>D</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>LR</given-names></string-name>, <string-name><surname>Ceppe</surname><given-names>A</given-names></string-name>, <string-name><surname>Muhlebach</surname><given-names>MS</given-names></string-name></person-group>. <year>2021</year>. <article-title>Phenotypic characteristics of incident and chronic MRSA isolates in cystic fibrosis</article-title>. <source>J Cyst Fibros</source><volume>20</volume>:<fpage>692</fpage>–<lpage>698</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jcf.2021.05.015</pub-id>doi:<ext-link xlink:href="34103251" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34103251</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17</label>
      <mixed-citation publication-type="webpage"><article-title>Prevalence and antibiotic resistance of Stenotrophomonas maltophilia in respiratory tract samples: a 10-year epidemiological snapshot - PMC</article-title>. <year>2022</year>. <comment>Available from</comment>: <ext-link xlink:href="Https://Www.Ncbi.Nlm.NIH.Gov/Pmc/articles/Pmc6698998/" ext-link-type="uri">Https://Www.Ncbi.Nlm.NIH.Gov/Pmc/articles/Pmc6698998/</ext-link>. <comment>Retrieved</comment><date-in-citation>14 September 2022</date-in-citation>.</mixed-citation>
    </ref>
    <ref id="B18">
      <label>18</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>WX</given-names></string-name>, <string-name><surname>Lei</surname><given-names>X</given-names></string-name>, <string-name><surname>Ai</surname><given-names>HL</given-names></string-name>, <string-name><surname>Bai</surname><given-names>X</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>He</surname><given-names>J</given-names></string-name>, <string-name><surname>Li</surname><given-names>ZH</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>YS</given-names></string-name>, <string-name><surname>Feng</surname><given-names>T</given-names></string-name>, <string-name><surname>Liu</surname><given-names>JK</given-names></string-name></person-group>. <year>2019</year>. <article-title>Cytochalasans from the endophytic fungus xylaria cf. curta with resistance reversal activity against fluconazole-resistant Candida albicans</article-title>. <source>Org Lett</source><volume>21</volume>:<fpage>1108</fpage>–<lpage>1111</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.orglett.9b00015</pub-id>doi:<ext-link xlink:href="30681869" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30681869</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Risum</surname><given-names>M</given-names></string-name>, <string-name><surname>Hare</surname><given-names>RK</given-names></string-name>, <string-name><surname>Gertsen</surname><given-names>JB</given-names></string-name>, <string-name><surname>Kristensen</surname><given-names>L</given-names></string-name>, <string-name><surname>Johansen</surname><given-names>HK</given-names></string-name>, <string-name><surname>Helweg-Larsen</surname><given-names>J</given-names></string-name>, <string-name><surname>Abou-Chakra</surname><given-names>N</given-names></string-name>, <string-name><surname>Pressler</surname><given-names>T</given-names></string-name>, <string-name><surname>Skov</surname><given-names>M</given-names></string-name>, <string-name><surname>Jensen-Fangel</surname><given-names>S</given-names></string-name>, <string-name><surname>Arendrup</surname><given-names>MC</given-names></string-name></person-group>. <year>2020</year>. <article-title>Azole-resistant Aspergillus Fumigatus among Danish cystic fibrosis patients: Increasing prevalence and dominance of Tr34/L98H. frontiers in Microbiology</article-title>. <source>Front. Microbiol</source><volume>11</volume>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2020.01850</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Varela</surname><given-names>MC</given-names></string-name>, <string-name><surname>Roch</surname><given-names>M</given-names></string-name>, <string-name><surname>Taglialegna</surname><given-names>A</given-names></string-name>, <string-name><surname>Long</surname><given-names>SW</given-names></string-name>, <string-name><surname>Saavedra</surname><given-names>MO</given-names></string-name>, <string-name><surname>Rose</surname><given-names>WE</given-names></string-name>, <string-name><surname>Davis</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>LR</given-names></string-name>, <string-name><surname>Hernandez</surname><given-names>RE</given-names></string-name>, <string-name><surname>Rosato</surname><given-names>RR</given-names></string-name>, <string-name><surname>Rosato</surname><given-names>AE</given-names></string-name></person-group>. <year>2020</year>. <article-title>Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA</article-title>. <source>Commun Biol</source><volume>3</volume>:<fpage>599</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s42003-020-01313-5</pub-id>doi:<ext-link xlink:href="33093601" ext-link-type="pmid"/><pub-id pub-id-type="pmid">33093601</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scoffone</surname><given-names>VC</given-names></string-name>, <string-name><surname>Barbieri</surname><given-names>G</given-names></string-name>, <string-name><surname>Buroni</surname><given-names>S</given-names></string-name>, <string-name><surname>Scarselli</surname><given-names>M</given-names></string-name>, <string-name><surname>Pizza</surname><given-names>M</given-names></string-name>, <string-name><surname>Rappuoli</surname><given-names>R</given-names></string-name>, <string-name><surname>Riccardi</surname><given-names>G</given-names></string-name></person-group>. <year>2020</year>. <article-title>Vaccines to overcome antibiotic resistance: the challenge of Burkholderia cenocepacia</article-title>. <source>Trends Microbiol</source><volume>28</volume>:<fpage>315</fpage>–<lpage>326</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tim.2019.12.005</pub-id>doi:<ext-link xlink:href="31932141" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31932141</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Degiacomi</surname><given-names>G</given-names></string-name>, <string-name><surname>Sammartino</surname><given-names>JC</given-names></string-name>, <string-name><surname>Chiarelli</surname><given-names>LR</given-names></string-name>, <string-name><surname>Riabova</surname><given-names>O</given-names></string-name>, <string-name><surname>Makarov</surname><given-names>V</given-names></string-name>, <string-name><surname>Pasca</surname><given-names>MR</given-names></string-name></person-group>. <year>2019</year>. <article-title>Mycobacterium abscessus, an emerging and worrisome pathogen among cystic fibrosis patients</article-title>. <source>Int J Mol Sci</source><volume>20</volume>:<elocation-id>5868</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/ijms20235868</pub-id>doi:<ext-link xlink:href="31766758" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31766758</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Henrichfreise</surname><given-names>B</given-names></string-name>, <string-name><surname>Wiegand</surname><given-names>I</given-names></string-name>, <string-name><surname>Pfister</surname><given-names>W</given-names></string-name>, <string-name><surname>Wiedemann</surname><given-names>B</given-names></string-name></person-group>. <year>2007</year>. <article-title>Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation</article-title>. <source>Antimicrob Agents Chemother</source><volume>51</volume>:<fpage>4062</fpage>–<lpage>4070</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00148-07</pub-id>doi:<ext-link xlink:href="17876002" ext-link-type="pmid"/><pub-id pub-id-type="pmid">17876002</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ciofu</surname><given-names>O</given-names></string-name>, <string-name><surname>Tolker-Nielsen</surname><given-names>T</given-names></string-name></person-group>. <year>2019</year>. <article-title>Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents-how P. aeruginosa can escape antibiotics</article-title>. <source>Front Microbiol</source><volume>10</volume>:<fpage>913</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2019.00913</pub-id>doi:<ext-link xlink:href="31130925" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31130925</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25</label>
      <mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name><surname>Parry</surname><given-names>J</given-names></string-name></person-group>. <year>2022</year>. <article-title>New Yale center to advance Phage understanding, treatments, training, education</article-title>. <comment>Available from</comment>: <ext-link xlink:href="https://medicine.yale.edu/news-article/new-yale-center-to-advance-phage-understanding-treatments-training-education/" ext-link-type="uri">https://medicine.yale.edu/news-article/new-yale-center-to-advance-phage-understanding-treatments-training-education/</ext-link>. <comment>Retrieved</comment><date-in-citation>6 Dec 2022</date-in-citation>.</mixed-citation>
    </ref>
    <ref id="B26">
      <label>26</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chan</surname><given-names>BK</given-names></string-name>, <string-name><surname>Stanley</surname><given-names>G</given-names></string-name>, <string-name><surname>Modak</surname><given-names>M</given-names></string-name>, <string-name><surname>Koff</surname><given-names>JL</given-names></string-name>, <string-name><surname>Turner</surname><given-names>PE</given-names></string-name></person-group>. <year>2021</year>. <article-title>Bacteriophage therapy for infections in CF</article-title>. <source>Pediatr Pulmonol</source><volume>56</volume>:<fpage>S4</fpage>–<lpage>S9</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ppul.25190</pub-id>doi:<ext-link xlink:href="33434411" ext-link-type="pmid"/><pub-id pub-id-type="pmid">33434411</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koff</surname><given-names>J</given-names></string-name></person-group>. <year>2022</year>. <article-title>Cystic fibrosis bacterioPHage study at yale (CYPHY): a single-site, randomized, double-blind, placebo-controlled study of bacteriophage therapy YPT-01 for Pseudomonas aeruginosa infections in adults with cystic fibrosis</article-title>. <source>Clinical trial registration. clinicaltrials.gov</source></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johansen</surname><given-names>MD</given-names></string-name>, <string-name><surname>Alcaraz</surname><given-names>M</given-names></string-name>, <string-name><surname>Dedrick</surname><given-names>RM</given-names></string-name>, <string-name><surname>Roquet-Banères</surname><given-names>F</given-names></string-name>, <string-name><surname>Hamela</surname><given-names>C</given-names></string-name>, <string-name><surname>Hatfull</surname><given-names>GF</given-names></string-name>, <string-name><surname>Kremer</surname><given-names>L</given-names></string-name></person-group>. <year>2021</year>. <article-title>Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus</article-title>. <source>Dis Model Mech</source><volume>14</volume>:<elocation-id>dmm049159</elocation-id>. doi:<pub-id pub-id-type="doi">10.1242/dmm.049159</pub-id>doi:<ext-link xlink:href="34530447" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34530447</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lauman</surname><given-names>P</given-names></string-name>, <string-name><surname>Dennis</surname><given-names>JJ</given-names></string-name></person-group>. <year>2021</year>. <article-title>Advances in phage therapy: targeting the Burkholderia cepacia complex</article-title>. <source>Viruses</source><volume>13</volume>:<elocation-id>1331</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/v13071331</pub-id>doi:<ext-link xlink:href="34372537" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34372537</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reid</surname><given-names>G</given-names></string-name>, <string-name><surname>Kao</surname><given-names>SC</given-names></string-name>, <string-name><surname>Pavlakis</surname><given-names>N</given-names></string-name>, <string-name><surname>Brahmbhatt</surname><given-names>H</given-names></string-name>, <string-name><surname>MacDiarmid</surname><given-names>J</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>S</given-names></string-name>, <string-name><surname>Boyer</surname><given-names>M</given-names></string-name>, <string-name><surname>van Zandwijk</surname><given-names>N</given-names></string-name></person-group>. <year>2016</year>. <article-title>Clinical development of targomirs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer</article-title>. <source>Epigenomics</source><volume>8</volume>:<fpage>1079</fpage>–<lpage>1085</lpage>. doi:<pub-id pub-id-type="doi">10.2217/epi-2016-0035</pub-id>doi:<ext-link xlink:href="27185582" ext-link-type="pmid"/><pub-id pub-id-type="pmid">27185582</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Zandwijk</surname><given-names>N</given-names></string-name>, <string-name><surname>Pavlakis</surname><given-names>N</given-names></string-name>, <string-name><surname>Kao</surname><given-names>SC</given-names></string-name>, <string-name><surname>Linton</surname><given-names>A</given-names></string-name>, <string-name><surname>Boyer</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>S</given-names></string-name>, <string-name><surname>Huynh</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chrzanowska</surname><given-names>A</given-names></string-name>, <string-name><surname>Fulham</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Bailey</surname><given-names>DL</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>WA</given-names></string-name>, <string-name><surname>Kritharides</surname><given-names>L</given-names></string-name>, <string-name><surname>Ridley</surname><given-names>L</given-names></string-name>, <string-name><surname>Pattison</surname><given-names>ST</given-names></string-name>, <string-name><surname>MacDiarmid</surname><given-names>J</given-names></string-name>, <string-name><surname>Brahmbhatt</surname><given-names>H</given-names></string-name>, <string-name><surname>Reid</surname><given-names>G</given-names></string-name></person-group>. <year>2017</year>. <article-title>Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study</article-title>. <source>Lancet Oncol</source><volume>18</volume>:<fpage>1386</fpage>–<lpage>1396</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(17)30621-6</pub-id>doi:<ext-link xlink:href="28870611" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28870611</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reid</surname><given-names>G</given-names></string-name>, <string-name><surname>Pel</surname><given-names>ME</given-names></string-name>, <string-name><surname>Kirschner</surname><given-names>MB</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>YY</given-names></string-name>, <string-name><surname>Mugridge</surname><given-names>N</given-names></string-name>, <string-name><surname>Weiss</surname><given-names>J</given-names></string-name>, <string-name><surname>Williams</surname><given-names>M</given-names></string-name>, <string-name><surname>Wright</surname><given-names>C</given-names></string-name>, <string-name><surname>Edelman</surname><given-names>JJB</given-names></string-name>, <string-name><surname>Vallely</surname><given-names>MP</given-names></string-name>, <string-name><surname>McCaughan</surname><given-names>BC</given-names></string-name>, <string-name><surname>Klebe</surname><given-names>S</given-names></string-name>, <string-name><surname>Brahmbhatt</surname><given-names>H</given-names></string-name>, <string-name><surname>MacDiarmid</surname><given-names>JA</given-names></string-name>, <string-name><surname>van Zandwijk</surname><given-names>N</given-names></string-name></person-group>. <year>2013</year>. <article-title>Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma</article-title>. <source>Ann Oncol</source><volume>24</volume>:<fpage>3128</fpage>–<lpage>3135</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdt412</pub-id>doi:<ext-link xlink:href="24148817" ext-link-type="pmid"/><pub-id pub-id-type="pmid">24148817</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beg</surname><given-names>MS</given-names></string-name>, <string-name><surname>Brenner</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Sachdev</surname><given-names>J</given-names></string-name>, <string-name><surname>Borad</surname><given-names>M</given-names></string-name>, <string-name><surname>Kang</surname><given-names>Y-K</given-names></string-name>, <string-name><surname>Stoudemire</surname><given-names>J</given-names></string-name>, <string-name><surname>Smith</surname><given-names>S</given-names></string-name>, <string-name><surname>Bader</surname><given-names>AG</given-names></string-name>, <string-name><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name><surname>Hong</surname><given-names>DS</given-names></string-name></person-group>. <year>2017</year>. <article-title>Phase I study of Mrx34, a liposomal miR-34A mimic, administered twice weekly in patients with advanced solid tumors</article-title>. <source>Invest New Drugs</source><volume>35</volume>:<fpage>180</fpage>–<lpage>188</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10637-016-0407-y</pub-id>doi:<ext-link xlink:href="27917453" ext-link-type="pmid"/><pub-id pub-id-type="pmid">27917453</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Daige</surname><given-names>CL</given-names></string-name>, <string-name><surname>Wiggins</surname><given-names>JF</given-names></string-name>, <string-name><surname>Priddy</surname><given-names>L</given-names></string-name>, <string-name><surname>Nelligan-Davis</surname><given-names>T</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name><surname>Brown</surname><given-names>D</given-names></string-name></person-group>. <year>2014</year>. <article-title>Systemic delivery of a Mir34A mimic as a potential therapeutic for liver cancer</article-title>. <source>Mol Cancer Ther</source><volume>13</volume>:<fpage>2352</fpage>–<lpage>2360</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0209</pub-id>doi:<ext-link xlink:href="25053820" ext-link-type="pmid"/><pub-id pub-id-type="pmid">25053820</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keskin</surname><given-names>S</given-names></string-name>, <string-name><surname>Brouwers</surname><given-names>CC</given-names></string-name>, <string-name><surname>Sogorb-Gonzalez</surname><given-names>M</given-names></string-name>, <string-name><surname>Martier</surname><given-names>R</given-names></string-name>, <string-name><surname>Depla</surname><given-names>JA</given-names></string-name>, <string-name><surname>Vallès</surname><given-names>A</given-names></string-name>, <string-name><surname>van Deventer</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Konstantinova</surname><given-names>P</given-names></string-name>, <string-name><surname>Evers</surname><given-names>MM</given-names></string-name></person-group>. <year>2019</year>. <article-title>Aav5-miHTT Lower huntingtin mRNA and protein without off-target effects in patient-derived neuronal cultures and astrocytes</article-title>. <source>Mol Ther Methods Clin Dev</source><volume>15</volume>:<fpage>275</fpage>–<lpage>284</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.omtm.2019.09.010</pub-id>doi:<ext-link xlink:href="31737741" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31737741</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miniarikova</surname><given-names>J</given-names></string-name>, <string-name><surname>Zanella</surname><given-names>I</given-names></string-name>, <string-name><surname>Huseinovic</surname><given-names>A</given-names></string-name>, <string-name><surname>van der Zon</surname><given-names>T</given-names></string-name>, <string-name><surname>Hanemaaijer</surname><given-names>E</given-names></string-name>, <string-name><surname>Martier</surname><given-names>R</given-names></string-name>, <string-name><surname>Koornneef</surname><given-names>A</given-names></string-name>, <string-name><surname>Southwell</surname><given-names>AL</given-names></string-name>, <string-name><surname>Hayden</surname><given-names>MR</given-names></string-name>, <string-name><surname>van Deventer</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Petry</surname><given-names>H</given-names></string-name>, <string-name><surname>Konstantinova</surname><given-names>P</given-names></string-name></person-group>. <year>2016</year>. <article-title>Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for huntington's disease</article-title>. <source>Mol Ther Nucleic Acids</source><volume>5</volume>:<elocation-id>e297</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/mtna.2016.7</pub-id>doi:<ext-link xlink:href="27003755" ext-link-type="pmid"/><pub-id pub-id-type="pmid">27003755</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gallant-Behm</surname><given-names>CL</given-names></string-name>, <string-name><surname>Piper</surname><given-names>J</given-names></string-name>, <string-name><surname>Lynch</surname><given-names>JM</given-names></string-name>, <string-name><surname>Seto</surname><given-names>AG</given-names></string-name>, <string-name><surname>Hong</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Mustoe</surname><given-names>TA</given-names></string-name>, <string-name><surname>Maari</surname><given-names>C</given-names></string-name>, <string-name><surname>Pestano</surname><given-names>LA</given-names></string-name>, <string-name><surname>Dalby</surname><given-names>CM</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>AL</given-names></string-name>, <string-name><surname>Rubin</surname><given-names>P</given-names></string-name>, <string-name><surname>Marshall</surname><given-names>WS</given-names></string-name></person-group>. <year>2019</year>. <article-title>A microrna-29 mimic (Remlarsen) represses extracellular matrix expression and fibroplasia in the skin</article-title>. <source>J Invest Dermatol</source><volume>139</volume>:<fpage>1073</fpage>–<lpage>1081</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jid.2018.11.007</pub-id>doi:<ext-link xlink:href="30472058" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30472058</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koeppen</surname><given-names>K</given-names></string-name>, <string-name><surname>Nymon</surname><given-names>A</given-names></string-name>, <string-name><surname>Barnaby</surname><given-names>R</given-names></string-name>, <string-name><surname>Bashor</surname><given-names>L</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name>, <string-name><surname>Liefeld</surname><given-names>AE</given-names></string-name>, <string-name><surname>Kolling</surname><given-names>FW</given-names></string-name>, <string-name><surname>LaCroix</surname><given-names>IS</given-names></string-name>, <string-name><surname>Gerber</surname><given-names>SA</given-names></string-name>, <string-name><surname>Hogan</surname><given-names>DA</given-names></string-name>, <string-name><surname>Kasetty</surname><given-names>S</given-names></string-name>, <string-name><surname>Nadell</surname><given-names>CD</given-names></string-name>, <string-name><surname>Stanton</surname><given-names>BA</given-names></string-name></person-group>. <year>2021</year>. <article-title>Let-7B-5P in vesicles secreted by human airway cells reduces biofilm formation and increases antibiotic sensitivity of P. aeruginosa</article-title>. <source>Proc Natl Acad Sci USA</source><volume>118</volume>:<elocation-id>e2105370118</elocation-id>. doi:<pub-id pub-id-type="doi">10.1073/pnas.2105370118</pub-id>doi:<ext-link xlink:href="34260396" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34260396</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Dean</surname><given-names>RA</given-names></string-name></person-group>. <year>2020</year>. <article-title>Movement of small Rnas in and between plants and fungi</article-title>. <source>Mol Plant Pathol</source><volume>21</volume>:<fpage>589</fpage>–<lpage>601</lpage>. doi:<pub-id pub-id-type="doi">10.1111/mpp.12911</pub-id>doi:<ext-link xlink:href="32027079" ext-link-type="pmid"/><pub-id pub-id-type="pmid">32027079</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cai</surname><given-names>Q</given-names></string-name>, <string-name><surname>Qiao</surname><given-names>L</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>He</surname><given-names>B</given-names></string-name>, <string-name><surname>Lin</surname><given-names>FM</given-names></string-name>, <string-name><surname>Palmquist</surname><given-names>J</given-names></string-name>, <string-name><surname>Huang</surname><given-names>SD</given-names></string-name>, <string-name><surname>Jin</surname><given-names>H</given-names></string-name></person-group>. <year>2018</year>. <article-title>Plants send small Rnas in extracellular vesicles to fungal pathogen to silence virulence genes</article-title>. <source>Science</source><volume>360</volume>:<fpage>1126</fpage>–<lpage>1129</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aar4142</pub-id>doi:<ext-link xlink:href="29773668" ext-link-type="pmid"/><pub-id pub-id-type="pmid">29773668</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nowara</surname><given-names>D</given-names></string-name>, <string-name><surname>Gay</surname><given-names>A</given-names></string-name>, <string-name><surname>Lacomme</surname><given-names>C</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>J</given-names></string-name>, <string-name><surname>Ridout</surname><given-names>C</given-names></string-name>, <string-name><surname>Douchkov</surname><given-names>D</given-names></string-name>, <string-name><surname>Hensel</surname><given-names>G</given-names></string-name>, <string-name><surname>Kumlehn</surname><given-names>J</given-names></string-name>, <string-name><surname>Schweizer</surname><given-names>P</given-names></string-name></person-group>. <year>2010</year>. <article-title>HIGS: host-induced gene silencing in the obligate biotrophic fungal pathogen Blumeria graminis</article-title>. <source>Plant Cell</source><volume>22</volume>:<fpage>3130</fpage>–<lpage>3141</lpage>. doi:<pub-id pub-id-type="doi">10.1105/tpc.110.077040</pub-id>doi:<ext-link xlink:href="20884801" ext-link-type="pmid"/><pub-id pub-id-type="pmid">20884801</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Dean</surname><given-names>RA</given-names></string-name></person-group>. <year>2022</year>. <article-title>Host induced gene silencing of Magnaporthe oryzae by targeting pathogenicity and development genes to control rice blast disease</article-title>. <source>Front Plant Sci</source><volume>13</volume>:<fpage>959641</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fpls.2022.959641</pub-id>doi:<ext-link xlink:href="36035704" ext-link-type="pmid"/><pub-id pub-id-type="pmid">36035704</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name><surname>da Cunha</surname><given-names>AP</given-names></string-name>, <string-name><surname>Rezende</surname><given-names>RM</given-names></string-name>, <string-name><surname>Cialic</surname><given-names>R</given-names></string-name>, <string-name><surname>Wei</surname><given-names>Z</given-names></string-name>, <string-name><surname>Bry</surname><given-names>L</given-names></string-name>, <string-name><surname>Comstock</surname><given-names>LE</given-names></string-name>, <string-name><surname>Gandhi</surname><given-names>R</given-names></string-name>, <string-name><surname>Weiner</surname><given-names>HL</given-names></string-name></person-group>. <year>2016</year>. <article-title>The host shapes the gut microbiota via fecal microrna</article-title>. <source>Cell Host Microbe</source><volume>19</volume>:<fpage>32</fpage>–<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2015.12.005</pub-id>doi:<ext-link xlink:href="26764595" ext-link-type="pmid"/><pub-id pub-id-type="pmid">26764595</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>T</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name><surname>Cai</surname><given-names>W</given-names></string-name>, <string-name><surname>Shi</surname><given-names>R</given-names></string-name>, <string-name><surname>Duan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>L</given-names></string-name>, <string-name><surname>Xing</surname><given-names>C</given-names></string-name></person-group>. <year>2022</year>. <article-title>Colon specific delivery of miR-155 inhibitor alleviates estrogen deficiency related phenotype via microbiota remodeling</article-title>. <source>Drug Deliv</source><volume>29</volume>:<fpage>2610</fpage>–<lpage>2620</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10717544.2022.2108163</pub-id>doi:<ext-link xlink:href="35938574" ext-link-type="pmid"/><pub-id pub-id-type="pmid">35938574</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Markelova</surname><given-names>N</given-names></string-name>, <string-name><surname>Glazunova</surname><given-names>O</given-names></string-name>, <string-name><surname>Alikina</surname><given-names>O</given-names></string-name>, <string-name><surname>Panyukov</surname><given-names>V</given-names></string-name>, <string-name><surname>Shavkunov</surname><given-names>K</given-names></string-name>, <string-name><surname>Ozoline</surname><given-names>O</given-names></string-name></person-group>. <year>2021</year>. <article-title>Suppression of Escherichia coli growth dynamics via Rnas secreted by competing bacteria</article-title>. <source>Frontiers in molecular BioSci</source><volume>8</volume>. doi:<pub-id pub-id-type="doi">10.3389/fmolb.2021.609979</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stanton</surname><given-names>BA</given-names></string-name></person-group>. <year>2021</year>. <article-title>Extracellular Vesicles and host–pathogen interactions: A review of inter-kingdom signaling by small Noncoding RNA</article-title>. <source>Genes (Basel)</source><volume>12</volume>:<elocation-id>1010</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/genes12071010</pub-id>doi:<ext-link xlink:href="34208860" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34208860</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koeppen</surname><given-names>K</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name>, <string-name><surname>Jarek</surname><given-names>M</given-names></string-name>, <string-name><surname>Scharfe</surname><given-names>M</given-names></string-name>, <string-name><surname>Gerber</surname><given-names>SA</given-names></string-name>, <string-name><surname>Mielcarz</surname><given-names>DW</given-names></string-name>, <string-name><surname>Demers</surname><given-names>EG</given-names></string-name>, <string-name><surname>Dolben</surname><given-names>EL</given-names></string-name>, <string-name><surname>Hammond</surname><given-names>JH</given-names></string-name>, <string-name><surname>Hogan</surname><given-names>DA</given-names></string-name>, <string-name><surname>Stanton</surname><given-names>BA</given-names></string-name></person-group>. <year>2016</year>. <article-title>A novel mechanism of host-pathogen interaction through sRNA in bacterial outer membrane Vesicles</article-title>. <source>PLoS Pathog</source><volume>12</volume>:<elocation-id>e1005672</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.ppat.1005672</pub-id>doi:<ext-link xlink:href="27295279" ext-link-type="pmid"/><pub-id pub-id-type="pmid">27295279</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Woith</surname><given-names>E</given-names></string-name>, <string-name><surname>Fuhrmann</surname><given-names>G</given-names></string-name>, <string-name><surname>Melzig</surname><given-names>MF</given-names></string-name></person-group>. <year>2019</year>. <article-title>Extracellular vesicles connecting kingdoms</article-title>. <source>Int J Mol Sci</source><volume>20</volume>:<elocation-id>5695</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/ijms20225695</pub-id>doi:<ext-link xlink:href="31739393" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31739393</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weiberg</surname><given-names>A</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Lin</surname><given-names>FM</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Kaloshian</surname><given-names>I</given-names></string-name>, <string-name><surname>Huang</surname><given-names>HD</given-names></string-name>, <string-name><surname>Jin</surname><given-names>H</given-names></string-name></person-group>. <year>2013</year>. <article-title>Fungal small Rnas suppress plant immunity by hijacking host RNA interference pathways</article-title>. <source>Science</source><volume>342</volume>:<fpage>118</fpage>–<lpage>123</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1239705</pub-id>doi:<ext-link xlink:href="24092744" ext-link-type="pmid"/><pub-id pub-id-type="pmid">24092744</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Weiberg</surname><given-names>A</given-names></string-name>, <string-name><surname>Dellota</surname><given-names>E</given-names></string-name>, <string-name><surname>Yamane</surname><given-names>D</given-names></string-name>, <string-name><surname>Jin</surname><given-names>H</given-names></string-name></person-group>. <year>2017</year>. <article-title>Botrytis small RNA BC-Sir37 suppresses plant defense genes by cross-kingdom Rnai</article-title>. <source>RNA Biol</source><volume>14</volume>:<fpage>421</fpage>–<lpage>428</lpage>. doi:<pub-id pub-id-type="doi">10.1080/15476286.2017.1291112</pub-id>doi:<ext-link xlink:href="28267415" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28267415</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Halder</surname><given-names>LD</given-names></string-name>, <string-name><surname>Babych</surname><given-names>S</given-names></string-name>, <string-name><surname>Palme</surname><given-names>DI</given-names></string-name>, <string-name><surname>Mansouri-Ghahnavieh</surname><given-names>E</given-names></string-name>, <string-name><surname>Ivanov</surname><given-names>L</given-names></string-name>, <string-name><surname>Ashonibare</surname><given-names>V</given-names></string-name>, <string-name><surname>Langenhorst</surname><given-names>D</given-names></string-name>, <string-name><surname>Prusty</surname><given-names>B</given-names></string-name>, <string-name><surname>Rambach</surname><given-names>G</given-names></string-name>, <string-name><surname>Wich</surname><given-names>M</given-names></string-name>, <string-name><surname>Trinks</surname><given-names>N</given-names></string-name>, <string-name><surname>Blango</surname><given-names>MG</given-names></string-name>, <string-name><surname>Kornitzer</surname><given-names>D</given-names></string-name>, <string-name><surname>Terpitz</surname><given-names>U</given-names></string-name>, <string-name><surname>Speth</surname><given-names>C</given-names></string-name>, <string-name><surname>Jungnickel</surname><given-names>B</given-names></string-name>, <string-name><surname>Beyersdorf</surname><given-names>N</given-names></string-name>, <string-name><surname>Zipfel</surname><given-names>PF</given-names></string-name>, <string-name><surname>Brakhage</surname><given-names>AA</given-names></string-name>, <string-name><surname>Skerka</surname><given-names>C</given-names></string-name></person-group>. <year>2021</year>. <article-title>Candida albicans induces cross-kingdom miRNA trafficking in human monocytes to promote fungal growth</article-title>. <source>mBio</source><volume>13</volume>:<elocation-id>e0356321</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/mbio.03563-21</pub-id>doi:<ext-link xlink:href="35132877" ext-link-type="pmid"/><pub-id pub-id-type="pmid">35132877</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Simons</surname><given-names>LE</given-names></string-name>, <string-name><surname>Hess</surname><given-names>CW</given-names></string-name>, <string-name><surname>Choate</surname><given-names>ES</given-names></string-name>, <string-name><surname>Van Orden</surname><given-names>AR</given-names></string-name>, <string-name><surname>Tremblay-McGaw</surname><given-names>AG</given-names></string-name>, <string-name><surname>Menendez</surname><given-names>M</given-names></string-name>, <string-name><surname>Boothroyd</surname><given-names>DB</given-names></string-name>, <string-name><surname>Parvathinathan</surname><given-names>G</given-names></string-name>, <string-name><surname>Griffin</surname><given-names>A</given-names></string-name>, <string-name><surname>Caruso</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Stinson</surname><given-names>J</given-names></string-name>, <string-name><surname>Weisman</surname><given-names>A</given-names></string-name>, <string-name><surname>Liu</surname><given-names>T</given-names></string-name>, <string-name><surname>Koeppen</surname><given-names>K</given-names></string-name></person-group>. <year>2022</year>. <article-title>Virtual reality-augmented physiotherapy for chronic pain in youth: protocol for a randomized controlled trial enhanced with a single-case experimental design</article-title>. <source>JMIR Res Protoc</source><volume>11</volume>:<elocation-id>e40705</elocation-id>. doi:<pub-id pub-id-type="doi">10.2196/40705</pub-id>doi:<ext-link xlink:href="36508251" ext-link-type="pmid"/><pub-id pub-id-type="pmid">36508251</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Teng</surname><given-names>G</given-names></string-name>, <string-name><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name><surname>Dai</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name><surname>Chu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name></person-group>. <year>2013</year>. <article-title>Let-7B is involved in the inflammation and immune responses associated with helicobacter pylori infection by targeting toll-like receptor 4</article-title>. <source>PLoS One</source><volume>8</volume>:<elocation-id>e56709</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0056709</pub-id>doi:<ext-link xlink:href="23437218" ext-link-type="pmid"/><pub-id pub-id-type="pmid">23437218</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mandolesi</surname><given-names>G</given-names></string-name>, <string-name><surname>Rizzo</surname><given-names>FR</given-names></string-name>, <string-name><surname>Balletta</surname><given-names>S</given-names></string-name>, <string-name><surname>Stampanoni Bassi</surname><given-names>M</given-names></string-name>, <string-name><surname>Gilio</surname><given-names>L</given-names></string-name>, <string-name><surname>Guadalupi</surname><given-names>L</given-names></string-name>, <string-name><surname>Nencini</surname><given-names>M</given-names></string-name>, <string-name><surname>Moscatelli</surname><given-names>A</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>CP</given-names></string-name>, <string-name><surname>Licursi</surname><given-names>V</given-names></string-name>, <string-name><surname>Dolcetti</surname><given-names>E</given-names></string-name>, <string-name><surname>Musella</surname><given-names>A</given-names></string-name>, <string-name><surname>Gentile</surname><given-names>A</given-names></string-name>, <string-name><surname>Fresegna</surname><given-names>D</given-names></string-name>, <string-name><surname>Bullitta</surname><given-names>S</given-names></string-name>, <string-name><surname>Caioli</surname><given-names>S</given-names></string-name>, <string-name><surname>Vanni</surname><given-names>V</given-names></string-name>, <string-name><surname>Sanna</surname><given-names>K</given-names></string-name>, <string-name><surname>Bruno</surname><given-names>A</given-names></string-name>, <string-name><surname>Buttari</surname><given-names>F</given-names></string-name>, <string-name><surname>Castelli</surname><given-names>C</given-names></string-name>, <string-name><surname>Presutti</surname><given-names>C</given-names></string-name>, <string-name><surname>De Santa</surname><given-names>F</given-names></string-name>, <string-name><surname>Finardi</surname><given-names>A</given-names></string-name>, <string-name><surname>Furlan</surname><given-names>R</given-names></string-name>, <string-name><surname>Centonze</surname><given-names>D</given-names></string-name>, <string-name><surname>De Vito</surname><given-names>F</given-names></string-name></person-group>. <year>2021</year>. <article-title>The microRNA Let-7B-5P is negatively associated with inflammation and disease severity in multiple sclerosis</article-title>. <source>Cells</source><volume>10</volume>:<elocation-id>330</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/cells10020330</pub-id>doi:<ext-link xlink:href="33562569" ext-link-type="pmid"/><pub-id pub-id-type="pmid">33562569</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lim</surname><given-names>LP</given-names></string-name>, <string-name><surname>Lau</surname><given-names>NC</given-names></string-name>, <string-name><surname>Garrett-Engele</surname><given-names>P</given-names></string-name>, <string-name><surname>Grimson</surname><given-names>A</given-names></string-name>, <string-name><surname>Schelter</surname><given-names>JM</given-names></string-name>, <string-name><surname>Castle</surname><given-names>J</given-names></string-name>, <string-name><surname>Bartel</surname><given-names>DP</given-names></string-name>, <string-name><surname>Linsley</surname><given-names>PS</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>JM</given-names></string-name></person-group>. <year>2005</year>. <article-title>Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs</article-title>. <source>Nature</source><volume>433</volume>:<fpage>769</fpage>–<lpage>773</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature03315</pub-id>doi:<ext-link xlink:href="15685193" ext-link-type="pmid"/><pub-id pub-id-type="pmid">15685193</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Friedman</surname><given-names>RC</given-names></string-name>, <string-name><surname>Farh</surname><given-names>KH</given-names></string-name>, <string-name><surname>Burge</surname><given-names>CB</given-names></string-name>, <string-name><surname>Bartel</surname><given-names>DP</given-names></string-name></person-group>. <year>2009</year>. <article-title>Most mammalian mRNAs are conserved targets of microRNAs</article-title>. <source>Genome Res</source><volume>19</volume>:<fpage>92</fpage>–<lpage>105</lpage>. doi:<pub-id pub-id-type="doi">10.1101/gr.082701.108</pub-id>doi:<ext-link xlink:href="18955434" ext-link-type="pmid"/><pub-id pub-id-type="pmid">18955434</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <label>57</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rooda</surname><given-names>I</given-names></string-name>, <string-name><surname>Hensen</surname><given-names>K</given-names></string-name>, <string-name><surname>Kaselt</surname><given-names>B</given-names></string-name>, <string-name><surname>Kasvandik</surname><given-names>S</given-names></string-name>, <string-name><surname>Pook</surname><given-names>M</given-names></string-name>, <string-name><surname>Kurg</surname><given-names>A</given-names></string-name>, <string-name><surname>Salumets</surname><given-names>A</given-names></string-name>, <string-name><surname>Velthut-Meikas</surname><given-names>A</given-names></string-name></person-group>. <year>2020</year>. <article-title>Target prediction and validation of microRNAs expressed from FSHR and aromatase genes in human ovarian granulosa cells</article-title>. <source>Sci Rep</source><volume>10</volume>:<fpage>2300</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-020-59186-x</pub-id>doi:<ext-link xlink:href="32042028" ext-link-type="pmid"/><pub-id pub-id-type="pmid">32042028</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <label>58</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Busch</surname><given-names>A</given-names></string-name>, <string-name><surname>Richter</surname><given-names>AS</given-names></string-name>, <string-name><surname>Backofen</surname><given-names>R</given-names></string-name></person-group>. <year>2008</year>. <article-title>Intarna: efficient prediction of bacterial sRNA targets incorporating target site accessibility and seed regions</article-title>. <source>Bioinformatics</source><volume>24</volume>:<fpage>2849</fpage>–<lpage>2856</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btn544</pub-id>doi:<ext-link xlink:href="18940824" ext-link-type="pmid"/><pub-id pub-id-type="pmid">18940824</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <label>59</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Azeredo</surname><given-names>J</given-names></string-name>, <string-name><surname>Azevedo</surname><given-names>NF</given-names></string-name>, <string-name><surname>Briandet</surname><given-names>R</given-names></string-name>, <string-name><surname>Cerca</surname><given-names>N</given-names></string-name>, <string-name><surname>Coenye</surname><given-names>T</given-names></string-name>, <string-name><surname>Costa</surname><given-names>AR</given-names></string-name>, <string-name><surname>Desvaux</surname><given-names>M</given-names></string-name>, <string-name><surname>Di Bonaventura</surname><given-names>G</given-names></string-name>, <string-name><surname>Hébraud</surname><given-names>M</given-names></string-name>, <string-name><surname>Jaglic</surname><given-names>Z</given-names></string-name>, <string-name><surname>Kačániová</surname><given-names>M</given-names></string-name>, <string-name><surname>Knøchel</surname><given-names>S</given-names></string-name>, <string-name><surname>Lourenço</surname><given-names>A</given-names></string-name>, <string-name><surname>Mergulhão</surname><given-names>F</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>RL</given-names></string-name>, <string-name><surname>Nychas</surname><given-names>G</given-names></string-name>, <string-name><surname>Simões</surname><given-names>M</given-names></string-name>, <string-name><surname>Tresse</surname><given-names>O</given-names></string-name>, <string-name><surname>Sternberg</surname><given-names>C</given-names></string-name></person-group>. <year>2017</year>. <article-title>Critical review on biofilm methods</article-title>. <source>Crit Rev Microbiol</source><volume>43</volume>:<fpage>313</fpage>–<lpage>351</lpage>. doi:<pub-id pub-id-type="doi">10.1080/1040841X.2016.1208146</pub-id>doi:<ext-link xlink:href="27868469" ext-link-type="pmid"/><pub-id pub-id-type="pmid">27868469</pub-id></mixed-citation>
    </ref>
    <ref id="B60">
      <label>60</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wainwright</surname><given-names>CE</given-names></string-name>, <string-name><surname>Quittner</surname><given-names>AL</given-names></string-name>, <string-name><surname>Geller</surname><given-names>DE</given-names></string-name>, <string-name><surname>Nakamura</surname><given-names>C</given-names></string-name>, <string-name><surname>Wooldridge</surname><given-names>JL</given-names></string-name>, <string-name><surname>Gibson</surname><given-names>RL</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>S</given-names></string-name>, <string-name><surname>Montgomery</surname><given-names>AB</given-names></string-name></person-group>. <year>2011</year>. <article-title>Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa</article-title>. <source>J Cyst Fibros</source><volume>10</volume>:<fpage>234</fpage>–<lpage>242</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jcf.2011.02.007</pub-id>doi:<ext-link xlink:href="21441078" ext-link-type="pmid"/><pub-id pub-id-type="pmid">21441078</pub-id></mixed-citation>
    </ref>
    <ref id="B61">
      <label>61</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bahamondez-Canas</surname><given-names>TF</given-names></string-name>, <string-name><surname>Heersema</surname><given-names>LA</given-names></string-name>, <string-name><surname>Smyth</surname><given-names>HDC</given-names></string-name></person-group>. <year>2019</year>. <article-title>Current status of in vitro models and assays for susceptibility testing for wound biofilm infections</article-title>. <source>Biomedicines</source><volume>7</volume>:<elocation-id>34</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/biomedicines7020034</pub-id>doi:<ext-link xlink:href="31052271" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31052271</pub-id></mixed-citation>
    </ref>
    <ref id="B62">
      <label>62</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Festini</surname><given-names>F</given-names></string-name>, <string-name><surname>Buzzetti</surname><given-names>R</given-names></string-name>, <string-name><surname>Bassi</surname><given-names>C</given-names></string-name>, <string-name><surname>Braggion</surname><given-names>C</given-names></string-name>, <string-name><surname>Salvatore</surname><given-names>D</given-names></string-name>, <string-name><surname>Taccetti</surname><given-names>G</given-names></string-name>, <string-name><surname>Mastella</surname><given-names>G</given-names></string-name></person-group>. <year>2006</year>. <article-title>Isolation measures for prevention of infection with respiratory pathogens in cystic fibrosis: a systematic review</article-title>. <source>J Hosp Infect</source><volume>64</volume>:<fpage>1</fpage>–<lpage>6</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jhin.2006.02.021</pub-id>doi:<ext-link xlink:href="16835001" ext-link-type="pmid"/><pub-id pub-id-type="pmid">16835001</pub-id></mixed-citation>
    </ref>
    <ref id="B63">
      <label>63</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Magalhães</surname><given-names>AP</given-names></string-name>, <string-name><surname>Lopes</surname><given-names>SP</given-names></string-name>, <string-name><surname>Pereira</surname><given-names>MO</given-names></string-name></person-group>. <year>2016</year>. <article-title>Insights into cystic fibrosis polymicrobial consortia: the role of species interactions in biofilm development, phenotype, and response to in-use antibiotics</article-title>. <source>Front Microbiol</source><volume>7</volume>:<fpage>2146</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2016.02146</pub-id>doi:<ext-link xlink:href="28133457" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28133457</pub-id></mixed-citation>
    </ref>
    <ref id="B64">
      <label>64</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stuart</surname><given-names>B</given-names></string-name>, <string-name><surname>Lin</surname><given-names>JH</given-names></string-name>, <string-name><surname>Mogayzel</surname><given-names>PJ</given-names></string-name></person-group>. <year>2010</year>. <article-title>Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis</article-title>. <source>Paediatr Respir Rev</source><volume>11</volume>:<fpage>177</fpage>–<lpage>184</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.prrv.2010.05.003</pub-id>doi:<ext-link xlink:href="20692633" ext-link-type="pmid"/><pub-id pub-id-type="pmid">20692633</pub-id></mixed-citation>
    </ref>
    <ref id="B65">
      <label>65</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krause</surname><given-names>KM</given-names></string-name>, <string-name><surname>Haglund</surname><given-names>CM</given-names></string-name>, <string-name><surname>Hebner</surname><given-names>C</given-names></string-name>, <string-name><surname>Serio</surname><given-names>AW</given-names></string-name>, <string-name><surname>Lee</surname><given-names>G</given-names></string-name>, <string-name><surname>Nieto</surname><given-names>V</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>F</given-names></string-name>, <string-name><surname>Kane</surname><given-names>TR</given-names></string-name>, <string-name><surname>Machajewski</surname><given-names>TD</given-names></string-name>, <string-name><surname>Hildebrandt</surname><given-names>D</given-names></string-name>, <string-name><surname>Pillar</surname><given-names>C</given-names></string-name>, <string-name><surname>Thwaites</surname><given-names>M</given-names></string-name>, <string-name><surname>Hall</surname><given-names>D</given-names></string-name>, <string-name><surname>Miesel</surname><given-names>L</given-names></string-name>, <string-name><surname>Hackel</surname><given-names>M</given-names></string-name>, <string-name><surname>Burek</surname><given-names>A</given-names></string-name>, <string-name><surname>Andrews</surname><given-names>LD</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>E</given-names></string-name>, <string-name><surname>Swem</surname><given-names>L</given-names></string-name>, <string-name><surname>Jubb</surname><given-names>A</given-names></string-name>, <string-name><surname>Cirz</surname><given-names>RT</given-names></string-name></person-group>. <year>2019</year>. <article-title>Potent Lpxc inhibitors with in Vitro activity against multidrug-resistant Pseudomonas aeruginosa</article-title>. <source>Antimicrob Agents Chemother</source><volume>63</volume>:<elocation-id>e00977-19</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00977-19</pub-id>doi:<ext-link xlink:href="31451507" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31451507</pub-id></mixed-citation>
    </ref>
    <ref id="B66">
      <label>66</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yan</surname><given-names>TH</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>C</given-names></string-name>, <string-name><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name><surname>Li</surname><given-names>WH</given-names></string-name></person-group>. <year>2018</year>. <article-title>Mir-877-5p suppresses cell growth, migration and invasion by targeting cyclin dependent kinase 14 and predicts prognosis in hepatocellular carcinoma</article-title>. <source>Eur Rev Med Pharmacol Sci</source><volume>22</volume>:<fpage>3038</fpage>–<lpage>3046</lpage>. doi:<pub-id pub-id-type="doi">10.26355/eurrev_201805_15061</pub-id>doi:<ext-link xlink:href="29863248" ext-link-type="pmid"/><pub-id pub-id-type="pmid">29863248</pub-id></mixed-citation>
    </ref>
    <ref id="B67">
      <label>67</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name><surname>Diao</surname><given-names>H</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name><surname>Guan</surname><given-names>F</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H</given-names></string-name></person-group>. <year>2021</year>. <article-title>microRNA-877-5p exerts tumor-suppressive functions in prostate cancer through repressing transcription of forkhead box M1</article-title>. <source>Bioengineered</source><volume>12</volume>:<fpage>9094</fpage>–<lpage>9102</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21655979.2021.1989969</pub-id>doi:<ext-link xlink:href="34654353" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34654353</pub-id></mixed-citation>
    </ref>
    <ref id="B68">
      <label>68</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Cao</surname><given-names>L</given-names></string-name>, <string-name><surname>Yin</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L</given-names></string-name></person-group>. <year>2022</year>. <article-title>Microrna-877-5p inhibits cell progression by targeting Foxm1 in lung cancer</article-title>. <source>Can Respir J</source><volume>2022</volume>:<fpage>4256172</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2022/4256172</pub-id>doi:<ext-link xlink:href="35756697" ext-link-type="pmid"/><pub-id pub-id-type="pmid">35756697</pub-id></mixed-citation>
    </ref>
    <ref id="B69">
      <label>69</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name><surname>Yu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Wei</surname><given-names>W</given-names></string-name>, <string-name><surname>Xie</surname><given-names>D</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Y</given-names></string-name>, <string-name><surname>Xiao</surname><given-names>Q</given-names></string-name></person-group>. <year>2020</year>. <article-title>miR-877-5p suppresses gastric cancer cell proliferation through targeting Foxm1</article-title>. <source>Onco Targets Ther</source><volume>13</volume>:<fpage>4731</fpage>–<lpage>4742</lpage>. doi:<pub-id pub-id-type="doi">10.2147/OTT.S251916</pub-id>doi:<ext-link xlink:href="32547102" ext-link-type="pmid"/><pub-id pub-id-type="pmid">32547102</pub-id></mixed-citation>
    </ref>
    <ref id="B70">
      <label>70</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>K</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Tian</surname><given-names>S</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>J</given-names></string-name>, <string-name><surname>Zou</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>F</given-names></string-name></person-group>. <year>2021</year>. <article-title>Microrna-877-5p alleviates ARDS via enhancing Pi3K/AKT path by targeting Cdkn1B both in vivo and in vitro</article-title>. <source>Int Immunopharmacol</source><volume>95</volume>:<fpage>107530</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.intimp.2021.107530</pub-id>doi:<ext-link xlink:href="33735715" ext-link-type="pmid"/><pub-id pub-id-type="pmid">33735715</pub-id></mixed-citation>
    </ref>
    <ref id="B71">
      <label>71</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cigana</surname><given-names>C</given-names></string-name>, <string-name><surname>Bianconi</surname><given-names>I</given-names></string-name>, <string-name><surname>Baldan</surname><given-names>R</given-names></string-name>, <string-name><surname>De Simone</surname><given-names>M</given-names></string-name>, <string-name><surname>Riva</surname><given-names>C</given-names></string-name>, <string-name><surname>Sipione</surname><given-names>B</given-names></string-name>, <string-name><surname>Rossi</surname><given-names>G</given-names></string-name>, <string-name><surname>Cirillo</surname><given-names>DM</given-names></string-name>, <string-name><surname>Bragonzi</surname><given-names>A</given-names></string-name></person-group>. <year>2018</year>. <article-title>Staphylococcus aureus impacts Pseudomonas aeruginosa chronic respiratory disease in murine models</article-title>. <source>J Infect Dis</source><volume>217</volume>:<fpage>933</fpage>–<lpage>942</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jix621</pub-id>doi:<ext-link xlink:href="29216403" ext-link-type="pmid"/><pub-id pub-id-type="pmid">29216403</pub-id></mixed-citation>
    </ref>
    <ref id="B72">
      <label>72</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jean-Pierre</surname><given-names>F</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name>, <string-name><surname>Schultz</surname><given-names>D</given-names></string-name>, <string-name><surname>Hogan</surname><given-names>DA</given-names></string-name>, <string-name><surname>Groleau</surname><given-names>MC</given-names></string-name>, <string-name><surname>Déziel</surname><given-names>E</given-names></string-name>, <string-name><surname>O’Toole</surname><given-names>GA</given-names></string-name></person-group>. <year>2023</year>. <article-title>Community composition shapes microbial-specific phenotypes in a cystic fibrosis polymicrobial model system</article-title>. <source>Elife</source><volume>12</volume>:<elocation-id>e81604</elocation-id>. doi:<pub-id pub-id-type="doi">10.7554/eLife.81604</pub-id>doi:<ext-link xlink:href="36661299" ext-link-type="pmid"/><pub-id pub-id-type="pmid">36661299</pub-id></mixed-citation>
    </ref>
    <ref id="B73">
      <label>73</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Durda-Masny</surname><given-names>M</given-names></string-name>, <string-name><surname>Goździk-Spychalska</surname><given-names>J</given-names></string-name>, <string-name><surname>John</surname><given-names>A</given-names></string-name>, <string-name><surname>Czaiński</surname><given-names>W</given-names></string-name>, <string-name><surname>Stróżewska</surname><given-names>W</given-names></string-name>, <string-name><surname>Pawłowska</surname><given-names>N</given-names></string-name>, <string-name><surname>Wlizło</surname><given-names>J</given-names></string-name>, <string-name><surname>Batura-Gabryel</surname><given-names>H</given-names></string-name>, <string-name><surname>Szwed</surname><given-names>A</given-names></string-name></person-group>. <year>2021</year>. <article-title>The determinants of survival among adults with cystic fibrosis-a cohort study</article-title>. <source>J Physiol Anthropol</source><volume>40</volume>:<fpage>19</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40101-021-00269-7</pub-id>doi:<ext-link xlink:href="34749804" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34749804</pub-id></mixed-citation>
    </ref>
    <ref id="B74">
      <label>74</label>
      <mixed-citation publication-type="report"><year>2021</year>. <source>CF Patient Registry Annual Data Report</source></mixed-citation>
    </ref>
    <ref id="B75">
      <label>75</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zemanick</surname><given-names>ET</given-names></string-name>, <string-name><surname>Harris</surname><given-names>JK</given-names></string-name>, <string-name><surname>Wagner</surname><given-names>BD</given-names></string-name>, <string-name><surname>Robertson</surname><given-names>CE</given-names></string-name>, <string-name><surname>Sagel</surname><given-names>SD</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Accurso</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Laguna</surname><given-names>TA</given-names></string-name></person-group>. <year>2013</year>. <article-title>Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations</article-title>. <source>PLoS One</source><volume>8</volume>:<elocation-id>e62917</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0062917</pub-id>doi:<ext-link xlink:href="23646159" ext-link-type="pmid"/><pub-id pub-id-type="pmid">23646159</pub-id></mixed-citation>
    </ref>
    <ref id="B76">
      <label>76</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wexler</surname><given-names>AG</given-names></string-name>, <string-name><surname>Goodman</surname><given-names>AL</given-names></string-name></person-group>. <year>2017</year>. <article-title>An insider's perspective: bacteroides as a window into the microbiome</article-title>. <source>Nat Microbiol</source><volume>2</volume>:<fpage>17026</fpage>. doi:<pub-id pub-id-type="doi">10.1038/nmicrobiol.2017.26</pub-id>doi:<ext-link xlink:href="28440278" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28440278</pub-id></mixed-citation>
    </ref>
    <ref id="B77">
      <label>77</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wexler</surname><given-names>HM</given-names></string-name></person-group><year>2007</year>. <article-title>Bacteroides: the good, the bad, and the nitty-gritty</article-title>. <source>Clin Microbiol Rev</source><volume>20</volume>:<fpage>593</fpage>–<lpage>621</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CMR.00008-07</pub-id>doi:<ext-link xlink:href="17934076" ext-link-type="pmid"/><pub-id pub-id-type="pmid">17934076</pub-id></mixed-citation>
    </ref>
    <ref id="B78">
      <label>78</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sears</surname><given-names>CL</given-names></string-name>, <string-name><surname>Geis</surname><given-names>AL</given-names></string-name>, <string-name><surname>Housseau</surname><given-names>F</given-names></string-name></person-group>. <year>2014</year>. <article-title>Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis</article-title>. <source>J Clin Invest</source><volume>124</volume>:<fpage>4166</fpage>–<lpage>4172</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI72334</pub-id>doi:<ext-link xlink:href="25105360" ext-link-type="pmid"/><pub-id pub-id-type="pmid">25105360</pub-id></mixed-citation>
    </ref>
    <ref id="B79">
      <label>79</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hayden</surname><given-names>HS</given-names></string-name>, <string-name><surname>Eng</surname><given-names>A</given-names></string-name>, <string-name><surname>Pope</surname><given-names>CE</given-names></string-name>, <string-name><surname>Brittnacher</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Vo</surname><given-names>AT</given-names></string-name>, <string-name><surname>Weiss</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Hager</surname><given-names>KR</given-names></string-name>, <string-name><surname>Martin</surname><given-names>BD</given-names></string-name>, <string-name><surname>Leung</surname><given-names>DH</given-names></string-name>, <string-name><surname>Heltshe</surname><given-names>SL</given-names></string-name>, <string-name><surname>Borenstein</surname><given-names>E</given-names></string-name>, <string-name><surname>Miller</surname><given-names>SI</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>LR</given-names></string-name></person-group>. <year>2020</year>. <article-title>Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure</article-title>. <source>Nat Med</source><volume>26</volume>:<fpage>215</fpage>–<lpage>221</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-019-0714-x</pub-id>doi:<ext-link xlink:href="31959989" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31959989</pub-id></mixed-citation>
    </ref>
    <ref id="B80">
      <label>80</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rogers</surname><given-names>GB</given-names></string-name>, <string-name><surname>Narkewicz</surname><given-names>MR</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>LR</given-names></string-name></person-group>. <year>2016</year>. <article-title>The CF gastrointestinal microbiome: structure and clinical impact</article-title>. <source>Pediatr Pulmonol</source><volume>51</volume>:<fpage>S35</fpage>–<lpage>S44</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ppul.23544</pub-id>doi:<ext-link xlink:href="27662102" ext-link-type="pmid"/><pub-id pub-id-type="pmid">27662102</pub-id></mixed-citation>
    </ref>
    <ref id="B81">
      <label>81</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pukatzki</surname><given-names>S</given-names></string-name>, <string-name><surname>Ma</surname><given-names>AT</given-names></string-name>, <string-name><surname>Revel</surname><given-names>AT</given-names></string-name>, <string-name><surname>Sturtevant</surname><given-names>D</given-names></string-name>, <string-name><surname>Mekalanos</surname><given-names>JJ</given-names></string-name></person-group>. <year>2007</year>. <article-title>Type VI secretion system translocates a Phage tail spike-like protein into target cells where it cross-links actin</article-title>. <source>Proc Natl Acad Sci USA</source><volume>104</volume>:<fpage>15508</fpage>–<lpage>15513</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0706532104</pub-id>doi:<ext-link xlink:href="17873062" ext-link-type="pmid"/><pub-id pub-id-type="pmid">17873062</pub-id></mixed-citation>
    </ref>
    <ref id="B82">
      <label>82</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mougous</surname><given-names>JD</given-names></string-name>, <string-name><surname>Cuff</surname><given-names>ME</given-names></string-name>, <string-name><surname>Raunser</surname><given-names>S</given-names></string-name>, <string-name><surname>Shen</surname><given-names>A</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>M</given-names></string-name>, <string-name><surname>Gifford</surname><given-names>CA</given-names></string-name>, <string-name><surname>Goodman</surname><given-names>AL</given-names></string-name>, <string-name><surname>Joachimiak</surname><given-names>G</given-names></string-name>, <string-name><surname>Ordoñez</surname><given-names>CL</given-names></string-name>, <string-name><surname>Lory</surname><given-names>S</given-names></string-name>, <string-name><surname>Walz</surname><given-names>T</given-names></string-name>, <string-name><surname>Joachimiak</surname><given-names>A</given-names></string-name>, <string-name><surname>Mekalanos</surname><given-names>JJ</given-names></string-name></person-group>. <year>2006</year>. <article-title>A virulence locus of Pseudomonas aeruginosa encodes a protein secretion apparatus</article-title>. <source>Science</source><volume>312</volume>:<fpage>1526</fpage>–<lpage>1530</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1128393</pub-id>doi:<ext-link xlink:href="16763151" ext-link-type="pmid"/><pub-id pub-id-type="pmid">16763151</pub-id></mixed-citation>
    </ref>
    <ref id="B83">
      <label>83</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Russell</surname><given-names>AB</given-names></string-name>, <string-name><surname>Wexler</surname><given-names>AG</given-names></string-name>, <string-name><surname>Harding</surname><given-names>BN</given-names></string-name>, <string-name><surname>Whitney</surname><given-names>JC</given-names></string-name>, <string-name><surname>Bohn</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Goo</surname><given-names>YA</given-names></string-name>, <string-name><surname>Tran</surname><given-names>BQ</given-names></string-name>, <string-name><surname>Barry</surname><given-names>NA</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>H</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>SB</given-names></string-name>, <string-name><surname>Chou</surname><given-names>S</given-names></string-name>, <string-name><surname>Gonen</surname><given-names>T</given-names></string-name>, <string-name><surname>Goodlett</surname><given-names>DR</given-names></string-name>, <string-name><surname>Goodman</surname><given-names>AL</given-names></string-name>, <string-name><surname>Mougous</surname><given-names>JD</given-names></string-name></person-group>. <year>2014</year>. <article-title>A type VI secretion-related pathway in bacteroidetes mediates Interbacterial antagonism</article-title>. <source>Cell Host Microbe</source><volume>16</volume>:<fpage>227</fpage>–<lpage>236</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2014.07.007</pub-id>doi:<ext-link xlink:href="25070807" ext-link-type="pmid"/><pub-id pub-id-type="pmid">25070807</pub-id></mixed-citation>
    </ref>
    <ref id="B84">
      <label>84</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hood</surname><given-names>RD</given-names></string-name>, <string-name><surname>Singh</surname><given-names>P</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>F</given-names></string-name>, <string-name><surname>Güvener</surname><given-names>T</given-names></string-name>, <string-name><surname>Carl</surname><given-names>MA</given-names></string-name>, <string-name><surname>Trinidad</surname><given-names>RRS</given-names></string-name>, <string-name><surname>Silverman</surname><given-names>JM</given-names></string-name>, <string-name><surname>Ohlson</surname><given-names>BB</given-names></string-name>, <string-name><surname>Hicks</surname><given-names>KG</given-names></string-name>, <string-name><surname>Plemel</surname><given-names>RL</given-names></string-name>, <string-name><surname>Li</surname><given-names>M</given-names></string-name>, <string-name><surname>Schwarz</surname><given-names>S</given-names></string-name>, <string-name><surname>Wang</surname><given-names>WY</given-names></string-name>, <string-name><surname>Merz</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Goodlett</surname><given-names>DR</given-names></string-name>, <string-name><surname>Mougous</surname><given-names>JD</given-names></string-name></person-group>. <year>2010</year>. <article-title>A type VI secretion system of Pseudomonas aeruginosa targets a toxin to bacteria</article-title>. <source>Cell Host Microbe</source><volume>7</volume>:<fpage>25</fpage>–<lpage>37</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2009.12.007</pub-id>doi:<ext-link xlink:href="20114026" ext-link-type="pmid"/><pub-id pub-id-type="pmid">20114026</pub-id></mixed-citation>
    </ref>
    <ref id="B85">
      <label>85</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Russell</surname><given-names>AB</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>SB</given-names></string-name>, <string-name><surname>Mougous</surname><given-names>JD</given-names></string-name></person-group>. <year>2014</year>. <article-title>Type VI secretion system effectors: poisons with a purpose</article-title>. <source>Nat Rev Microbiol</source><volume>12</volume>:<fpage>137</fpage>–<lpage>148</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrmicro3185</pub-id>doi:<ext-link xlink:href="24384601" ext-link-type="pmid"/><pub-id pub-id-type="pmid">24384601</pub-id></mixed-citation>
    </ref>
    <ref id="B86">
      <label>86</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cherrak</surname><given-names>Y</given-names></string-name>, <string-name><surname>Flaugnatti</surname><given-names>N</given-names></string-name>, <string-name><surname>Durand</surname><given-names>E</given-names></string-name>, <string-name><surname>Journet</surname><given-names>L</given-names></string-name>, <string-name><surname>Cascales</surname><given-names>E</given-names></string-name></person-group>. <year>2019</year>. <article-title>Structure and activity of the type VI secretion system</article-title>. <source>Microbiol Spectr</source><volume>7</volume>. doi:<pub-id pub-id-type="doi">10.1128/microbiolspec.PSIB-0031-2019</pub-id>doi:<ext-link xlink:href="31298206" ext-link-type="pmid"/></mixed-citation>
    </ref>
    <ref id="B87">
      <label>87</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cherrak</surname><given-names>Y</given-names></string-name>, <string-name><surname>Rapisarda</surname><given-names>C</given-names></string-name>, <string-name><surname>Pellarin</surname><given-names>R</given-names></string-name>, <string-name><surname>Bouvier</surname><given-names>G</given-names></string-name>, <string-name><surname>Bardiaux</surname><given-names>B</given-names></string-name>, <string-name><surname>Allain</surname><given-names>F</given-names></string-name>, <string-name><surname>Malosse</surname><given-names>C</given-names></string-name>, <string-name><surname>Rey</surname><given-names>M</given-names></string-name>, <string-name><surname>Chamot-Rooke</surname><given-names>J</given-names></string-name>, <string-name><surname>Cascales</surname><given-names>E</given-names></string-name>, <string-name><surname>Fronzes</surname><given-names>R</given-names></string-name>, <string-name><surname>Durand</surname><given-names>E</given-names></string-name></person-group>. <year>2018</year>. <article-title>Biogenesis and structure of a type VI secretion baseplate</article-title>. <source>Nat Microbiol</source><volume>3</volume>:<fpage>1404</fpage>–<lpage>1416</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41564-018-0260-1</pub-id>doi:<ext-link xlink:href="30323254" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30323254</pub-id></mixed-citation>
    </ref>
    <ref id="B88">
      <label>88</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Verster</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Ross</surname><given-names>BD</given-names></string-name>, <string-name><surname>Radey</surname><given-names>MC</given-names></string-name>, <string-name><surname>Bao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Goodman</surname><given-names>AL</given-names></string-name>, <string-name><surname>Mougous</surname><given-names>JD</given-names></string-name>, <string-name><surname>Borenstein</surname><given-names>E</given-names></string-name></person-group>. <year>2017</year>. <article-title>The landscape of type VI secretion across human gut microbiomes reveals its role in community composition</article-title>. <source>Cell Host Microbe</source><volume>22</volume>:<fpage>411</fpage>–<lpage>419</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2017.08.010</pub-id>doi:<ext-link xlink:href="28910638" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28910638</pub-id></mixed-citation>
    </ref>
    <ref id="B89">
      <label>89</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ross</surname><given-names>BD</given-names></string-name>, <string-name><surname>Verster</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Radey</surname><given-names>MC</given-names></string-name>, <string-name><surname>Schmidtke</surname><given-names>DT</given-names></string-name>, <string-name><surname>Pope</surname><given-names>CE</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>LR</given-names></string-name>, <string-name><surname>Hajjar</surname><given-names>AM</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>SB</given-names></string-name>, <string-name><surname>Borenstein</surname><given-names>E</given-names></string-name>, <string-name><surname>Mougous</surname><given-names>JD</given-names></string-name></person-group>. <year>2019</year>. <article-title>Human gut bacteria contain acquired Interbacterial defence systems</article-title>. <source>Nature</source><volume>575</volume>:<fpage>224</fpage>–<lpage>228</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-019-1708-z</pub-id>doi:<ext-link xlink:href="31666699" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31666699</pub-id></mixed-citation>
    </ref>
    <ref id="B90">
      <label>90</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>SM</given-names></string-name>, <string-name><surname>Donaldson</surname><given-names>GP</given-names></string-name>, <string-name><surname>Mikulski</surname><given-names>Z</given-names></string-name>, <string-name><surname>Boyajian</surname><given-names>S</given-names></string-name>, <string-name><surname>Ley</surname><given-names>K</given-names></string-name>, <string-name><surname>Mazmanian</surname><given-names>SK</given-names></string-name></person-group>. <year>2013</year>. <article-title>Bacterial colonization factors control specificity and stability of the gut microbiota</article-title>. <source>Nature</source><volume>501</volume>:<fpage>426</fpage>–<lpage>429</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature12447</pub-id>doi:<ext-link xlink:href="23955152" ext-link-type="pmid"/><pub-id pub-id-type="pmid">23955152</pub-id></mixed-citation>
    </ref>
    <ref id="B91">
      <label>91</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dejea</surname><given-names>CM</given-names></string-name>, <string-name><surname>Fathi</surname><given-names>P</given-names></string-name>, <string-name><surname>Craig</surname><given-names>JM</given-names></string-name>, <string-name><surname>Boleij</surname><given-names>A</given-names></string-name>, <string-name><surname>Taddese</surname><given-names>R</given-names></string-name>, <string-name><surname>Geis</surname><given-names>AL</given-names></string-name>, <string-name><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name><surname>DeStefano Shields</surname><given-names>CE</given-names></string-name>, <string-name><surname>Hechenbleikner</surname><given-names>EM</given-names></string-name>, <string-name><surname>Huso</surname><given-names>DL</given-names></string-name>, <string-name><surname>Anders</surname><given-names>RA</given-names></string-name>, <string-name><surname>Giardiello</surname><given-names>FM</given-names></string-name>, <string-name><surname>Wick</surname><given-names>EC</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name><surname>Wu</surname><given-names>S</given-names></string-name>, <string-name><surname>Pardoll</surname><given-names>DM</given-names></string-name>, <string-name><surname>Housseau</surname><given-names>F</given-names></string-name>, <string-name><surname>Sears</surname><given-names>CL</given-names></string-name></person-group>. <year>2018</year>. <article-title>Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria</article-title>. <source>Science</source><volume>359</volume>:<fpage>592</fpage>–<lpage>597</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aah3648</pub-id>doi:<ext-link xlink:href="29420293" ext-link-type="pmid"/><pub-id pub-id-type="pmid">29420293</pub-id></mixed-citation>
    </ref>
    <ref id="B92">
      <label>92</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>W</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name></person-group>. <year>2019</year>. <article-title>Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data</article-title>. <source>Genome Biol</source><volume>20</volume>:<elocation-id>18</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s13059-019-1629-z</pub-id>doi:<ext-link xlink:href="30670076" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30670076</pub-id></mixed-citation>
    </ref>
    <ref id="B93">
      <label>93</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name></person-group>. <year>2020</year>. <article-title>miRDB: An online database for prediction of functional microRNA targets</article-title>. <source>Nucleic Acids Res</source><volume>48</volume>:<fpage>D127</fpage>–<lpage>D131</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkz757</pub-id>doi:<ext-link xlink:href="31504780" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31504780</pub-id></mixed-citation>
    </ref>
    <ref id="B94">
      <label>94</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bertucci</surname><given-names>A</given-names></string-name>, <string-name><surname>Prasetyanto</surname><given-names>EA</given-names></string-name>, <string-name><surname>Septiadi</surname><given-names>D</given-names></string-name>, <string-name><surname>Manicardi</surname><given-names>A</given-names></string-name>, <string-name><surname>Brognara</surname><given-names>E</given-names></string-name>, <string-name><surname>Gambari</surname><given-names>R</given-names></string-name>, <string-name><surname>Corradini</surname><given-names>R</given-names></string-name>, <string-name><surname>De Cola</surname><given-names>L</given-names></string-name></person-group>. <year>2015</year>. <article-title>Combined delivery of Temozolomide and anti-Mir221 PNA using Mesoporous silica nanoparticles induces apoptosis in resistant glioma cells</article-title>. <source>Small</source><volume>11</volume>:<fpage>5687</fpage>–<lpage>5695</lpage>. doi:<pub-id pub-id-type="doi">10.1002/smll.201500540</pub-id>doi:<ext-link xlink:href="26395266" ext-link-type="pmid"/><pub-id pub-id-type="pmid">26395266</pub-id></mixed-citation>
    </ref>
    <ref id="B95">
      <label>95</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Neill</surname><given-names>CP</given-names></string-name>, <string-name><surname>Dwyer</surname><given-names>RM</given-names></string-name></person-group>. <year>2020</year>. <article-title>Nanoparticle-based delivery of tumor suppressor microRNA for cancer therapy</article-title>. <source>Cells</source><volume>9</volume>:<elocation-id>521</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/cells9020521</pub-id>doi:<ext-link xlink:href="32102476" ext-link-type="pmid"/><pub-id pub-id-type="pmid">32102476</pub-id></mixed-citation>
    </ref>
    <ref id="B96">
      <label>96</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Yoo</surname><given-names>JY</given-names></string-name>, <string-name><surname>Shu</surname><given-names>D</given-names></string-name>, <string-name><surname>Li</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Yu</surname><given-names>JG</given-names></string-name>, <string-name><surname>Jaime-Ramirez</surname><given-names>AC</given-names></string-name>, <string-name><surname>Acunzo</surname><given-names>M</given-names></string-name>, <string-name><surname>Romano</surname><given-names>G</given-names></string-name>, <string-name><surname>Cui</surname><given-names>R</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H-L</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Z</given-names></string-name>, <string-name><surname>Old</surname><given-names>M</given-names></string-name>, <string-name><surname>Kaur</surname><given-names>B</given-names></string-name>, <string-name><surname>Guo</surname><given-names>P</given-names></string-name>, <string-name><surname>Croce</surname><given-names>CM</given-names></string-name></person-group>. <year>2017</year>. <article-title>RNA nanoparticle-based targeted therapy for glioblastoma through inhibition of Oncogenic miR-21</article-title>. <source>Mol Ther</source><volume>25</volume>:<fpage>1544</fpage>–<lpage>1555</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymthe.2016.11.016</pub-id>doi:<ext-link xlink:href="28109960" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28109960</pub-id></mixed-citation>
    </ref>
    <ref id="B97">
      <label>97</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goss</surname><given-names>CH</given-names></string-name>, <string-name><surname>Muhlebach</surname><given-names>MS</given-names></string-name></person-group>. <year>2011</year>. <article-title>Review: Staphylococcus aureus and MRSA in cystic fibrosis</article-title>. <source>J Cyst Fibros</source><volume>10</volume>:<fpage>298</fpage>–<lpage>306</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jcf.2011.06.002</pub-id>doi:<ext-link xlink:href="21719362" ext-link-type="pmid"/><pub-id pub-id-type="pmid">21719362</pub-id></mixed-citation>
    </ref>
    <ref id="B98">
      <label>98</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Skov</surname><given-names>RL</given-names></string-name>, <string-name><surname>Jensen</surname><given-names>KS</given-names></string-name></person-group>. <year>2009</year>. <article-title>Community-associated Meticillin-resistant Staphylococcus aureus as a cause of hospital-acquired infections</article-title>. <source>J Hosp Infect</source><volume>73</volume>:<fpage>364</fpage>–<lpage>370</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jhin.2009.07.004</pub-id>doi:<ext-link xlink:href="19786313" ext-link-type="pmid"/><pub-id pub-id-type="pmid">19786313</pub-id></mixed-citation>
    </ref>
    <ref id="B99">
      <label>99</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Z</given-names></string-name></person-group>. <year>2011</year>. <part-title>The guideline of the design and validation of Mirna mimics</part-title>, <comment>p</comment><fpage>211</fpage>–<lpage>223</lpage>. In <person-group person-group-type="editor"><string-name><surname>Wu</surname><given-names>W</given-names></string-name></person-group> (ed), <source>Microrna and cancer: Methods and protocols. Humana press</source>. <publisher-name>Humana Press</publisher-name>, <publisher-loc>Totowa</publisher-loc>.</mixed-citation>
    </ref>
    <ref id="B100">
      <label>100</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Younger</surname><given-names>ST</given-names></string-name>, <string-name><surname>Corey</surname><given-names>DR</given-names></string-name></person-group>. <year>2011</year>. <article-title>Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters</article-title>. <source>Nucleic Acids Res</source><volume>39</volume>:<fpage>5682</fpage>–<lpage>5691</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkr155</pub-id>doi:<ext-link xlink:href="21427083" ext-link-type="pmid"/><pub-id pub-id-type="pmid">21427083</pub-id></mixed-citation>
    </ref>
    <ref id="B101">
      <label>101</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hart</surname><given-names>M</given-names></string-name>, <string-name><surname>Nickl</surname><given-names>L</given-names></string-name>, <string-name><surname>Walch-Rueckheim</surname><given-names>B</given-names></string-name>, <string-name><surname>Krammes</surname><given-names>L</given-names></string-name>, <string-name><surname>Rheinheimer</surname><given-names>S</given-names></string-name>, <string-name><surname>Diener</surname><given-names>C</given-names></string-name>, <string-name><surname>Taenzer</surname><given-names>T</given-names></string-name>, <string-name><surname>Kehl</surname><given-names>T</given-names></string-name>, <string-name><surname>Sester</surname><given-names>M</given-names></string-name>, <string-name><surname>Lenhof</surname><given-names>HP</given-names></string-name>, <string-name><surname>Keller</surname><given-names>A</given-names></string-name>, <string-name><surname>Meese</surname><given-names>E</given-names></string-name></person-group>. <year>2020</year>. <article-title>Wrinkle in the plan: Mir-34A-5P impacts Chemokine signaling by Modulating Cxcl10/Cxcl11/Cxcr3-axis in Cd4+, Cd8+ T cells, and M1 Macrophages</article-title>. <source>J Immunother cancer</source><volume>8</volume>:<elocation-id>e001617</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/jitc-2020-001617</pub-id>doi:<ext-link xlink:href="33229509" ext-link-type="pmid"/><pub-id pub-id-type="pmid">33229509</pub-id></mixed-citation>
    </ref>
    <ref id="B102">
      <label>102</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Segal</surname><given-names>M</given-names></string-name>, <string-name><surname>Slack</surname><given-names>FJ</given-names></string-name></person-group>. <year>2020</year>. <article-title>Challenges identifying efficacious miRNA Therapeutics for cancer</article-title>. <source>Expert Opin Drug Discov</source><volume>15</volume>:<fpage>987</fpage>–<lpage>992</lpage>. doi:<pub-id pub-id-type="doi">10.1080/17460441.2020.1765770</pub-id>doi:<ext-link xlink:href="32421364" ext-link-type="pmid"/><pub-id pub-id-type="pmid">32421364</pub-id></mixed-citation>
    </ref>
    <ref id="B103">
      <label>103</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Richards</surname><given-names>AM</given-names></string-name></person-group>. <year>2021</year>. <article-title>Effective tools for RNA-derived Therapeutics: SiRNA interference or miRNA Mimicry</article-title>. <source>Theranostics</source><volume>11</volume>:<fpage>8771</fpage>–<lpage>8796</lpage>. doi:<pub-id pub-id-type="doi">10.7150/thno.62642</pub-id>doi:<ext-link xlink:href="34522211" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34522211</pub-id></mixed-citation>
    </ref>
    <ref id="B104">
      <label>104</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huckaby</surname><given-names>JT</given-names></string-name>, <string-name><surname>Lai</surname><given-names>SK</given-names></string-name></person-group>. <year>2018</year>. <article-title>Pegylation for enhancing nanoparticle diffusion in mucus</article-title>. <source>Adv Drug Deliv Rev</source><volume>124</volume>:<fpage>125</fpage>–<lpage>139</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.addr.2017.08.010</pub-id>doi:<ext-link xlink:href="28882703" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28882703</pub-id></mixed-citation>
    </ref>
    <ref id="B105">
      <label>105</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schuster</surname><given-names>BS</given-names></string-name>, <string-name><surname>Suk</surname><given-names>JS</given-names></string-name>, <string-name><surname>Woodworth</surname><given-names>GF</given-names></string-name>, <string-name><surname>Hanes</surname><given-names>J</given-names></string-name></person-group>. <year>2013</year>. <article-title>Nanoparticle diffusion in respiratory mucus from humans without lung disease</article-title>. <source>Biomaterials</source><volume>34</volume>:<fpage>3439</fpage>–<lpage>3446</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.01.064</pub-id>doi:<ext-link xlink:href="23384790" ext-link-type="pmid"/><pub-id pub-id-type="pmid">23384790</pub-id></mixed-citation>
    </ref>
    <ref id="B106">
      <label>106</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Crater</surname><given-names>JS</given-names></string-name>, <string-name><surname>Carrier</surname><given-names>RL</given-names></string-name></person-group>. <year>2010</year>. <article-title>Barrier properties of gastrointestinal mucus to nanoparticle transport</article-title>. <source>Macromol Biosci</source><volume>10</volume>:<fpage>1473</fpage>–<lpage>1483</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mabi.201000137</pub-id>doi:<ext-link xlink:href="20857389" ext-link-type="pmid"/><pub-id pub-id-type="pmid">20857389</pub-id></mixed-citation>
    </ref>
    <ref id="B107">
      <label>107</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yeh</surname><given-names>Y-C</given-names></string-name>, <string-name><surname>Huang</surname><given-names>T-H</given-names></string-name>, <string-name><surname>Yang</surname><given-names>S-C</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C-C</given-names></string-name>, <string-name><surname>Fang</surname><given-names>J-Y</given-names></string-name></person-group>. <year>2020</year>. <article-title>Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances</article-title>. <source>Front Chem</source><volume>8</volume>:<fpage>286</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fchem.2020.00286</pub-id>doi:<ext-link xlink:href="32391321" ext-link-type="pmid"/><pub-id pub-id-type="pmid">32391321</pub-id></mixed-citation>
    </ref>
    <ref id="B108">
      <label>108</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koeppen</surname><given-names>K</given-names></string-name>, <string-name><surname>Stanton</surname><given-names>BA</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name></person-group>. <year>2017</year>. <article-title>Scangeo: parallel mining of high-throughput gene expression data</article-title>. <source>Bioinformatics</source><volume>33</volume>:<fpage>3500</fpage>–<lpage>3501</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btx452</pub-id>doi:<ext-link xlink:href="29036513" ext-link-type="pmid"/><pub-id pub-id-type="pmid">29036513</pub-id></mixed-citation>
    </ref>
    <ref id="B109">
      <label>109</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name><surname>Koeppen</surname><given-names>K</given-names></string-name>, <string-name><surname>Holden</surname><given-names>VI</given-names></string-name>, <string-name><surname>Neff</surname><given-names>SL</given-names></string-name>, <string-name><surname>Cengher</surname><given-names>L</given-names></string-name>, <string-name><surname>Demers</surname><given-names>EG</given-names></string-name>, <string-name><surname>Mould</surname><given-names>DL</given-names></string-name>, <string-name><surname>Stanton</surname><given-names>BA</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name></person-group>. <year>2021</year>. <article-title>GAUGE-Annotated microbial Transcriptomic data facilitate parallel mining and high-throughput Reanalysis to form data-driven hypotheses</article-title>. <source>mSystems</source><volume>6</volume>:<elocation-id>e01305-20</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/mSystems.01305-20</pub-id>doi:<ext-link xlink:href="33758032" ext-link-type="pmid"/><pub-id pub-id-type="pmid">33758032</pub-id></mixed-citation>
    </ref>
    <ref id="B110">
      <label>110</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neff</surname><given-names>SL</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name>, <string-name><surname>Puerner</surname><given-names>C</given-names></string-name>, <string-name><surname>Cengher</surname><given-names>L</given-names></string-name>, <string-name><surname>Doing</surname><given-names>G</given-names></string-name>, <string-name><surname>Lee</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Koeppen</surname><given-names>K</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>AL</given-names></string-name>, <string-name><surname>Hogan</surname><given-names>DA</given-names></string-name>, <string-name><surname>Cramer</surname><given-names>RA</given-names></string-name>, <string-name><surname>Stanton</surname><given-names>BA</given-names></string-name></person-group>. <year>2022</year>. <article-title>CF-Seq, an accessible web application for rapid re-analysis of cystic fibrosis pathogen RNA sequencing studies</article-title>. <source>Sci Data</source><volume>9</volume>:<fpage>343</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41597-022-01431-1</pub-id>doi:<ext-link xlink:href="35710652" ext-link-type="pmid"/><pub-id pub-id-type="pmid">35710652</pub-id></mixed-citation>
    </ref>
    <ref id="B111">
      <label>111</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koeppen</surname><given-names>K</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name>, <string-name><surname>Neff</surname><given-names>SL</given-names></string-name>, <string-name><surname>Stanton</surname><given-names>BA</given-names></string-name></person-group>. <year>2022</year>. <article-title>ESKAPE act plus: Pathway activation analysis for bacterial pathogens</article-title>. <source>mSystems</source><volume>7</volume>:<elocation-id>e0046822</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/msystems.00468-22</pub-id>doi:<ext-link xlink:href="36259735" ext-link-type="pmid"/><pub-id pub-id-type="pmid">36259735</pub-id></mixed-citation>
    </ref>
    <ref id="B112">
      <label>112</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Furuno</surname><given-names>M</given-names></string-name>, <string-name><surname>Kasukawa</surname><given-names>T</given-names></string-name>, <string-name><surname>Saito</surname><given-names>R</given-names></string-name>, <string-name><surname>Adachi</surname><given-names>J</given-names></string-name>, <string-name><surname>Suzuki</surname><given-names>H</given-names></string-name>, <string-name><surname>Baldarelli</surname><given-names>R</given-names></string-name>, <string-name><surname>Hayashizaki</surname><given-names>Y</given-names></string-name>, <string-name><surname>Okazaki</surname><given-names>Y</given-names></string-name></person-group>. <year>2003</year>. <article-title>CDS annotation in full-length cDNA sequence</article-title>. <source>Genome Res</source><volume>13</volume>:<fpage>1478</fpage>–<lpage>1487</lpage>. doi:<pub-id pub-id-type="doi">10.1101/gr.1060303</pub-id>doi:<ext-link xlink:href="12819146" ext-link-type="pmid"/><pub-id pub-id-type="pmid">12819146</pub-id></mixed-citation>
    </ref>
    <ref id="B113">
      <label>113</label>
      <mixed-citation publication-type="journal">. <article-title>What are UniProtKB’s criteria for defining a CDS as a protein?</article-title>
<source>| UniProt help | UniProt</source>. <ext-link xlink:href="https://www.uniprot.org/help/cds_protein_definition" ext-link-type="uri">https://www.uniprot.org/help/cds_protein_definition</ext-link>. <date-in-citation>Retrieved 9 December 2022</date-in-citation>.</mixed-citation>
    </ref>
    <ref id="B114">
      <label>114</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chipman</surname><given-names>LB</given-names></string-name>, <string-name><surname>Pasquinelli</surname><given-names>AE</given-names></string-name></person-group>. <year>2019</year>. <article-title>miRNA targeting: Growing beyond the seed</article-title>. <source>Trends Genet</source><volume>35</volume>:<fpage>215</fpage>–<lpage>222</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tig.2018.12.005</pub-id>doi:<ext-link xlink:href="30638669" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30638669</pub-id></mixed-citation>
    </ref>
    <ref id="B115">
      <label>115</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schnall-Levin</surname><given-names>M</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Perrimon</surname><given-names>N</given-names></string-name>, <string-name><surname>Berger</surname><given-names>B</given-names></string-name></person-group>. <year>2010</year>. <article-title>Conserved microRNA targeting in Drosophila is as widespread in coding regions as in 3'Utrs</article-title>. <source>Proc Natl Acad Sci USA</source><volume>107</volume>:<fpage>15751</fpage>–<lpage>15756</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1006172107</pub-id>doi:<ext-link xlink:href="20729470" ext-link-type="pmid"/><pub-id pub-id-type="pmid">20729470</pub-id></mixed-citation>
    </ref>
    <ref id="B116">
      <label>116</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fromm</surname><given-names>B</given-names></string-name>, <string-name><surname>Domanska</surname><given-names>D</given-names></string-name>, <string-name><surname>Høye</surname><given-names>E</given-names></string-name>, <string-name><surname>Ovchinnikov</surname><given-names>V</given-names></string-name>, <string-name><surname>Kang</surname><given-names>W</given-names></string-name>, <string-name><surname>Aparicio-Puerta</surname><given-names>E</given-names></string-name>, <string-name><surname>Johansen</surname><given-names>M</given-names></string-name>, <string-name><surname>Flatmark</surname><given-names>K</given-names></string-name>, <string-name><surname>Mathelier</surname><given-names>A</given-names></string-name>, <string-name><surname>Hovig</surname><given-names>E</given-names></string-name>, <string-name><surname>Hackenberg</surname><given-names>M</given-names></string-name>, <string-name><surname>Friedländer</surname><given-names>MR</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>KJ</given-names></string-name></person-group>. <year>2020</year>. <article-title>Mirgenedb 2.0: The Metazoan microRNA complement</article-title>. <source>Nucleic Acids Res</source><volume>48</volume>:<elocation-id>D1172</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkz1016</pub-id>doi:<ext-link xlink:href="31642479" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31642479</pub-id></mixed-citation>
    </ref>
    <ref id="B117">
      <label>117</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mann</surname><given-names>M</given-names></string-name>, <string-name><surname>Wright</surname><given-names>PR</given-names></string-name>, <string-name><surname>Backofen</surname><given-names>R</given-names></string-name></person-group>. <year>2017</year>. <article-title>Intarna 2.0: Enhanced and Customizable prediction of RNA-RNA interactions</article-title>. <source>Nucleic Acids Res</source><volume>45</volume>:<fpage>W435</fpage>–<lpage>W439</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkx279</pub-id>doi:<ext-link xlink:href="28472523" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28472523</pub-id></mixed-citation>
    </ref>
    <ref id="B118">
      <label>118</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krüger</surname><given-names>J</given-names></string-name>, <string-name><surname>Rehmsmeier</surname><given-names>M</given-names></string-name></person-group>. <year>2006</year>. <article-title>Rnahybrid: Microrna target prediction easy, fast and flexible</article-title>. <source>Nucleic Acids Res</source><volume>34</volume>:<fpage>W451</fpage>–<lpage>4</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkl243</pub-id>doi:<ext-link xlink:href="16845047" ext-link-type="pmid"/><pub-id pub-id-type="pmid">16845047</pub-id></mixed-citation>
    </ref>
    <ref id="B119">
      <label>119</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tafer</surname><given-names>H</given-names></string-name>, <string-name><surname>Hofacker</surname><given-names>IL</given-names></string-name></person-group>. <year>2008</year>. <article-title>Rnaplex: A fast tool for RNA-RNA interaction search</article-title>. <source>Bioinformatics</source><volume>24</volume>:<fpage>2657</fpage>–<lpage>2663</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btn193</pub-id>doi:<ext-link xlink:href="18434344" ext-link-type="pmid"/><pub-id pub-id-type="pmid">18434344</pub-id></mixed-citation>
    </ref>
    <ref id="B120">
      <label>120</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Wickham</surname><given-names>H</given-names></string-name></person-group><year>2022</year>. <part-title>Stringr: Simple</part-title>. <source>Consistent Wrappers for Common String Operations</source></mixed-citation>
    </ref>
    <ref id="B121">
      <label>121</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Uni Prot Consortium</collab></person-group>. <year>2023</year>. <article-title>Uniprot: The universal protein Knowledgebase in 2023</article-title>. <source>Nucleic Acids Res</source><volume>51</volume>:<fpage>D523</fpage>–<lpage>D531</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkac1052</pub-id>doi:<ext-link xlink:href="36408920" ext-link-type="pmid"/><pub-id pub-id-type="pmid">36408920</pub-id></mixed-citation>
    </ref>
    <ref id="B122">
      <label>122</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Geistlinger</surname><given-names>L</given-names></string-name>, <string-name><surname>Csaba</surname><given-names>G</given-names></string-name>, <string-name><surname>Zimmer</surname><given-names>R</given-names></string-name></person-group>. <year>2016</year>. <article-title>Bioconductor's Enrichmentbrowser: Seamless navigation through combined results of Set- &amp; network-based enrichment analysis</article-title>. <source>BMC Bioinformatics</source><volume>17</volume>:<elocation-id>45</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s12859-016-0884-1</pub-id>doi:<ext-link xlink:href="26791995" ext-link-type="pmid"/><pub-id pub-id-type="pmid">26791995</pub-id></mixed-citation>
    </ref>
    <ref id="B123">
      <label>123</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>R Core Team</collab></person-group>. <year>2021</year>. <source>R: a language and environment for statistical computing</source>:<elocation-id>Vienna, Austria</elocation-id>.</mixed-citation>
    </ref>
    <ref id="B124">
      <label>124</label>
      <mixed-citation publication-type="book">. <person-group person-group-type="author"><collab>RStudio Team</collab></person-group>. <year>2020</year>. <source>RStudio: Integrated Development for R Studio</source>. <publisher-name>PBC</publisher-name>, <publisher-loc>Boston, MA</publisher-loc>.</mixed-citation>
    </ref>
    <ref id="B125">
      <label>125</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Chang</surname><given-names>W</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>J</given-names></string-name>, <string-name><surname>Allaire</surname><given-names>J</given-names></string-name>, <string-name><surname>Sievert</surname><given-names>C</given-names></string-name>, <string-name><surname>Schloerke</surname><given-names>B</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Y</given-names></string-name>, <string-name><surname>Allen</surname><given-names>J</given-names></string-name>, <string-name><surname>McPherson</surname><given-names>J</given-names></string-name>, <string-name><surname>Dipert</surname><given-names>A</given-names></string-name>, <string-name><surname>Borges</surname><given-names>B</given-names></string-name></person-group>. <year>2022</year>. <source>Shiny: Web application framework for R</source></mixed-citation>
    </ref>
    <ref id="B126">
      <label>126</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Chang</surname><given-names>W</given-names></string-name>, <string-name><surname>Borges Ribeiro</surname><given-names>B</given-names></string-name></person-group>. <year>2021</year>. <source>Shinydashboard: Create Dashboards with shiny</source></mixed-citation>
    </ref>
    <ref id="B127">
      <label>127</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Attali</surname><given-names>D</given-names></string-name></person-group>. <year>2021</year>. <source>Shinyjs: easily improve the user experience of your shiny apps in seconds</source></mixed-citation>
    </ref>
    <ref id="B128">
      <label>128</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Bailey</surname><given-names>E</given-names></string-name></person-group>. <year>2022</year>. <source>shinyBS: twitter bootstrap components for shiny</source></mixed-citation>
    </ref>
    <ref id="B129">
      <label>129</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><given-names>Y</given-names><surname>Xie</surname></string-name>, <string-name><given-names>J</given-names><surname>Cheng</surname></string-name>, <string-name><given-names>X</given-names><surname>Tan</surname></string-name></person-group>. <year>2022</year>. <source>DT: a wrapper of the javascript library datatables</source></mixed-citation>
    </ref>
    <ref id="B130">
      <label>130</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Sali</surname><given-names>A</given-names></string-name></person-group>. <year>2020</year>. <article-title>“Shinycssloaders: Add loading Animations to a “shiny” output while it’s Recalculating”</article-title></mixed-citation>
    </ref>
    <ref id="B131">
      <label>131</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Sievert</surname><given-names>C</given-names></string-name></person-group>. <year>2020</year>. <source>Interactive web-based data visualization with R, Plotly, and shiny</source></mixed-citation>
    </ref>
    <ref id="B132">
      <label>132</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Wilkinson</surname><given-names>S</given-names></string-name></person-group><year>2018</year>. <article-title>Kmer: an R package for fast alignment-free clustering of biological sequences</article-title></mixed-citation>
    </ref>
    <ref id="B133">
      <label>133</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Ripley</surname><given-names>B</given-names></string-name>, <string-name><surname>Venables</surname><given-names>B</given-names></string-name>, <string-name><surname>Bates</surname><given-names>DM</given-names></string-name></person-group>. <year>1998</year>. <article-title>(Partial port, ca 1998) AG (partial port, firth D. 2023. mass: support functions and datasets for venables and ripley’s MASS</article-title>:<fpage>3</fpage>–<lpage>60</lpage>.</mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables v1.3 20210610//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-archive-oasis-article1-3.dtd?>
<?SourceDTD.Version 1.3?>
<?ConverterInfo.XSLTName jats-oasis2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">mSystems</journal-id>
    <journal-id journal-id-type="iso-abbrev">mSystems</journal-id>
    <journal-id journal-id-type="publisher-id">msystems</journal-id>
    <journal-title-group>
      <journal-title>mSystems</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2379-5077</issn>
    <publisher>
      <publisher-name>American Society for Microbiology</publisher-name>
      <publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10734502</article-id>
    <article-id pub-id-type="pmid">37975659</article-id>
    <article-id pub-id-type="publisher-id">00653-23</article-id>
    <article-id pub-id-type="doi">10.1128/msystems.00653-23</article-id>
    <article-id pub-id-type="publisher-id">msystems.00653-23</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Resource Report</subject>
      </subj-group>
      <subj-group subj-group-type="article-attributes">
        <compound-subject>
          <compound-subject-part content-type="code">editors-pick</compound-subject-part>
          <compound-subject-part content-type="label">Editor’s PickOpen Peer Review</compound-subject-part>
        </compound-subject>
      </subj-group>
      <subj-group subj-group-type="biological-terms">
        <compound-subject>
          <compound-subject-part content-type="code">computational-biology</compound-subject-part>
          <compound-subject-part content-type="label">Computational Biology</compound-subject-part>
        </compound-subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5993-8445</contrib-id>
        <name>
          <surname>Neff</surname>
          <given-names>Samuel L.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0543-402X</contrib-id>
        <name>
          <surname>Hampton</surname>
          <given-names>Thomas H.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1094-0621</contrib-id>
        <name>
          <surname>Koeppen</surname>
          <given-names>Katja</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sarkar</surname>
          <given-names>Sharanya</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Latario</surname>
          <given-names>Casey J.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ross</surname>
          <given-names>Benjamin D.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1661-407X</contrib-id>
        <name>
          <surname>Stanton</surname>
          <given-names>Bruce A.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="cor1" ref-type="corresp"/>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review and editing</role>
        <email>bruce.a.stanton@dartmouth.edu</email>
      </contrib>
      <aff id="aff1"><label>1</label><institution-wrap><institution>Department of Microbiology and Immunology, Geisel School of Medicine, Dartmouth College</institution></institution-wrap>, <city>Hanover</city>, <state>New Hampshire</state>, <country>USA</country></aff>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <role>Editor</role>
        <name>
          <surname>Gilbert</surname>
          <given-names>Jack A.</given-names>
        </name>
        <aff><institution-wrap><institution>University of California San Diego</institution></institution-wrap>, <city>La Jolla</city>, <state>California</state>, <country>USA</country></aff>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="cor1">Address correspondence to Bruce A. Stanton, <email xlink:href="mailto:bruce.a.stanton@dartmouth.edu">bruce.a.stanton@dartmouth.edu</email></corresp>
      <fn fn-type="COI-statement">
        <p>The authors declare no conflict of interest.</p>
      </fn>
    </author-notes>
    <pub-date publication-format="electronic" date-type="collection">
      <season>Nov-Dec</season>
      <year>2023</year>
    </pub-date>
    <pub-date date-type="pub" publication-format="electronic">
      <day>17</day>
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>17</day>
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
    <volume>8</volume>
    <issue>6</issue>
    <elocation-id>e00653-23</elocation-id>
    <history>
      <date date-type="received">
        <day>22</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>06</day>
        <month>10</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2023 Neff et al.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>Neff et al.</copyright-holder>
      <ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2023-11-17"/>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="msystems.00653-23.pdf"/>
    <self-uri content-type="reviewer_comments" xlink:href="reviewer-comments.pdf"/>
    <abstract abstract-type="primary">
      <title>ABSTRACT</title>
      <p>Developing software tools that leverage biological data sets to accelerate drug discovery is an important aspect of bioinformatic research. Here, we present a novel example: a web application called Rocket-miR that applies an existing bioinformatic algorithm (IntaRNA) to predict cross-species miRNA-mRNA interactions and identify human miRNAs with potential antimicrobial activity against antibiotic-resistant bacterial infections. Rocket-miR is the logical extension of our prior finding that human miRNA let-7b-5p impairs the ability of the ubiquitous opportunistic pathogen <italic toggle="yes">Pseudomonas aeruginosa</italic> to form biofilms and resist the bactericidal effect of β-lactam antibiotics. Rocket-miR’s point and click interface enables researchers without programming expertise to predict additional human-miRNA-pathogen interactions. Identified miRNAs can be developed into novel antimicrobials effective against the 24 clinically relevant pathogens, implicated in diseases of the lung, gut, and other organs, that are included in the application. The paper incorporates three case studies contributed by microbiologists that study human pathogens to demonstrate the usefulness and usability of the application. Rocket-miR is accessible at the following link: <ext-link xlink:href="http://scangeo.dartmouth.edu/RocketmiR/" ext-link-type="uri">http://scangeo.dartmouth.edu/RocketmiR/</ext-link>.</p>
      <sec>
        <title>IMPORTANCE</title>
        <p>Antimicrobial-resistant infections contribute to millions of deaths worldwide every year. In particular, the group of bacteria collectively known as ESKAPE (<italic toggle="yes">Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,</italic> and <italic toggle="yes">Enterobacter</italic> sp<italic toggle="yes">.</italic>) pathogens are of considerable medical concern due to their virulence and exceptional ability to develop antibiotic resistance. New kinds of antimicrobial therapies are urgently needed to treat patients for whom existing antibiotics are ineffective. The Rocket-miR application predicts targets of human miRNAs in bacterial and fungal pathogens, rapidly identifying candidate miRNA-based antimicrobials. The application’s target audience are microbiologists that have the laboratory resources to test the application’s predictions. The Rocket-miR application currently supports 24 recognized human pathogens that are relevant to numerous diseases including cystic fibrosis, chronic obstructive pulmonary disease (COPD), urinary tract infections, and pneumonia. Furthermore, the application code was designed to be easily extendible to other human pathogens that commonly cause hospital-acquired infections.</p>
      </sec>
    </abstract>
    <kwd-group>
      <title>KEYWORDS</title>
      <kwd>cystic fibrosis</kwd>
      <kwd>bioinformatics</kwd>
      <kwd>miRNA</kwd>
      <kwd>CF pathogens</kwd>
      <kwd>antimicrobial agents</kwd>
      <kwd>host-pathogen interactions</kwd>
      <kwd>ESKAPE pathogens</kwd>
    </kwd-group>
    <funding-group specific-use="FundRef">
      <award-group award-type="grant" id="award-1">
        <funding-source>
          <institution-wrap>
            <institution>Cystic Fibrosis Foundation (CFF)</institution>
          </institution-wrap>
        </funding-source>
        <award-id>STANTO19R0</award-id>
        <principal-award-recipient>
          <name>
            <surname>Neff</surname>
            <given-names>Samuel L.</given-names>
          </name>
          <name>
            <surname>Hampton</surname>
            <given-names>Thomas H.</given-names>
          </name>
          <name>
            <surname>Koeppen</surname>
            <given-names>Katja</given-names>
          </name>
          <name>
            <surname>Sarkar</surname>
            <given-names>Sharanya</given-names>
          </name>
          <name>
            <surname>Stanton</surname>
            <given-names>Bruce A.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group award-type="grant" id="award-2">
        <funding-source>
          <institution-wrap>
            <institution>HHS | National Institutes of Health (NIH)</institution>
          </institution-wrap>
        </funding-source>
        <award-id>P30 DK117469, R01 HL151385</award-id>
        <principal-award-recipient>
          <name>
            <surname>Hampton</surname>
            <given-names>Thomas H.</given-names>
          </name>
          <name>
            <surname>Koeppen</surname>
            <given-names>Katja</given-names>
          </name>
          <name>
            <surname>Sarkar</surname>
            <given-names>Sharanya</given-names>
          </name>
          <name>
            <surname>Stanton</surname>
            <given-names>Bruce A.</given-names>
          </name>
          <name>
            <surname>Neff</surname>
            <given-names>Samuel L.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group award-type="grant" id="award-3">
        <funding-source>
          <institution-wrap>
            <institution>HHS | National Institutes of Health (NIH)</institution>
          </institution-wrap>
        </funding-source>
        <award-id>R35 GM142685</award-id>
        <principal-award-recipient>
          <name>
            <surname>Latario</surname>
            <given-names>Casey J.</given-names>
          </name>
          <name>
            <surname>Ross</surname>
            <given-names>Benjamin</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group award-type="grant" id="award-4">
        <funding-source>
          <institution-wrap>
            <institution>The Flatley Foundation</institution>
          </institution-wrap>
        </funding-source>
        <principal-award-recipient>
          <name>
            <surname>Neff</surname>
            <given-names>Samuel L.</given-names>
          </name>
          <name>
            <surname>Hampton</surname>
            <given-names>Thomas H.</given-names>
          </name>
          <name>
            <surname>Koeppen</surname>
            <given-names>Katja</given-names>
          </name>
          <name>
            <surname>Sarkar</surname>
            <given-names>Sharanya</given-names>
          </name>
          <name>
            <surname>Stanton</surname>
            <given-names>Bruce A.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <counts>
      <count count="2" count-type="supplementary-material"/>
      <count count-type="authors" count="7"/>
      <fig-count count="8"/>
      <table-count count="4"/>
      <ref-count count="133"/>
      <page-count count="25"/>
      <word-count count="15082"/>
    </counts>
    <custom-meta-group>
      <custom-meta>
        <meta-name>cover-date</meta-name>
        <meta-value>November/December 2023</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="s1">
    <title>INTRODUCTION</title>
    <p>Antimicrobial resistance (AMR) is a chief global health threat of the 21st century. AMR infections affect more than 2.8 million people and cause 35,000 deaths in the USA per year according to a recent report by the Centers for Disease Control and Prevention (CDC) (<xref rid="B1" ref-type="bibr">1</xref>). A systematic literature review in <italic toggle="yes">The Lancet</italic>, drawing from hospital records and public health surveillance data, attributed over 1.2 million deaths worldwide to bacterial AMR in 2019, the majority of which were caused by lower respiratory tract infections (<xref rid="B2" ref-type="bibr">2</xref>). The Organization for Economic Co-operation and Development further estimated in 2018 that over the next 30 years (2020–2050), managing the complications of AMR will carry a cost of $3.5 billion per year to the global economy (<xref rid="B3" ref-type="bibr">3</xref>). Unfortunately, for a variety of technical and economic reasons, relatively few drug and biotechnology companies are developing new antibiotics (<xref rid="B4" ref-type="bibr">4</xref>). Thus, there is a pressing need for novel therapies to treat AMR.</p>
    <p>The risk of AMR is especially acute for people with chronic diseases, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), that render individuals immune-compromised and prone to chronic antibiotic-resistant infections. The application described in this paper was specifically developed to identify human miRNAs that target AMR genes in CF-related pathogens but is relevant to drug-resistant pathogens in general. Common CF pathogens <italic toggle="yes">Pseudomonas aeruginosa</italic> and <italic toggle="yes">Staphylococcus aureus</italic>, for example, are also listed among the six ESKAPE (<italic toggle="yes">Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,</italic> and <italic toggle="yes">Enterobacter</italic> sp<italic toggle="yes">.</italic>) pathogens, a group of antibiotic-resistant bacteria that are a common cause of hospital-acquired infections and recognized by the WHO as pathogens in urgent need of new antibiotics (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>).</p>
    <p><italic toggle="yes">Pseudomonas aeruginosa</italic> is the most prevalent lung pathogen in people with CF (pwCF), especially adults, and a significant contributor to morbidity and mortality (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). In the CF lungs, mutations in the cystic fibrosis transmembrane conductance regulator (<italic toggle="yes">CFTR</italic>) gene lead to the production of highly viscous, hyper-concentrated mucus (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>). The physiological consequences are obstructed breathing, dysregulation of the immune system, and poor airway clearance that enables infection by opportunistic pathogens, notably drug-resistant <italic toggle="yes">P. aeruginosa</italic> (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). A recent study found that the risk of death for pwCF doubled with <italic toggle="yes">P. aeruginosa</italic> lung infection and increased eightfold when the bacteria acquired resistance to antibiotics (<xref rid="B13" ref-type="bibr">13</xref>). Furthermore, a recent meta-analysis involving <italic toggle="yes">P. aeruginosa</italic> isolates treated with common anti-pseudomonal antibiotics determined that for a majority of the 22 antibiotics surveyed, over one-third of clinical isolates are resistant (<xref rid="B14" ref-type="bibr">14</xref>). A range of other pathogens are also known to contribute to CF lung disease, such as <italic toggle="yes">Burkholderia cenocepacia</italic>, <italic toggle="yes">Stenotrophomonas maltophilia</italic>, <italic toggle="yes">S. aureus</italic> (particularly methicillin-resistant strains), <italic toggle="yes">Mycobacterium abscessus</italic>, and the fungal species <italic toggle="yes">Aspergillus fumigatus</italic> and <italic toggle="yes">Candida albicans</italic> (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). For many of these pathogens, researchers have documented increases in the proportion of bacterial strains resistant to common antibiotics over the past several decades (<xref rid="B17" ref-type="bibr">17</xref><xref rid="B18" ref-type="bibr">–</xref><xref rid="B22" ref-type="bibr">22</xref>).</p>
    <p>AMR occurs through a variety of well-known mechanisms. In <italic toggle="yes">P. aeruginosa</italic>, for example, AMR is driven by a range of biological changes, including the transition to a biofilm-forming state, increased activity of drug efflux pumps, and the development of β-lactamase activity (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>). In response to the failure of conventional antibiotics, researchers are turning to more innovative forms of antimicrobial therapy. Yale University recently launched its Center for Phage Biology and Therapy, with certain researchers focused on developing phage therapy for CF pathogens including <italic toggle="yes">P. aeruginosa</italic> (<xref rid="B25" ref-type="bibr">25</xref><xref rid="B26" ref-type="bibr">–</xref><xref rid="B27" ref-type="bibr">27</xref>). Scientists at other institutions are working to develop phage therapy for additional antibiotic-resistant CF pathogens like the non-tuberculosis mycobacteria species, including <italic toggle="yes">M. abscessus</italic>, or the CF pathogen <italic toggle="yes">B. cenocepacia</italic> (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>).</p>
    <p>Another potential strategy for treating AMR infections is to use miRNAs as antimicrobial therapeutics. Most ongoing efforts at miRNA-based drug development have involved modulating the expression of miRNAs to suppress the genes that contribute to cancer (<xref rid="B30" ref-type="bibr">30</xref><xref rid="B31" ref-type="bibr">–</xref><xref rid="B34" ref-type="bibr">34</xref>), though recent studies have involved other diseases including Huntington’s and keloid disease (<xref rid="B35" ref-type="bibr">35</xref><xref rid="B36" ref-type="bibr">–</xref><xref rid="B37" ref-type="bibr">37</xref>). In addition to the use of human miRNAs to target cancer-causing genes in human cells, we have shown that human miRNA let-7b-5p inhibits several genes that contribute to biofilm formation and antibiotic resistance in <italic toggle="yes">P. aeruginosa</italic> (<xref rid="B38" ref-type="bibr">38</xref>).</p>
    <p>The potential for cross-kingdom miRNA targeting interactions has been recognized for well over a decade. Studies since the early 2010s have demonstrated that small RNAs are transferred between crop species and parasitic fungal pathogens—a natural plant defense mechanism that limits fungal growth (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>). Recognizing the biological possibility of this plant-fungal exchange, crop scientists have developed genetic engineering techniques to augment the expression of plant small RNAs as a strategy to limit pathogen growth and preserve crop yield (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). Cross-kingdom interactions have also been observed in the human gut microbiome. Researchers have demonstrated the ability of human miRNA mimics to enter and reduce the growth rates of intestinal pathogens (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>). Conversely, other studies have utilized human and plant-derived miRNAs to enhance the growth or metabolite production of commensal gut bacteria and ameliorate disease symptoms. Furthermore, it is known that bacteria are capable of releasing small RNAs that influence protein expression in other bacteria (<xref rid="B45" ref-type="bibr">45</xref>), human cells (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B47" ref-type="bibr">47</xref>), or plant cells (<xref rid="B48" ref-type="bibr">48</xref><xref rid="B49" ref-type="bibr">–</xref><xref rid="B50" ref-type="bibr">50</xref>).</p>
    <p>More recent research has identified cross-kingdom interactions in the lungs, including our own prior work (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>). We have previously shown that human miRNA let-7b-5p is delivered through extracellular vesicles (EVs) secreted by human airway cells to <italic toggle="yes">P. aeruginosa</italic>. Once delivered, let-7b-5p decreases the abundance of proteins essential for biofilm formation. Let-7b-5p also reduces resistance to β-lactam antibiotics by inhibiting the expression of antibiotic efflux pumps (<xref rid="B38" ref-type="bibr">38</xref>). Moreover, other studies have shown that let-7b-5p is associated with reduced inflammation, suggesting additional beneficial effects, especially in pwCF who have a chronic hyperinflammatory response to chronic infection by <italic toggle="yes">P. aeruginosa</italic> and other CF pathogens (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>).</p>
    <p>A notable characteristic of miRNAs is that one miRNA may target hundreds of different genes (<xref rid="B55" ref-type="bibr">55</xref><xref rid="B56" ref-type="bibr">–</xref><xref rid="B57" ref-type="bibr">57</xref>). Thus, although bacteria can rapidly develop antimicrobial resistance by altering the expression of a few genes, miRNA targeting of hundreds of genes make it more challenging for microbes to develop antibiotic resistance. The research on miRNAs, including our work on let-7b-5p, suggests that it is possible to develop and deliver miRNA-based therapeutics, with or without antibiotics, in engineered extracellular vesicles to eliminate antibiotic-resistant infections. This therapeutic approach could theoretically be applied to all microbial pathogens including bacterial and fungal infections.</p>
    <p>The development of Rocket-miR (available online at the following link: <ext-link xlink:href="http://scangeo.dartmouth.edu/RocketmiR/" ext-link-type="uri">http://scangeo.dartmouth.edu/RocketmiR/</ext-link>) described herein enables scientists to target genes and pathways that potentiate antimicrobial resistance by providing miRNA target predictions for 24 clinically relevant pathogens (<xref rid="T1" ref-type="table">Table 1</xref>). The application leverages the popular bioinformatic tool IntaRNA to make miRNA-targeting predictions (described in detail in Materials and Methods) and provides a user-friendly environment to explore this prediction data and arrive at translational insights. Typically, miRNA target prediction requires extensive computational skill, and months of time to process and analyze prediction data. Our application requires no prior computational experience or effort to process and analyze data. The interactive, visual nature of the Rocket-miR application enables researchers to explore the biological potential of human miRNAs targeting genes and whole genetic pathways in human pathogens in a matter of minutes. Furthermore, genes and pathways in the application are represented by descriptive annotations—gene names, protein functions, and pathway identifiers that are recognizable to biologists. To the best of our knowledge there are no other programs that allow the rapid identification of miRNAs to target antimicrobial-resistant genes in microbial pathogens.</p>
    <table-wrap position="float" id="T1">
      <label>TABLE 1</label>
      <caption>
        <p>The 24 clinically relevant human pathogens that can be studied using the Rocket-miR application</p>
      </caption>
      <table frame="hsides" rules="groups">
        <colgroup span="1">
          <col span="1"/>
          <col span="1"/>
          <col span="1"/>
        </colgroup>
        <thead>
          <tr>
            <th align="left" valign="bottom" colspan="1" rowspan="1">Species</th>
            <th align="left" valign="bottom" colspan="1" rowspan="1">Strain</th>
            <th align="left" valign="bottom" colspan="1" rowspan="1">Type</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Achromobacter xylosoxidans</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">A8</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Acinetobacter baumannii</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">AYE</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Aspergillus fumigatus</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Strain 293</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Fungus</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Bacteroides fragilis</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">NCTC 9343</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Burkholderia cenocepacia</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">J2315</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Burkholderia multivorans</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">ATCC 17616 (Tohoku)</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Candida albicans</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">SC5314</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Fungus</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Clostridium difficile</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Strain 630</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Clostridium perfringens</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">ATCC 13124</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Enterobacter cloacae</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">ATCC 13047</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Enterococcus faecium</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">DO</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Escherichia coli</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">K12 (Substr. MG1655)</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Haemophilus influenza</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Strain 477</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Klebsiella pneumoniae</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">MGH 78578</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Mycobacterium abscessus</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">ATCC 19977</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Mycobacterium avium</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Strain 104</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Prevotella melaninogenica</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">ATCC 25845</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Pseudomonas aeruginosa</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">PAO1</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Staphylococcus aureus</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">NCTC 8325</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Stenotrophomonas maltophilia</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">K279a</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-negative bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Streptococcus parasanguinis</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">ATCC 15912</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Streptococcus pneumoniae</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">R6</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Streptococcus salivarius</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">CCHSS3</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
          <tr>
            <td align="left" valign="bottom" colspan="1" rowspan="1">
              <italic toggle="yes">Streptococcus sanguinis</italic>
            </td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">SK36</td>
            <td align="left" valign="bottom" colspan="1" rowspan="1">Gram-positive bacterium</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </sec>
  <sec sec-type="results" id="s2">
    <title>RESULTS</title>
    <sec id="s2-1">
      <title>Application overview</title>
      <p>The Rocket-miR application has five core sections (<xref rid="F1" ref-type="fig">Fig. 1</xref>). The first section is the “Summary View,” which offers a high-level perspective on how well the whole set of 630 human miRNAs incorporated in the application target the genes of a selected microbe. The other four sections—the “miRNA View,” “Pathway View,” “Compare Species” view, and the “Structural Analysis” view—offer a closer look at individual miRNAs, genes, and biological pathways. The “miRNA View” allows researchers to identify Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways that are most likely to be effectively targeted by each human miRNA. Users can follow external links to KEGG pathway images highlighting which genes in that pathway met user-defined targeting thresholds. Whether or not a pathway as a whole is predicted to be “effectively targeted” depends on the proportion of its genes/proteins that meet the targeting cutoffs set up in the application. These cutoffs, in turn, are based on prior published experimental data demonstrating the range of energy scores associated with significant downregulation of bacterial protein expression (the targeting cutoffs are described in more detail in Materials and Methods). The “Pathway View” offers the reverse perspective, showing the user a ranked list of human miRNAs that best target a chosen pathway of interest. The “Compare Species” view allows the user to pick multiple microbes and see how well a chosen human miRNA performs across the different species. Finally, the “Structural Analysis” view allows the user to examine and compare the nucleotide sequences of selected miRNAs.</p>
      <fig position="float" fig-type="figure" id="F1">
        <label>Fig 1</label>
        <caption>
          <p>The Rocket-miR application contains five sections. Enlarged versions of the panels in this figure are available as Fig. S1 to S5. After selecting a pathogen of interest, the user is presented with the Summary View (1), where they can view a summary of the target prediction data for all human miRNAs and all genes of the chosen pathogen. They can then navigate to the other four application views. The miRNA View (2) displays the KEGG pathways best targeted by each individual human miRNA in a chosen pathogen. The Pathway View (3) shows the reverse—the most effective miRNAs for targeting a given pathway. The Compare Species View (4) allows the user to compare the effect of a selected miRNA on different KEGG pathways across species. Finally, the Structural Analysis View (5) allows the user to view and compare the nucleotide structure of all the human miRNAs incorporated in the application.</p>
        </caption>
        <graphic xlink:href="msystems.00653-23.f001" position="float"/>
      </fig>
      <p>To demonstrate the usefulness of the application in a domain-specific context, Results includes three case studies from researchers who study cystic fibrosis pathogens at the Geisel School of Medicine. Prior to the case studies, we discuss how the vast array of prediction data in the application can be narrowed in scope to identify the miRNAs with the greatest antimicrobial potential.</p>
    </sec>
    <sec id="s2-2">
      <title>Identifying miRNAs with antimicrobial potential</title>
      <p>The Rocket-miR application contains a universe of miRNA-targeting predictions which could be validated by laboratories that study AMR pathogens. How are researchers who use the application to decide on the most promising human miRNAs for <italic toggle="yes">in vitro</italic> studies? Surveying and comparing the predicted targets of human miRNAs across all Rocket-miR pathogens illuminate several strategies to identify the most promising miRNAs and species to target. It also helps identify miRNAs with potential broad-spectrum antimicrobial effects that may target multiple species simultaneously. This section supports the case studies that follow and provides helpful guidance for the use of the Rocket-miR application.</p>
      <p>Throughout this and the following sections of the results, readers should keep in mind that the Rocket-miR results are bioinformatic predictions. <italic toggle="yes">In vitro</italic> experiments involving the miRNAs and pathogens included in the application might not yield exactly the results predicted. The miRNA-mRNA target prediction scores in the Rocket-miR application were generated using the target prediction algorithm IntaRNA, which predicts the strength of interaction based on both the free energy of miRNA-mRNA hybridization and the miRNA secondary structure (<xref rid="B58" ref-type="bibr">58</xref>). More negative targeting scores predict stronger miRNA-mRNA interactions. The Rocket-miR application includes three targeting cutoffs (strong: −16.98, medium: −15.35, weak, −13.47), varying from highest to lowest confidence that the miRNA-mRNA interaction will successfully suppress protein expression, based on prior data from our previous let-7b-5p study (<xref rid="B38" ref-type="bibr">38</xref>). The IntaRNA algorithm and choice of targeting cutoffs are explained further in Materials and Methods.</p>
      <p>A comparative analysis of miRNA target prediction data for all species in the application indicates that some species are likely to be more effectively targeted in general by human miRNAs than others. Approximately 5% of all energy score interactions for <italic toggle="yes">A. fumigatus</italic> meet or exceed the medium targeting score cutoff in the application. In contrast, the next best species in terms of overall targeting potential (<italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">A. xylosoxidans</italic>, <italic toggle="yes">S. maltophilia, M. abscessus</italic>) have between 2% and 3% of their interactions meeting the medium targeting cutoff. On the lower end, there are three species (<italic toggle="yes">C. perfringens</italic>, <italic toggle="yes">C. difficile</italic>, and <italic toggle="yes">S. aureus</italic>) with less than 1% of interactions meeting the cutoff (<xref rid="F2" ref-type="fig">Fig. 2</xref>).</p>
      <fig position="float" fig-type="figure" id="F2">
        <label>Fig 2</label>
        <caption>
          <p>The overall percentage of miRNA-targeting interactions for each species that meet or exceed the medium targeting cutoff (−15.35) varies between species. Each targeting interaction represents the likelihood of stable interaction between a human miRNA and a particular gene in each human pathogen.. The numbers inside of the bars represent the total number of miRNA-gene interactions that meet the cutoff for each species, whereas the y-axis represents the percentage of interactions meeting the cutoff out of the total number of interactions for each species. Species names are abbreviated as follows: AF, <italic toggle="yes">A. fumigatus</italic>; PA, <italic toggle="yes">P. aeruginosa</italic>; AX, <italic toggle="yes">A. xylosoxidans</italic>; SM, <italic toggle="yes">S. maltophilia</italic>; MAb, <italic toggle="yes">M. abscessus</italic>; MAv, <italic toggle="yes">M. avium</italic>; KP, <italic toggle="yes">K. pneumoniae</italic>; ECl, <italic toggle="yes">E. cloacae</italic>; CA, <italic toggle="yes">C. albicans</italic>; BF, <italic toggle="yes">B. fragilis</italic>; SSan, <italic toggle="yes">S. sanguinis</italic>; ECo, <italic toggle="yes">E. coli</italic>; PM, <italic toggle="yes">P. melaninogenica</italic>; BC, <italic toggle="yes">B. cenocepacia</italic>; SPa, <italic toggle="yes">S. parasanguinis</italic>; BM, <italic toggle="yes">B. multivorans</italic>; SPn, <italic toggle="yes">S. pneumoniae</italic>; SSal, <italic toggle="yes">S. salivarius</italic>; AB, <italic toggle="yes">A. baumannii</italic>; HI, <italic toggle="yes">H. influenza</italic>; EF, <italic toggle="yes">E. faecium</italic>; CP, <italic toggle="yes">C. perfringens</italic>; CD, <italic toggle="yes">C. difficile</italic>; SA, <italic toggle="yes">S. aureus</italic>.</p>
        </caption>
        <graphic xlink:href="msystems.00653-23.f002" position="float"/>
      </fig>
      <p>From <xref rid="F2" ref-type="fig">Fig. 2</xref>, one might conclude that only a small percentage of genes in human pathogens can be effectively targeted by human miRNAs. However, although most human miRNAs are not predicted to target very many human genes, a small number of human miRNAs are predicted to target many genes across multiple human pathogens. This small set of miRNAs therefore has great potential as possible antimicrobial agents. From a single-species perspective, our application identified 92 human miRNAs that are predicted to effectively target 10% or more of all genes in <italic toggle="yes">A. fumigatus</italic> (again at the medium targeting cutoff of −15.35). There are five additional species with 40 or more miRNAs that effectively target 10% or more genes (<italic toggle="yes">M. abscessus</italic>, <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">A. xylosoxidans</italic>, <italic toggle="yes">M. avium</italic>, and <italic toggle="yes">S. maltophilia</italic>) at the same cutoff. All but one species (<italic toggle="yes">S. aureus</italic>) has at least a single human miRNA that targets 10% or more of its genes (<xref rid="F3" ref-type="fig">Fig. 3A</xref>).</p>
      <fig position="float" fig-type="figure" id="F3">
        <label>Fig 3</label>
        <caption>
          <p>Identification of broadly effective miRNAs. (<bold>A</bold>) The number of human miRNAs that target 10% or more genes at or above the medium targeting cutoff (−15.35) varies between species. The height of the bars (and the numbers above the bars) represent the number of miRNAs that meet this criterion for each species. The cutoff of 10% was chosen as a simple measure to predict overall effectiveness of human miRNAs in different species. The Rocket-miR application can be used to predict how effectively individual miRNAs might target specific genes and pathways in each species. (<bold>B</bold>) Some miRNAs target 10% or more genes at or above the medium targeting cutoff (−15.35) in many different species. The word cloud provides a visual indication of which miRNAs have the best broad-spectrum effects—with miRNAs of a larger text size targeting 10% or more genes at the medium cutoff in a greater number of species. Species abbreviations in the upper panel are the same as <xref rid="F2" ref-type="fig">Fig. 2</xref>.</p>
        </caption>
        <graphic xlink:href="msystems.00653-23.f003" position="float"/>
      </fig>
      <p>Building on this single-species analysis, we considered whether some human miRNAs are predicted to target multiple pathogenic species simultaneously. <xref rid="F3" ref-type="fig">Figure 3B</xref> identifies the miRNAs most likely to be effective in multiple pathogens. These broadly effective miRNAs include let-7b-5p, miR-877–5p, miR-3127–5p, miR-3138–3p, miR-320-P1-3p, and miR-320-P3-3p. Each of these six human miRNAs are predicted to target 10% or more of genes in at least 20 of the 24 pathogens included in the Rocket-miR application (at the medium cutoff). <xref rid="T2" ref-type="table">Table 2</xref> further demonstrates, for each of the six broad-spectrum miRNAs, what proportion of all genes are targeted in each of the application’s 24 different species.</p>
      <table-wrap position="float" id="T2">
        <label>TABLE 2</label>
        <caption>
          <p>Six miRNAs that target 10% or more genes at the medium targeting cutoff in a combined 24 different CF pathogens<xref rid="T2_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p>
        </caption>
        <table frame="hsides" rules="groups">
          <colgroup span="1">
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
            <col span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" valign="bottom" colspan="1" rowspan="1">Species</th>
              <th align="left" valign="bottom" colspan="1" rowspan="1">let-7b-5p</th>
              <th align="left" valign="bottom" colspan="1" rowspan="1">877-5p</th>
              <th align="left" valign="bottom" colspan="1" rowspan="1">3127-5p</th>
              <th align="left" valign="bottom" colspan="1" rowspan="1">3138-3p</th>
              <th align="left" valign="bottom" colspan="1" rowspan="1">320-P1-3p</th>
              <th align="left" valign="bottom" colspan="1" rowspan="1">320-P3-3p</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Achromobacter xylosoxidans</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.31</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.51</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.26</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.16</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.23</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Acinetobacter baumannii</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.24</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.12</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.11</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Aspergillus fumigatus</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.53</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.78</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.45</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.56</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.51</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.52</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Bacteroides fragilis</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.33</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.10</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Burkholderia cenocepacia</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.26</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.30</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.12</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.11</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.10</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Burkholderia multivorans</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.22</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.30</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.12</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.11</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.12</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.09</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Candida albicans</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.35</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.32</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.11</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.17</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Clostridium difficile</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.06</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.04</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.02</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.03</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.01</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.03</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Clostridium perfringens</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.05</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.04</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.02</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.03</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.01</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.02</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Enterobacter cloacae</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.24</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.45</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Enterococcus faecium</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.10</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.17</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.06</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.11</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.05</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.08</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Escherichia coli</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.40</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.13</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.17</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.16</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Haemophilus influenza</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.12</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.10</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.12</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Klebsiella pneumoniae</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.24</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.49</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.14</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.22</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.22</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Mycobacterium abscessus</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.25</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.39</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.17</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.16</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.16</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Mycobacterium avium</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.29</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.35</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.17</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.13</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Prevotella melaninogenica</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.25</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.36</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.13</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.25</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.13</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Pseudomonas aeruginosa</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.41</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.61</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.27</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.27</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.35</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.29</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Staphylococcus aureus</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.09</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.06</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.04</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.04</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.02</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.03</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Stenotrophomonas maltophilia</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.32</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.44</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.23</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Streptococcus parasanguinis</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.34</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.16</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Streptococcus pneumoniae</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.30</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.13</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.17</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Streptococcus salivarius</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.30</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.13</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
            </tr>
            <tr>
              <td align="left" valign="bottom" colspan="1" rowspan="1">
                <italic toggle="yes">Streptococcus sanguinis</italic>
              </td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.19</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.37</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.15</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.20</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.18</td>
              <td align="left" valign="bottom" colspan="1" rowspan="1">0.21</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="T2_FN1">
            <label>
              <sup>
                <italic toggle="yes">a</italic>
              </sup>
            </label>
            <p>The exact percentage of genes targeted in each pathogen is listed for each of the five miRNAs.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Drawing on the combined information from <xref rid="F2 F3" ref-type="fig">Fig. 2 and 3</xref> ; <xref rid="T2" ref-type="table">Table 2</xref>, a researcher might make an educated decision about whether targeting a given species with human miRNAs is an endeavor worthy of laboratory resources, and if so, what miRNAs would be most promising to consider as antimicrobial candidates. Though predicted targeting of a large portion of genes in the genome is not a guarantee that a miRNA will effectively interfere with the growth and/or virulence capabilities of a given pathogen, it does increase the likelihood that the miRNA will have a potent effect.</p>
    </sec>
    <sec id="s2-3">
      <title>Experimental validation of Rocket-miR predictions</title>
      <p>To validate Rocket-miR predictions with <italic toggle="yes">in vitro</italic> experiments, the effect of let-7b-5p expression on the planktonic growth and biofilm formation of <italic toggle="yes">P. aeruginosa</italic> was performed using biofilm inoculator (peg lid) plates to measure colony forming units (CFUs; as described elsewhere) (<xref rid="B59" ref-type="bibr">59</xref>). An expression vector containing the let-7b-5p sequence was electroporated into <italic toggle="yes">P. aeruginosa</italic> to induce let-7b-5p expression, as described in Materials and Methods. As shown in <xref rid="F4" ref-type="fig">Fig. 4A</xref>, let-7b-5p expression reduced planktonic growth of <italic toggle="yes">P. aeruginosa</italic> in the presence and absence of aztreonam (1/2 the minimum inhibitory concentration), an antibiotic commonly used to treat people with CF, compared to empty vector control with and without aztreonam (<xref rid="B60" ref-type="bibr">60</xref>). <xref rid="F4" ref-type="fig">Figure 4B</xref> demonstrates that let-7b-5p inhibited biofilm formation of <italic toggle="yes">P. aeruginosa</italic> in the presence of aztreonam compared to empty vector control plus aztreonam (<xref rid="F4" ref-type="fig">Fig. 4B</xref>).</p>
      <fig position="float" fig-type="figure" id="F4">
        <label>Fig 4</label>
        <caption>
          <p>Let-7b-5p reduced planktonic growth and biofilm formation of <italic toggle="yes">P. aeruginosa</italic> as predicted by Rocket-miR. (<bold>A</bold>) <italic toggle="yes">P. aeruginosa</italic> transfected with let-7b-5p exhibited less planktonic growth compared to <italic toggle="yes">P. aeruginosa</italic> transfected with the empty plasmid in the presence and absence of aztreonam. (<bold>B</bold>) Let-7b-5p also significantly reduced biofilm formation by <italic toggle="yes">P. aeruginosa</italic> in the presence of aztreonam compared to empty vector in the presence of aztreonam. ***<italic toggle="yes">P</italic> &lt; 0.0001. Experiments were repeated four times.</p>
        </caption>
        <graphic xlink:href="msystems.00653-23.f004" position="float"/>
      </fig>
      <p>These new results are in line with previous experiments. In a prior study, we had demonstrated, using a crystal violet assay, that addition of aztreonam (1/2 the minimum inhibitory concentration) and expression of let-7b-5p in <italic toggle="yes">P. aeruginosa</italic> had an additive effect to reduce biofilm formation (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B61" ref-type="bibr">61</xref>). The additive effect of let-7b-5p and aztreonam is predicted based on the observation that let-7b-5p inhibits numerous genes in the biofilm formation pathways and inhibits aztreonam efflux pumps in <italic toggle="yes">P. aeruginosa</italic> (<xref rid="B38" ref-type="bibr">38</xref>).</p>
      <p>These experimental results confirm the Rocket-miR prediction that let-7b-5p effectively targets <italic toggle="yes">P. aeruginosa</italic>, with significant impacts on growth (planktonic and biofilm) and antibiotic sensitivity. They also demonstrate a simple approach for assessing the effects of human miRNAs on microbial cells that can be leveraged in future studies with different miRNAs, microorganisms, and antibiotics. To provide additional inspiration for future studies, the following three case studies explore how the Rocket-miR application can be used to predict the effects of human miRNAs on the level of individual genes and biological pathways in selected bacteria. The case studies cover several clinically relevant human pathogens.</p>
    </sec>
    <sec id="s2-4">
      <title>Case study #1: identifying antimicrobial miRNAs to target β-lactam resistance in <italic toggle="yes">Pseudomonas aeruginosa</italic></title>
      <sec id="s2-4-1">
        <title>Sharanya Sarkar, Ph.D. candidate, Stanton Lab, Geisel School of Medicine</title>
        <p>Although the CF lung is characterized by polymicrobial infections involving a wide variety of species such as <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Haemophilus influenzae</italic>, and <italic toggle="yes">Burkholderia cenocepacia</italic>, 50% of adult pwCF are colonized by <italic toggle="yes">Pseudomonas aeruginosa</italic> (<italic toggle="yes">P.a</italic>.) (<xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>). Prolonged colonization by <italic toggle="yes">P.a</italic>. is linked with worse lung function and enhanced mortality rates in pwCF (<xref rid="B64" ref-type="bibr">64</xref>). In the chronic state, <italic toggle="yes">P.a</italic>. escapes immune clearance and resists conventional antibiotics via mechanisms such as the production of β-lactamases to degrade antibiotics and efflux pumps to export antibiotics from <italic toggle="yes">Pseudomonas</italic> cells, reduced expression of porin channels to prevent antibiotic intake, and adopting a biofilm community structure that is less susceptible to antibiotic treatment (<xref rid="B65" ref-type="bibr">65</xref>). Thus, new treatments are required to reduce the <italic toggle="yes">P.a</italic>. burden in the CF lung by targeting pathways such as antibiotic resistance and biofilm formation. Accordingly, the Stanton lab is developing miRNA-based antimicrobial therapies to eliminate <italic toggle="yes">P.a</italic>. and other pathogens in the CF lung.</p>
        <p>Leveraging the analysis capabilities of this application, we were particularly interested in identifying novel therapeutic miRNAs that could target antibiotic resistance and biofilm formation pathways in <italic toggle="yes">P.a</italic>. After selecting <italic toggle="yes">Pseudomonas aeruginosa</italic> from the “Species Selection” tab in the sidebar, the “Summary View” arranged the human miRNAs in the order of how effectively they targeted genes in <italic toggle="yes">P.a</italic>. We found that miR-877–5p had the best median energy score—indicating that it was predicted to effectively target more genes in <italic toggle="yes">P. aeruginosa</italic> than any other human miRNA. From the “miRNA View” section of the application, we downloaded an excel file with the complete list of <italic toggle="yes">P.a</italic>. KEGG pathways and the corresponding percentage of genes targeted by miR-877-5p. Since we were most interested in virulence pathways such as biofilm formation and antibiotic resistance, we examined pathways associated with these terms and found that 46.0% of genes in the biofilm formation pathway and 54.8% of genes in the β-lactam resistance pathway were predicted to be effectively targeted by miR-877-5p. These values were obtained by selecting a “Strong” targeting cutoff, thereby giving us the maximum confidence in the likelihood of protein targeting by this miRNA. To understand exactly what genes in the two pathways were predicted to be targeted by miR-877-5p, we clicked on the hyperlinked pathway terms in the miRNA View. These hyperlinks opened two new windows on the browser depicting the targeted genes on a KEGG pathway diagram (<xref rid="F5" ref-type="fig">Fig. 5A and B</xref>). To further establish the targeting power of miRNA-877-5p vs other human miRNAs, we used the “Pathway View” section of the application and selected biofilm formation and β-lactam resistance as our chosen pathways. The Pathway View indicated that miRNA-877-5p was indeed the human miRNA predicted to target these two pathways most effectively, with the second most effective miRNA targeting as much as 15% fewer genes in both cases.</p>
        <fig position="float" fig-type="figure" id="F5">
          <label>Fig 5</label>
          <caption>
            <p>Key genes targeted by human 877-5p in (i) the biofilm formation pathway and (ii) the β-lactam resistance pathway in <italic toggle="yes">Pseudomonas aeruginosa</italic> are highlighted in blue. Highlighted genes meet the application’s strong targeting cutoff, with a predicted energy score less than or equal to −16.98 (a more negative energy score being indicative of stronger predicted targeting). Green genes are present in the <italic toggle="yes">P. aeruginosa</italic> genome but not strongly targeted. The rationale for the values of the targeting cutoffs is described further in Materials and Methods.</p>
          </caption>
          <graphic xlink:href="msystems.00653-23.f005" position="float"/>
        </fig>
        <p>Since much of our prior work in the lab has focused on let-7b-5p, we wanted to run an analysis to compare the predicted effects of miR-877-5p and let-7b-5p and consider miR-877-5p as a new candidate for future therapeutic developments. We performed the same analysis as outlined above in this case study for let-7b-5p and summarized our findings (<xref rid="T3" ref-type="table">Table 3</xref>). While let-7b-5p had a weaker performance as compared to miR-877-5p on most of the key parameters, the two miRNAs targeted complementary genes in some sub-pathways such as the chemosensory system, <italic toggle="yes">Pseudomonas</italic> quinolone signal(PQS) system, and β-lactamase classes. For instance, while let-7b-5p showed predicted targeting for the class C β-lactamase, miR-877-5p showed predicted targeting for the class D β-lactamase.</p>
        <table-wrap position="float" id="T3">
          <label>TABLE 3</label>
          <caption>
            <p>Comparative analyses of key parameters between miRNAs let-7b-5p and miR-877-5p</p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col span="1"/>
              <col span="1"/>
              <col span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" valign="top" rowspan="2" colspan="1">Key parameters</th>
                <th align="center" valign="top" colspan="2" rowspan="1">microRNA</th>
              </tr>
              <tr>
                <th align="left" valign="top" colspan="1" rowspan="1">let-7b-5p</th>
                <th align="left" valign="top" colspan="1" rowspan="1">miR-877-5p</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">Median interaction energy score for <italic toggle="yes">P.a</italic>.</td>
                <td align="left" valign="top" colspan="1" rowspan="1">14.67</td>
                <td align="left" valign="top" colspan="1" rowspan="1">16.33</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">% Genes targeted in biofilm formation pathway</td>
                <td align="left" valign="top" colspan="1" rowspan="1">31.0%</td>
                <td align="left" valign="top" colspan="1" rowspan="1">46.0%</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">% Genes targeted in β-lactam resistance pathway</td>
                <td align="left" valign="top" colspan="1" rowspan="1">29.0%</td>
                <td align="left" valign="top" colspan="1" rowspan="1">54.8%</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">Proteins targeted in biofilm formation pathway</td>
                <td align="left" valign="top" colspan="1" rowspan="1">PilJ, ChPa., CyaB, FleQ, PqsE, PA1611, PA1976, GacS, RetS, HSI-I, TpbB, RoeA, MucR, BifA, FleQ, Psl, FunX, FunW</td>
                <td align="left" valign="top" colspan="1" rowspan="1">PilI, ChPa, PilG, CyaB, CpdA, FleQ, ExsA, PqsA, MvtR, RhlR, RhlC, LecB, LasI, SagS, PA1976, HsbR, HsbA, LadS, RetS, HSI-I, WspB/D, Wsp-F, TpbB, RoeA, MucR, BifA, FleQ, Psl, PelB, PelD, PelE, PelF, PelG, FunX, FunW</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">Proteins targeted in β-lactam resistance pathway</td>
                <td align="left" valign="top" colspan="1" rowspan="1">OPaD, RND, Class C β-lactamase, AmpG, FtsI, NalC, AmpR, OprD, MexB/AcrB</td>
                <td align="left" valign="top" colspan="1" rowspan="1">OPaD, OMP, RND, MFP, Class D β-lactamase, AmpG, ParS, ParR, OprD, FtsI, NalC, MexZ, MexX, MexY, MexR, NalD, MexB/AcrB</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>This case study led to the development of the hypothesis that human microRNA 877-5p can be used as a potent antimicrobial candidate, specifically against the notorious CF pathogen <italic toggle="yes">Pseudomonas aeruginosa</italic>. This hypothesis can be easily translated to wet bench experiments, which in turn, will play an important role in understanding host-pathogen interactions in the context of eukaryotic miRNA regulation. For instance, naturally occurring EVs or synthetic polymeric nanoparticles, loaded with miR-877-5p, could be administered in CF mice models to test their efficacy in abating <italic toggle="yes">P.a</italic>. infection and inflammation. There is prior precedent for the study of miR-877-5p as a therapeutic agent. For example, miR-877-5p has been shown by several research groups to inhibit hepatocellular, prostate, lung, and gastric cancers (<xref rid="B66" ref-type="bibr">66</xref><xref rid="B67" ref-type="bibr">–</xref><xref rid="B69" ref-type="bibr">69</xref>). Furthermore, miR-877-5p has also been demonstrated to alleviate acute respiratory distress syndrome both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> (<xref rid="B70" ref-type="bibr">70</xref>). Therefore, utilizing this miRNA in the context of CF pathology would be a logical step. To achieve even better results, one might combine let-7b-5p with miR-877-5p in EVs or nanoparticles to achieve complementary gene targeting in multiple pathways. One might also co-load vesicles with a β-lactam antibiotic and miRNA-877-5p to improve the efficacy of the antibiotic while the β-lactam resistance pathway is rendered ineffective by the miRNA. The total analysis in this application took around 30 min, and outstanding features such as typing in direct terms in the search boxes (rather than scrolling through a long list) made the process even faster. Overall, Rocket-miR was a fast and user-friendly experience, and helped us to develop a testable hypothesis with results that could advance miRNA-based interventions as a therapeutic strategy for CF.</p>
      </sec>
    </sec>
    <sec id="s2-5">
      <title>Case study #2: targeting a polymicrobial community of CF pathogens</title>
      <sec id="s2-5-1">
        <title>Sharanya Sarkar, Ph.D. candidate, Stanton Lab, Geisel School of Medicine</title>
        <p>Building on the first case study, we wanted to explore the potential use of miR-877-5p to target four key CF pathogens simultaneously, namely, <italic toggle="yes">Prevotella melaninogenica</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, <italic toggle="yes">Staphylococcus aureus</italic>, and <italic toggle="yes">Streptococcus sanguinis</italic> (<xref rid="F6" ref-type="fig">Fig. 6</xref>). These four pathogens constitute a familiar CF “pulmotype” based on factors from prior research such as prevalence/abundance, co-occurrence, physical/spatial proximity, metabolic cross-feeding, and capacity to dictate health outcomes in pwCF (<xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B72" ref-type="bibr">72</xref>). <italic toggle="yes">P.a</italic>. has been shown to significantly influence the inflammatory responses, independent of <italic toggle="yes">S. aureus</italic> in chronic infection models, and also double the risk of death in adult pwCF (<xref rid="B73" ref-type="bibr">73</xref>). <italic toggle="yes">S. aureus</italic>, on the contrary, is usually more prevalent in younger, healthier CF patients (<xref rid="B74" ref-type="bibr">74</xref>). <italic toggle="yes">Prevotella</italic> is a common anaerobe found in the CF lung, and a study has reported that anaerobes like <italic toggle="yes">Prevotella</italic> detected in the sputum during periods of clinical pulmonary exacerbation were linked with lessened inflammation and better lung function, with respect to sputum samples containing <italic toggle="yes">P.a</italic>. (<xref rid="B75" ref-type="bibr">75</xref>). Therefore, reducing <italic toggle="yes">P.a</italic>. abundance relative to <italic toggle="yes">S. aureus</italic> and <italic toggle="yes">P. melaninogenica</italic> may improve clinical outcomes.</p>
        <fig position="float" fig-type="figure" id="F6">
          <label>Fig 6</label>
          <caption>
            <p>Community health bar graph demonstrating the β-lactam resistance pathway targeting of miRNA 877-5p in four key CF species<italic toggle="yes">—Prevotella melaninogenica, Pseudomonas aeruginosa, Staphylococcus aureus,</italic> and <italic toggle="yes">Streptococcus sanguinis</italic>. In this figure, downloaded directly from the Rocket-miR application, 100% protein targeting would indicate that all genes on the β-lactam resistance pathway are effectively targeted by a given miRNA. β-Lactam resistance is targeted most effectively by miRNA 877-5p in <italic toggle="yes">P.a</italic>. (54.8% of genes targeted) and least in <italic toggle="yes">S. aureus</italic> (11.1% of genes targeted).</p>
          </caption>
          <graphic xlink:href="msystems.00653-23.f006" position="float"/>
        </fig>
        <p>Expanding on these results, it may be possible to target the β-lactam resistance pathway in this community of species more effectively by leveraging multiple human miRNAs simultaneously. <xref rid="F7" ref-type="fig">Figure 7</xref> demonstrates the combined effect of the five broad-spectrum miRNAs identified in <xref rid="T2" ref-type="table">Table 2</xref> against the β-lactam resistance pathway for the four-species community as an example of how miRNAs may be combined. More genes on the β-lactam resistance pathway are effectively targeted when the six miRNAs are used together than when miR-877-5p is used alone—with one-third of the <italic toggle="yes">S. aureus</italic> genes on the β-lactam resistance pathway and more than 50% of the <italic toggle="yes">S. sanguinis</italic> genes on the pathway predicted to be targeted (compared to ~10% and ~25% for miR-877-5p alone). Targeting of <italic toggle="yes">P. melaninogenica</italic> and <italic toggle="yes">P. aeruginosa</italic> is also predicted to improve, with approximately 75% and 80% of genes targeted, respectively (compared to ~45% and ~55%, respectively).</p>
        <fig position="float" fig-type="figure" id="F7">
          <label>Fig 7</label>
          <caption>
            <p>The combined predicted effect of the six broad-spectrum human miRNAs shown in <xref rid="T3" ref-type="table">Table 3</xref> (let-7b-5p, 3127-5p, 3138-3p, 320-P1-3p, 320-P3-3p, 877-5p) on β-lactam resistance in this CF-relevant four-species microbial community is greater than the effect of the individual miRNAs 877-5p or let-7b-5p administered alone (<xref rid="F3" ref-type="fig">Fig. 3</xref>; <xref rid="T2" ref-type="table">Table 2</xref>). As in <xref rid="F3" ref-type="fig">Fig. 3</xref>, the most stringent cutoff in the application (−16.98) was used to determine which genes on the β-lactam resistance KEGG pathway were targeted effectively in each species. The height of the bars (and values inside the bars) represents the proportion of total genes in the β-lactam resistance KEGG pathway where at least one of the six miRNAs meet or exceed the targeting cutoff.</p>
          </caption>
          <graphic xlink:href="msystems.00653-23.f007" position="float"/>
        </fig>
      </sec>
    </sec>
    <sec id="s2-6">
      <title>Case study #3: human miRNAs target the <italic toggle="yes">Bacteroides fragilis</italic> type VI secretion system (T6SS)</title>
      <sec id="s2-6-1">
        <title>Casey Latario, Ph.D. candidate, Ross Lab, Geisel School of Medicine</title>
        <p>In this final case study, we sought to gain insight into the potential for host-microbe interactions mediated by miRNA targeting of a bacterium inhabiting a different site in the body, the colonic symbiont <italic toggle="yes">Bacteroides fragilis. B. fragilis</italic> is present exclusively in mammals and is both prevalent and relatively abundant in the healthy human gastrointestinal microbiome (<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>). <italic toggle="yes">B. fragilis</italic> is generally considered to be a beneficial organism, though enterotoxigenic strains can be associated with inflammatory intestinal disease and colonic tumorigenesis (<xref rid="B78" ref-type="bibr">78</xref>). In pwCF, <italic toggle="yes">Bacteroides</italic> species including <italic toggle="yes">B. fragilis</italic> are diminished in abundance compared to healthy controls and there is great interest in identifying avenues for the restoration of these populations back to healthy levels to alleviate gastrointestinal symptoms in CF (<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>).</p>
        <p>We used Rocket-miR to identify miRNA targets in the genome of the reference strain of <italic toggle="yes">B. fragilis</italic> NCTC 9343. The top hit predicted by Rocket-miR was 1913_3p, which targets <italic toggle="yes">tssG</italic> mRNA with an energy score of −30.97 (<xref rid="T4" ref-type="table">Table 4</xref>). TssG is an integral part of the T6SS, a nanomachine first discovered in <italic toggle="yes">Vibrio cholerae</italic> and <italic toggle="yes">Pseudomonas aeruginosa,</italic> but later found to be broadly distributed throughout Gram-negative bacteria (<xref rid="B81" ref-type="bibr">81</xref><xref rid="B82" ref-type="bibr">–</xref><xref rid="B83" ref-type="bibr">83</xref>). The T6SS functions to translocate toxic effector proteins in a contact-dependent manner to a recipient target cell (<xref rid="B84" ref-type="bibr">84</xref>). Since translocated effector proteins often possess endonuclease, protease, phospholipase, or other activities, their concerted action typically results in bacteriostasis or bacteriolysis of targeted cells, thereby providing a fitness advantage to the producing bacterium (<xref rid="B85" ref-type="bibr">85</xref>). The T6SS is composed of three subcomplexes: the membrane complex (MC), baseplate (BP), and tail-tube complex (TTC) (<xref rid="B86" ref-type="bibr">86</xref>). As yet only functionally characterized in Proteobacteria, TssG is an essential conserved component of the baseplate subcomplex, which is composed of six heterotetrameric “wedges” (<xref rid="B87" ref-type="bibr">87</xref>). TssG forms the core of each wedge (<xref rid="F8" ref-type="fig">Fig. 8</xref>). Deletion of <italic toggle="yes">tssG</italic> inhibits assembly of the baseplate and thus ablates T6SS activity. We predict that the outcome of miR-1913_3p inhibition of <italic toggle="yes">tssG</italic> would be the reduction of <italic toggle="yes">B. fragilis</italic> T6SS activity in the gut.</p>
        <table-wrap position="float" id="T4">
          <label>TABLE 4</label>
          <caption>
            <p>Sixteen <italic toggle="yes">B. fragilis</italic> T6SS genes and their predicted targeting by human miRNAs<xref rid="T4_FN1" ref-type="table-fn"><sup><italic toggle="yes">a</italic></sup></xref></p>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup span="1">
              <col span="1"/>
              <col span="1"/>
              <col span="1"/>
              <col span="1"/>
              <col span="1"/>
            </colgroup>
            <thead>
              <tr>
                <th align="left" valign="top" colspan="1" rowspan="1">Locus tag</th>
                <th align="left" valign="top" colspan="1" rowspan="1">T6SS nomenclature</th>
                <th align="left" valign="top" colspan="1" rowspan="1">Subcomplex</th>
                <th align="left" valign="top" colspan="1" rowspan="1">miRNA</th>
                <th align="left" valign="top" colspan="1" rowspan="1">Energy score</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09380/BF9343_1923</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TssG</td>
                <td align="left" valign="top" colspan="1" rowspan="1">BP</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.1913_3p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−30.9755</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09390/BF9343_1925</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TssN</td>
                <td align="left" valign="top" colspan="1" rowspan="1">MC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.3138_3p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−23.7509</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09415/BF9343_1930</td>
                <td align="left" valign="top" colspan="1" rowspan="1">VgrG</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TTC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.504.v2_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−22.4218</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09360/BF9343_1919</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TssR</td>
                <td align="left" valign="top" colspan="1" rowspan="1">MC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.877_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−21.4969</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09410/BF9343_1929</td>
                <td align="left" valign="top" colspan="1" rowspan="1">PAAR</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TTC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.3944_3p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−21.2825</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09465/BF9343_1940</td>
                <td align="left" valign="top" colspan="1" rowspan="1">ClpV</td>
                <td align="left" valign="top" colspan="1" rowspan="1">ATPase</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.185_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−21.2479</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09385/BF9343_1924</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TssK</td>
                <td align="left" valign="top" colspan="1" rowspan="1">BP</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.3138_3p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−20.2922</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09420/BF9343_1931</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TssF</td>
                <td align="left" valign="top" colspan="1" rowspan="1">BP</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.877_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−20.0846</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09430/BF9343_1933</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TagC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Unknown</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.4664_3p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−19.5252</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09405/BF9343_1928</td>
                <td align="left" valign="top" colspan="1" rowspan="1">bte2</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Effector</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.877_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−19.2061</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09400/BF9343_1927</td>
                <td align="left" valign="top" colspan="1" rowspan="1">bti2a</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Immunity</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Let.7.P1b_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−18.5971</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09485/BF9343_1944</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TetR</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Unknown</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Has.Mir.130.P4a_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−18.2097</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09365/BF9343_1920</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TssP</td>
                <td align="left" valign="top" colspan="1" rowspan="1">MC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.204.P1_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−18.1975</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09450/BF9343_1937</td>
                <td align="left" valign="top" colspan="1" rowspan="1">bte1</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Effector</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.139_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−18.1686</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09460/BF9343_1939</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hcp</td>
                <td align="left" valign="top" colspan="1" rowspan="1">TTC</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.432_5p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−17.4228</td>
              </tr>
              <tr>
                <td align="left" valign="top" colspan="1" rowspan="1">BF9343_RS09395/BF9343_1926</td>
                <td align="left" valign="top" colspan="1" rowspan="1">bti2b</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Immunity</td>
                <td align="left" valign="top" colspan="1" rowspan="1">Hsa.Mir.430.P24_3p</td>
                <td align="left" valign="top" colspan="1" rowspan="1">−16.8882</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="T4_FN1">
              <label>
                <sup>
                  <italic toggle="yes">a</italic>
                </sup>
              </label>
              <p>The <italic toggle="yes">B. fragilis</italic> NCTC 9343 strain locus tags are indicated for each gene, alongside the T6SS gene designation, the subcomplex to which each corresponds, and the Rocket-miR energy score for the human miRNA predicted to target the gene most effectively. A more negative energy score corresponds to a stronger interaction.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <fig position="float" fig-type="figure" id="F8">
          <label>Fig 8</label>
          <caption>
            <p>Rocket-miR identified the type VI secretion system gene <italic toggle="yes">tssG</italic> harbored by <italic toggle="yes">Bacteroides fragilis</italic> as the top predicted gene targeted by human miRNA. The schematic depicts a T6SS, composed of three distinct subcomplexes: the MC, BP, and TTC. The T6SS BP is formed by units of TssEFGK wedges (inset), with TssG as the central protein (indicated in dark blue). Below the T6SS is a <italic toggle="yes">B. fragilis</italic> T6SS locus, with the <italic toggle="yes">tssG</italic> gene shown in dark blue. The transcribed <italic toggle="yes">tssG</italic> (blue mRNA) is shown interacting with a potential inhibitory miRNA, 1913_3p (red miRNA). MC proteins and genes are indicated in red, TTC in purple.</p>
          </caption>
          <graphic xlink:href="msystems.00653-23.f008" position="float"/>
        </fig>
        <p>Notably, in addition to <italic toggle="yes">tssG</italic>, we found that many other <italic toggle="yes">B. fragilis</italic> T6SS genes were predicted by Rocket-miR to be the targets of human-encoded miRNAs with strong predicted energy scores. These genes included two other BP genes in addition to TssG, three MC genes, two TTC genes, the T6SS-associated ClpV ATPase, and two effector immunity gene pairs (<xref rid="T4" ref-type="table">Table 4</xref>). Inactivation of any of these genes could be inferred to impair or inactivate the T6SS. In sum, 16/26 (61.5%) <italic toggle="yes">B. fragilis</italic> T6SS genes are predicted to be effective targets for human miRNAs.</p>
        <p>Considering these data, we predict that exposure of <italic toggle="yes">B. fragilis</italic> cells to EVs released by colonic cells containing miR-1913_3p or other miRNAs listed in <xref rid="T4" ref-type="table">Table 4</xref> would result in reduced T6SS expression and subsequent diminishment of interbacterial antagonism. In addition, engineered extracellular vesicles or nanoparticles containing these miRNAs could be developed to reduce T6SS and therefore reduce the pathogenicity of <italic toggle="yes">B. fragilis</italic>. Since EVs secreted by colon cells are likely to exist in a gradient extending luminally from the epithelial layer, one potential function of this mechanism could be the dampening of T6SS-dependent bacterial lysis near the epithelium to prevent unwanted inflammatory responses to bacterial-derived cellular products. This dampening would also be predicted to lower <italic toggle="yes">B. fragilis</italic> fitness during interactions with other Gram-negative bacterial competitors, but may promote co-existence especially with other <italic toggle="yes">Bacteroides</italic> species (<xref rid="B88" ref-type="bibr">88</xref>, <xref rid="B89" ref-type="bibr">89</xref>). While the mucosal layer acts to buffer the epithelium from the bulk of the gut microbiota, <italic toggle="yes">B. fragilis</italic> can colonize colonic crypts and even form polymicrobial biofilms at sites of colonic polyp formation (<xref rid="B90" ref-type="bibr">90</xref>, <xref rid="B91" ref-type="bibr">91</xref>) . How or if <italic toggle="yes">B. fragilis</italic> biogeography and interbacterial interactions are impacted in CF is currently unknown. Further mechanistic investigation of the impact of miRNAs on <italic toggle="yes">B. fragilis</italic> T6SS in both healthy individuals and in the context of CF will be important to lend experimental credence to our observations and illuminate potential therapeutic avenues.</p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s3">
    <title>DISCUSSION</title>
    <p>By designing Rocket-miR as an accessible, point-and-click web application, we have made the results of miRNA target prediction accessible to a broad audience of researchers. Researchers at any level of computational experience can access target prediction data in Rocket-miR within a few minutes. Without such an application, it would take weeks for an experienced bioinformatician with access to high performance computing resources to gather and analyze the same target prediction data for just a single pathogen. While miRNA target prediction databases do exist (<xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B93" ref-type="bibr">93</xref>), they are limited to model organisms and other commonly studied species—not most microbial pathogens such as those that infect people with CF and other diseases. To our knowledge, Rocket-miR is the only data mining tool of its kind that exists for the microbiology community. The Rocket-miR application provides this research community a starting point to develop a new class of miRNA-based antimicrobial therapeutics. Drawing on public genomic sequencing data in bacteria, it aims to encourage new wet bench experiments that will expand the range of treatment options for drug-resistant pathogens. These experiments will also enhance biological understanding of host pathogen miRNA-mRNA interactions.</p>
    <p>As our case studies demonstrate, scientists may use human miRNAs to target individual genes and biological pathways composed of multiple functionally related genes. Targeting KEGG pathways related to antibiotic resistance, biofilm formation, or other virulence traits could help treat drug-resistant infections. Furthermore, while small molecule drugs are traditionally designed to target individual proteins, miRNA-based therapeutics would likely have a much broader effect, disrupting the function of many genes simultaneously. While a bacterium may evolve resistance to a small molecule that targets an individual protein, it is much less likely that this bacterium could evolve to resist an miRNA that is targeting many genes at once (<xref rid="B55" ref-type="bibr">55</xref><xref rid="B56" ref-type="bibr">–</xref><xref rid="B57" ref-type="bibr">57</xref>). An effective therapeutic regimen could even combine miRNA-based drugs with more precise small molecule drugs or traditional antibiotics. As a similar example, engineered vesicles or nanoparticles have been designed for cancer treatment that include both small RNAs or small RNA antagonists and chemotherapeutic agents. In addition to the synergistic effects they enable, these delivery vehicles also make the small RNAs more effective by protecting them from ribonucleases (<xref rid="B94" ref-type="bibr">94</xref><xref rid="B95" ref-type="bibr">–</xref><xref rid="B96" ref-type="bibr">96</xref>).</p>
    <p>The Rocket-miR application encourages researchers to consider not only the possibility of targeting individual pathogens, but also targeting multiple pathogens simultaneously. We have identified a set of miRNAs with predicted broad-spectrum effects across multiple CF pathogens. This includes let-7b-5p, which we have found in previous research to effectively target virulence pathways in <italic toggle="yes">Pseudomonas aeruginosa</italic>. We have further predicted that let-7b-5p will be effective against a community of species including <italic toggle="yes">P. aeruginosa</italic>, <italic toggle="yes">P. melaninogenica</italic>, <italic toggle="yes">S. aureus</italic>, and <italic toggle="yes">S. sanguinis</italic>.</p>
    <p>This analysis extends our understanding of human miRNA-pathogen mRNA interactions. Of the 24 CF pathogens included in the Rocket-miR application, we predict that the fungal species <italic toggle="yes">A. fumigatus</italic> would be most effectively targeted by human miRNAs—with approximately twice as many targeting interactions meeting the application’s medium targeting cutoff than the next best targeted species. An interesting topic of further study would be to explore the underlying reasons for the differences in predicted targeting across species shown in <xref rid="F2 F3" ref-type="fig">Fig. 2 and 3</xref>. Making and testing target predictions for additional species and/or strains of a bacterium may uncover the factors that underlie a pathogen’s susceptibility to targeting by human miRNAs. For example, it may be that the relative evolutionary closeness of <italic toggle="yes">Aspergillus</italic> and other fungal species to humans (i.e., both are eukaryotes) renders them more susceptible to targeting by human miRNAs in general than bacterial species. It is also possible that genomic features like GC content make a given pathogen more or less susceptible to targeting by human miRNAs.</p>
    <p>The pathogen that is predicted to be least effectively targeted by human miRNAs is the common Gram-positive bacterium <italic toggle="yes">S. aureus</italic>, with no human miRNAs predicted to target more than 10% of its genes (<xref rid="F3" ref-type="fig">Fig. 3A</xref>). However, it may be possible to treat less susceptible pathogens like <italic toggle="yes">S. aureus</italic> with a combination of human miRNAs to increase the total number of genes (and biological pathways) that can be effectively targeted (<xref rid="F7" ref-type="fig">Fig. 7</xref>). Investigations along these lines would be worthwhile, as antibiotic-resistant <italic toggle="yes">S. aureus</italic> infections are common in people with CF as well as in hospital-acquired infections (<xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B98" ref-type="bibr">98</xref>). Alternatively, as another way to target <italic toggle="yes">S. aureus</italic> and other CF pathogens as well, it may be possible to design miRNA mimics that are based on human miRNAs but altered in sequence to improve targeting success (<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B100" ref-type="bibr">100</xref>). Researchers could combine IntaRNA target predictions with Rocket-miR’s visualization to compare the predicted effects of their own designed miRNA mimics on <italic toggle="yes">S. aureus</italic> or other human pathogens.</p>
    <p>Though a demonstrably useful tool, the Rocket-miR application does have limitations. One drawback is that the application includes data on only one strain of each human pathogen, as we chose to prioritize including a diverse range of different pathogens rather than multiple strains of a smaller set of pathogens. Two strains of the same species are likely to have a large degree of genetic homology and consequently similar miRNA-targeting prediction data. In support for this assumption, several pairs of species from the same genus (e.g., <italic toggle="yes">B. cenocepacia</italic> and <italic toggle="yes">B. multivorans; C. difficile</italic> and <italic toggle="yes">C. perfringens</italic>) are included in the application and have very similar miRNA-targeting profiles. However, when comparing two strains, one may possess genes that the other lacks, and the sequence homology for a given gene will not be perfect, causing target predictions to differ. Future investigations of strain-specific miRNA targeting would be worthwhile.</p>
    <p>Another concern is challenges related to miRNA-based drug development, including side effects and delivery. As noted in the Introduction, a range of “miRNA mimics” (synthetic compounds that mimic the structure of miRNAs with known therapeutic properties) have been designed and tested in clinical trials for various human cancers, as well as several other diseases (<xref rid="B30" ref-type="bibr">30</xref><xref rid="B31" ref-type="bibr">–</xref><xref rid="B37" ref-type="bibr">37</xref>). However, in 2016, a liver cancer trial for a miR-34a-5p mimic reported serious immune system-related adverse events and the death of four patients (<xref rid="B101" ref-type="bibr">101</xref>). Since 2016, researchers have investigated the causes of the adverse events in this trial, and new approaches are being explored to deliver miRNA-based therapies that would limit dangerous side effects in the future. In the cancer context, this includes encapsulating miRNA mimics in nanoparticles that are designed to delay release of the miRNA until they reach the tumor environment (<xref rid="B102" ref-type="bibr">102</xref>). Research is also ongoing to identify miRNA sequence modifications and new encapsulation methods that would enhance cellular uptake and effectiveness of miRNA mimics inside of cells: curtailing degradation by nucleases in the systemic circulation and degradation within the endosomal compartment (<xref rid="B103" ref-type="bibr">103</xref>).</p>
    <p>To target microbial infections in the lung or gut, delivery of miRNA mimics faces the additional challenge of permeating mucus to reach colonizing microbes. The challenge is especially acute in a disease like CF where mucus is hyper-viscous. Nanoparticles engineered to breach the mucus barrier might overcome this problem (<xref rid="B104" ref-type="bibr">104</xref><xref rid="B105" ref-type="bibr">–</xref><xref rid="B106" ref-type="bibr">106</xref>). Also, to limit the likelihood of off-target side effects, delivery vehicles should be designed to target bacterial cells specifically (<xref rid="B107" ref-type="bibr">107</xref>), just as miRNA-based cancer therapeutics are being designed for selective release in the tumor environment.</p>
    <p>The Rocket-miR application adds to our suite of existing community-oriented bioinformatic tools—including three other R shiny applications (<ext-link xlink:href="http://scangeo.dartmouth.edu/ScanGEO/" ext-link-type="uri">ScanGEO</ext-link>,<ext-link xlink:href="https://iamsoshiny.shinyapps.io/gape/" ext-link-type="uri"> GAPE</ext-link>,<ext-link xlink:href="http://scangeo.dartmouth.edu/CFSeq/" ext-link-type="uri"> CF-Seq</ext-link>) that make insights from public transcriptomic data on human pathogens more accessible to non-computational scientists, and a fourth (<ext-link xlink:href="http://scangeo.dartmouth.edu/ESKAPE/" ext-link-type="uri">ESKAPE Act Plus</ext-link>) that enables researchers without computational experience to perform pathway activation analysis for ESKAPE pathogens (<xref rid="B108" ref-type="bibr">108</xref><xref rid="B109" ref-type="bibr">–</xref><xref rid="B111" ref-type="bibr">111</xref>). We envision Rocket-miR and these other applications as ongoing projects—tools that researchers studying any microbial pathogen can use and extend, to the ultimate benefit of patients with drug-resistant infections. Currently, the Rocket-miR application includes target prediction data for 24 CF pathogens and the so-called ESKAPE pathogens, renowned for their antibiotic resistance and tendency to cause hospital-acquired infections (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>). For other human pathogens of interest, researchers can follow the methods outlined in this paper, and the instructions in the Github repository, to build their own version of the application: <ext-link xlink:href="https://github.com/samlo777/Rocket-miR" ext-link-type="uri">https://github.com/samlo777/Rocket-miR</ext-link></p>
  </sec>
  <sec sec-type="materials|methods" id="s4">
    <title>MATERIALS AND METHODS</title>
    <sec id="s4-1">
      <title>Acquiring public sequence data</title>
      <p>The Rocket-miR application includes target prediction data for 24 human pathogens. Making these target predictions required downloading public data from the National Center for Biotechnology Information (NCBI) Assembly database. For each species and particular strain of interest, the genomic coding sequence (CDS) file was downloaded. The coding sequence is the string of nucleotides in an mRNA transcript that corresponds directly to the string of amino acids in the associated protein. Thus, it reflects the state of the transcript after non-coding sequences have been removed by RNA processing (<xref rid="B112" ref-type="bibr">112</xref>, <xref rid="B113" ref-type="bibr">113</xref>).</p>
      <p>Although researchers have traditionally operated on the assumption that human miRNAs target the 3´ untranslated region of human transcripts, more recent research suggests that miRNAs can target other elements of the transcript such as the coding region (<xref rid="B114" ref-type="bibr">114</xref>, <xref rid="B115" ref-type="bibr">115</xref>). Furthermore, IntaRNA target prediction data from our prior study on let-7b-5p targeting of <italic toggle="yes">P. aeruginosa</italic> suggest that in <italic toggle="yes">P. aeruginosa</italic>, human miRNAs are far more likely to interact with the coding region than the untranslated region of the transcript (<xref rid="B38" ref-type="bibr">38</xref>). Thus, the prediction data in the Rocket-miR application are based on coding sequences in CF pathogens (though future efforts to repurpose the application could assess the predicted targeting of non-coding regions as well).</p>
      <p>The CDS file contains the nucleotide sequence of all known protein-encoding genes for a given pathogen strain. It also contains gene identifier metadata that enables the genes to be mapped to KEGG biological pathways. For each of the species in the application, we chose strains that have annotations in the KEGG database, enabling us to make predictions about how specific miRNAs target KEGG pathways.</p>
      <p>The human miRNA sequence data were downloaded from the database MiRGeneDB, which recognizes 630 different human miRNAs as mature miRNA sequences. All the human miRNAs in MiRGeneDB were manually curated by the creators of the database. The creators of MiRGeneDB have noted that other miRNA databases, which encourage community submission of miRNA sequences and include several thousand putative human miRNAs, contain many false positives. Certain sequences labeled as miRNAs may belong to other classes of small RNAs. For this reason, we have chosen the 630 miRNAs in miRGeneDB as the gold standard for human miRNA sequences (<xref rid="B116" ref-type="bibr">116</xref>). That said, researchers may be interested in repurposing the application to predict targets of other small miRNAs. Researchers may also design new miRNA sequences (miRNA mimics) in an attempt to improve on the natural targeting capacity of human miRNAs. In both cases, IntaRNA can be used to make target predictions, which can then be visualized with the Rocket-miR application.</p>
    </sec>
    <sec id="s4-2">
      <title>Predicting miRNA targets</title>
      <p>The IntaRNA target prediction algorithm, designed by the Backofen Lab at the University of Freiburg, predicts hybridization between two RNAs, including miRNA and mRNA (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B117" ref-type="bibr">117</xref>). It considers not only the propensity for nucleotides in the two interacting RNAs to associate, but also the secondary structure of each individual RNA. Before two RNAs can interact, each must adopt an “open,” linearized conformation so that nucleotides in the two molecules are exposed to one another for interaction. If a given RNA has a higher tendency to fold up on itself and form interactions between its own nucleotides, it is less likely to interact with other RNAs, and therefore its predicted interaction score is less favorable.</p>
      <p>IntaRNA was selected as a target prediction algorithm for several reasons. First, databases that provide ready prediction data to the public are limited in scope. The database miRDB, for example, presents millions of predicted targets of miRNAs across five species (human, mouse, rat, dog, and chicken) (<xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B93" ref-type="bibr">93</xref>). However, databases like miRDB are limited to model organisms and other popular species—not microbial pathogens such as those that infect people with CF and other diseases. Though other prediction algorithms like IntaRNA exist that can predict interactions between different RNAs for any species, IntaRNA was chosen because it considers both the nucleotide sequence of pairing miRNAs and the intramolecular interactions of those miRNAs as outlined in the previous paragraph. Other available algorithms—RNAhybrid and RNAplex, for example—tend to focus on nucleotide pairing alone (<xref rid="B118" ref-type="bibr">118</xref>, <xref rid="B119" ref-type="bibr">119</xref>). Finally, the use of IntaRNA is supported by our own prior experience. We have used the algorithm in prior studies to predict miRNA targeting, and these predictions were born out by the results of wet bench experiments (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B52" ref-type="bibr">52</xref>). This gives us confidence in the algorithm’s predictive capacity for human pathogens.</p>
      <p>For each RNA-RNA interaction, IntaRNA calculates an energy score. This energy score is more negative when the interaction between the miRNA and mRNA is stronger. For example, an interaction between a miRNA and mRNA that has an energy score of −15 is predicted to be a stronger interaction than a miRNA-mRNA pair with an energy score of −8. Only negative energy scores are possible. Although RNA molecules possess the nucleotide uracil (U) instead of thymine (T), some RNA sequences in public databases (including those featured in the application) contain Ts in the place of Us. The IntaRNA algorithm recognizes this possibility and automatically converts all thymine nucleotides to uracil in order to predict RNA interactions (see note in the IntaRNA Github Repository:<ext-link xlink:href="https://github.com/BackofenLab/IntaRNA" ext-link-type="uri">
</ext-link><ext-link xlink:href="https://github.com/BackofenLab/IntaRNA" ext-link-type="uri">https://github.com/BackofenLab/IntaRNA</ext-link>).</p>
      <p>The energy cutoffs (strong: −16.98, medium: −15.35, weak, −13.47) in the application are set based on data from our prior work, in which we determined that <italic toggle="yes">Pseudomonas aeruginosa</italic> cells over-expressing let-7b-5p significantly downregulated a set of 48 proteins, with the targeted proteins having a distribution of predicted IntaRNA energy scores [Appendix, pg. 18 (<xref rid="B38" ref-type="bibr">38</xref>, <xref rid="B38" ref-type="bibr">38</xref>)]. The most stringent cutoff in the application corresponds to the first quartile value in this distribution, the medium targeting cutoff to the median, and the least stringent cutoff to the third quartile value. It is important to note that we chose to limit our analysis to proteins with predicted energy scores less than the least stringent cutoff to be downregulated significantly. Using more stringent cutoffs would increase confidence in the likelihood of targeting but identify fewer candidate miRNAS, a tradeoff that might be suboptimal for species that are less effectively targeted by human miRNAs.</p>
      <p>The IntaRNA program is typically run in a terminal window. When calling the program, a set of query sequences and a set of target sequences are specified in a text-based file. In the context of this study, the query sequence was always set up to contain the set of 630 human miRNA sequences, and the target file contained coding sequences from the different microbial pathogens included in the Rocket-miR application. This computational task was performed on a high-performance computing server. To make the computation more feasible (screening all 630 human miRNAs against 1,000 of mRNA transcripts at once would take up an excessive amount of memory on the server), each CDS file was divided into many small files of 250 mRNA transcripts a piece. Then, the 630 miRNAs were screened against each set of 250 transcripts individually—each with a single call of the IntaRNA algorithm. Using this approach, a microbial pathogen with 4,000 genes requires the IntaRNA algorithm to be applied 16 separate times. Ultimately, the 250-transcript files were stitched back together in a single “Energy Table” for inclusion in the application. All codes used in the command line to run IntaRNA on pathogens of interest, as well as the R script used to consolidate the 250-transcript files into Energy Tables, and data files including the energy tables themselves are available in our GitHub repository:<ext-link xlink:href="https://github.com/samlo777/Rocket-miR" ext-link-type="uri">
</ext-link><ext-link xlink:href="https://github.com/samlo777/Rocket-miR" ext-link-type="uri">https://github.com/samlo777/Rocket-miR</ext-link></p>
    </sec>
    <sec id="s4-3">
      <title>Gathering gene and pathway annotations</title>
      <p>As mentioned above, the microbial strains featured in the application were chosen because they had associated KEGG pathway annotations. This enables users to visualize pathway targeting for their pathogens of interest in addition to the targeting of individual genes. Once the target prediction data were generated for a particular pathogen using IntaRNA, and the “Energy Table” was consolidated, the gene IDs were extracted from that energy table using regex functions from the “stringr” package in R (<xref rid="B120" ref-type="bibr">120</xref>). There are multiple gene IDs housed in the CDS files, though the kinds of IDs present can differ between species. When available, the NCBI Gene ID was extracted. If not, the RefSeq protein ID was extracted.</p>
      <p>Using the ID Mapping feature on the Uniprot website (<ext-link xlink:href="https://www.uniprot.org/id-mapping" ext-link-type="uri">https://www.uniprot.org/id-mapping</ext-link>), NCBI Gene IDs or RefSeq protein IDs were mapped first to Uniprot IDs, and then to KEGG gene IDs in a multistep process (<xref rid="B121" ref-type="bibr">121</xref>). This ID mapping was performed for all the species. In addition, the R “EnrichmentBrowser” package was used to identify the genes on each KEGG pathway (each pathway has its own pathway identifier) (<xref rid="B122" ref-type="bibr">122</xref>). Ultimately, the KEGG gene IDs and KEGG pathway identifiers were all merged into a single table. All gene annotation files are available in the Github repository.</p>
    </sec>
    <sec id="s4-4">
      <title>Application development</title>
      <p>The Rocket-miR application was developed in multiple stages. The first, outlined in the sections above, involved gathering the target prediction and annotation data together in the right format. Once the data were prepared for several pathogens, the various sections of the application were prototyped. The application was carefully designed so that when the time came for new prediction data to be added, it could be seamlessly integrated without changing any of the application code.</p>
      <p>The Rocket-miR application, like all R shiny applications, requires a specific code architecture—a single file labeled app.R with a section for user interface (UI) code (defining the appearance of the application) and a subsequent section for server code (defining the functional code of the application). In addition to the app.R file, a “Data Processing” script was prepared to generate the energy tables for inclusion in the application, and a “Data Setup” script to combine the energy tables with gene annotations. The “Data Setup” file also performed some preliminary calculations on the energy table data so that users of the application could run the application and visualize data more quickly instead of waiting for those calculations to run. All these code files are available in the Github repository.</p>
      <p>The application, developed in R using the RStudio IDE, employs a number of publicly available, open-source R packages (<xref rid="B123" ref-type="bibr">123</xref>, <xref rid="B124" ref-type="bibr">124</xref>). In addition to the “shiny” package, which is required for all shiny applications, the Rocket-miR application makes use of the “shinydashboard” package for its application layout (<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B126" ref-type="bibr">126</xref>). The “shinyjs” package was used to enable users to switch between different modules in the application (<xref rid="B127" ref-type="bibr">127</xref>). The “shinyBS” package was used to create custom buttons (<xref rid="B128" ref-type="bibr">128</xref>). The “DT” package was used to generate data tables that are filterable and searchable (<xref rid="B129" ref-type="bibr">129</xref>). The “stringr” package was used to simplify the text in these tables (e.g., from long gene annotations to a simple gene name) (<xref rid="B120" ref-type="bibr">120</xref>). The “shinycssloaders” package enabled loading animations (<xref rid="B130" ref-type="bibr">130</xref>). Finally, for data analysis and visualization, the “plotly” package was used to create interactive figures, and the “kmer” package was utilized to analyze the structure of miRNA sequences (<xref rid="B131" ref-type="bibr">131</xref>, <xref rid="B132" ref-type="bibr">132</xref>).</p>
    </sec>
    <sec id="s4-5">
      <title><italic toggle="yes">In vitro</italic> validation experiment</title>
      <p>PA14 was electroporated to introduce a pMQ70 expression vector (with arabinose-inducible promoter and carbenicillin resistance as selectable marker) containing either the mature let-7b-5p sequence as an insert (PA14-let-7b-5p) or no insert (PA14-Empty vector), as described previously (<xref rid="B38" ref-type="bibr">38</xref>). The glycerol stocks of these two strains were first streaked out on two different Luria broth (LB) agar plates containing 300 µg/mL carbenicillin. The colonies from the plates were then inoculated in LB broth containing 150 µg/mL carbenicillin for two overnight grow-ups. Twenty-five thousand CFU per mL of the control strain or PA14-let-7b-5p was then plated in MBEC Assay Biofilm Inoculator Plates (Innovotech) with 100 µM arabinose to induce the expression from the promoters and with or without 1.2 µg/mL aztreonam. The plate was placed on a shaker at 110 rpm and 37°C. Twenty-four hours later, the coverlid, composed of the pegs, was washed twice with PBS++ (ThermoFisher DPBS with added calcium and magnesium). The coverlid was then placed into a new 96-well plate containing 200 µL fresh LB/well and sonicated for 10 min in a water-bath sonicator (VWR Symphony model). The LB from the wells was serially diluted, plated on LB agar plates, and incubated overnight at 37°C. CFU were counted and final counts were adjusted by multiplying the dilution factor. Data were analyzed using GraphPad Prism (version 9.1.2; San Diego, CA) and the R software environment for statistical computing and graphics version 4.1.0 (<xref rid="B123" ref-type="bibr">123</xref>). The R package MASS was used to calculate <italic toggle="yes">P</italic>-values from the binomial generalized linear models (<xref rid="B133" ref-type="bibr">133</xref>).</p>
    </sec>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="d96e291">
      <caption>
        <title>Reviewer comments</title>
      </caption>
      <media xlink:href="reviewer-comments.pdf"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <title>ACKNOWLEDGMENTS</title>
    <p>Support for these studies was provided by the Cystic Fibrosis Foundation (STANTO19R0–CFF), the NIH (grants P30 DK117469, R01 HL151385, R35 GM142685), and The Flatley Foundation.</p>
    <p>S.L.N. developed the Rocket-miR application and wrote the manuscript apart from the case studies. T.H.H. and K.K. helped guide the initial formulation of the project. T.H.H. provided helpful feedback on the application and manuscript throughout their development. K.K. contributed code enabling the miRNA target predictions that form the basis of the application. S.S. contributed the first two case studies, while C.J.L. and B.D.R. contributed the third. T.H.H., K.K., S.S., C.J.L., B.D.R., and B.A.S. all provided input on the development of the application and contributed to manuscript preparation for submission.</p>
  </ack>
  <sec sec-type="data-availability" id="s5-1">
    <title>DATA AVAILABILITY</title>
    <p>The source code for the Rocket-miR application was written in R, using the R Studio integrated development environment. The application is accessible online at the following address:<ext-link xlink:href="http://scangeo.dartmouth.edu/RocketmiR/" ext-link-type="uri">
</ext-link><ext-link xlink:href="http://scangeo.dartmouth.edu/RocketmiR/" ext-link-type="uri">http://scangeo.dartmouth.edu/RocketmiR/</ext-link>. The source code and application data are accessible in our Github Repository and can be run independently using RStudio on a personal device by following the instructions in the repository’s README file:<ext-link xlink:href="https://github.com/samlo777/Rocket-miR" ext-link-type="uri">
</ext-link><ext-link xlink:href="https://github.com/samlo777/Rocket-miR" ext-link-type="uri">https://github.com/samlo777/Rocket-miR</ext-link>.</p>
  </sec>
  <sec sec-type="supplementary-material" id="s5-2">
    <title>SUPPLEMENTAL MATERIAL</title>
    <p specific-use="print-only">The following material is available online at <ext-link xlink:href="https://doi.org/10.1128/msystems.00653-23" ext-link-type="uri">https://doi.org/10.1128/msystems.00653-23</ext-link>.</p>
    <supplementary-material id="SuF1" position="float" content-type="local-data">
      <object-id pub-id-type="doi">10.1128/msystems.00653-23.SuF1</object-id>
      <label>Supplemental figures</label>
      <caption>
        <title>msystems.00653-23-s0001.pdf</title>
        <p>Fig. S1 to S5.</p>
      </caption>
      <media xlink:href="msystems.00653-23-s0001.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="SuF2" position="float" content-type="local-data">
      <object-id pub-id-type="doi">10.1128/msystems.00653-23.SuF2</object-id>
      <label>OPEN PEER REVIEW</label>
      <caption>
        <title>reviewer-comments.pdf</title>
      </caption>
      <media xlink:href="reviewer-comments.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <p specific-use="online-only">ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse. </p>
  </sec>
  <ref-list>
    <title>REFERENCES</title>
    <ref id="B1">
      <label>1</label>
      <mixed-citation publication-type="journal">. <person-group person-group-type="author"><collab>CDC</collab></person-group>. <year>2022</year>. <article-title>What Exactly is Antibiotic Resistance?</article-title>
<source>Centers for Disease Control and Prevention</source>. <ext-link xlink:href="https://www.cdc.gov/drugresistance/about.html" ext-link-type="uri">https://www.cdc.gov/drugresistance/about.html</ext-link>. <date-in-citation>13 April 2023</date-in-citation>.</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Murray</surname><given-names>CJL</given-names></string-name>, <string-name><surname>Ikuta</surname><given-names>KS</given-names></string-name>, <string-name><surname>Sharara</surname><given-names>F</given-names></string-name>, <string-name><surname>Swetschinski</surname><given-names>L</given-names></string-name>, <string-name><surname>Robles Aguilar</surname><given-names>G</given-names></string-name>, <string-name><surname>Gray</surname><given-names>A</given-names></string-name>, <string-name><surname>Han</surname><given-names>C</given-names></string-name>, <string-name><surname>Bisignano</surname><given-names>C</given-names></string-name>, <string-name><surname>Rao</surname><given-names>P</given-names></string-name>, <string-name><surname>Wool</surname><given-names>E</given-names></string-name>, <etal>et al.</etal></person-group>. <year>2022</year>. <article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title>. <source>The Lancet</source><volume>399</volume>:<fpage>629</fpage>–<lpage>655</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3</label>
      <mixed-citation publication-type="webpage"><article-title>Stemming the Superbug tide: Just A few dollars more | en | OECD</article-title>. <year>2022</year>. <comment>Available from</comment>: <ext-link xlink:href="https://www.oecd.org/health/stemming-the-superbug-tide-9789264307599-en.htm" ext-link-type="uri">https://www.oecd.org/health/stemming-the-superbug-tide-9789264307599-en.htm</ext-link></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4</label>
      <mixed-citation publication-type="webpage"><article-title>Lack of innovation set to undermine antibiotic performance and health gains</article-title>. <year>2023</year>. <comment>Available from</comment>: <ext-link xlink:href="https://www.who.int/news/item/22-06-2022-22-06-2022-lack-of-innovation-set-to-undermine-antibiotic-performance-and-health-gains" ext-link-type="uri">https://www.who.int/news/item/22-06-2022-22-06-2022-lack-of-innovation-set-to-undermine-antibiotic-performance-and-health-gains</ext-link></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mulani</surname><given-names>MS</given-names></string-name>, <string-name><surname>Kamble</surname><given-names>EE</given-names></string-name>, <string-name><surname>Kumkar</surname><given-names>SN</given-names></string-name>, <string-name><surname>Tawre</surname><given-names>MS</given-names></string-name>, <string-name><surname>Pardesi</surname><given-names>KR</given-names></string-name></person-group>. <year>2019</year>. <article-title>Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review</article-title>. <source>Front Microbiol</source><volume>10</volume>:<elocation-id>539</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2019.00539</pub-id>doi:<ext-link xlink:href="30988669" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30988669</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6</label>
      <mixed-citation publication-type="webpage"><article-title>WHO publishes list of bacteria for which new antibiotics are urgently needed</article-title>. <year>2022</year>. <comment>Available from</comment>: <ext-link xlink:href="https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed" ext-link-type="uri">https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed</ext-link></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parkins</surname><given-names>MD</given-names></string-name>, <string-name><surname>Somayaji</surname><given-names>R</given-names></string-name>, <string-name><surname>Waters</surname><given-names>VJ</given-names></string-name></person-group>. <year>2018</year>. <article-title>Epidemiology, biology, and impact of clonal Pseudomonas aeruginosa infections in cystic fibrosis</article-title>. <source>Clin Microbiol Rev</source><volume>31</volume>:<elocation-id>e00019-18</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/CMR.00019-18</pub-id>doi:<ext-link xlink:href="30158299" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30158299</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>LiPuma</surname><given-names>JJ</given-names></string-name></person-group>. <year>2010</year>. <article-title>The changing microbial epidemiology in cystic fibrosis</article-title>. <source>Clin Microbiol Rev</source><volume>23</volume>:<fpage>299</fpage>–<lpage>323</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CMR.00068-09</pub-id>doi:<ext-link xlink:href="20375354" ext-link-type="pmid"/><pub-id pub-id-type="pmid">20375354</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kreda</surname><given-names>SM</given-names></string-name>, <string-name><surname>Davis</surname><given-names>CW</given-names></string-name>, <string-name><surname>Rose</surname><given-names>MC</given-names></string-name></person-group>. <year>2012</year>. <article-title>CFTR, mucins, and mucus obstruction in cystic fibrosis</article-title>. <source>Cold Spring Harb Perspect Med</source><volume>2</volume>:<elocation-id>a009589</elocation-id>. doi:<pub-id pub-id-type="doi">10.1101/cshperspect.a009589</pub-id>doi:<ext-link xlink:href="22951447" ext-link-type="pmid"/><pub-id pub-id-type="pmid">22951447</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rubin</surname><given-names>BK</given-names></string-name></person-group>. <year>2007</year>. <article-title>Mucus structure and properties in cystic fibrosis</article-title>. <source>Paediatr Respir Rev</source><volume>8</volume>:<fpage>4</fpage>–<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.prrv.2007.02.004</pub-id>doi:<ext-link xlink:href="17419972" ext-link-type="pmid"/><pub-id pub-id-type="pmid">17419972</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Livraghi</surname><given-names>A</given-names></string-name>, <string-name><surname>Randell</surname><given-names>SH</given-names></string-name></person-group>. <year>2007</year>. <article-title>Cystic fibrosis and other respiratory diseases of impaired mucus clearance</article-title>. <source>Toxicol pathol</source><volume>35</volume>:<fpage>116</fpage>–<lpage>129</lpage>. doi:<pub-id pub-id-type="doi">10.1080/01926230601060025</pub-id>doi:<ext-link xlink:href="17325980" ext-link-type="pmid"/><pub-id pub-id-type="pmid">17325980</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Esther</surname><given-names>CR</given-names></string-name>, <string-name><surname>Muhlebach</surname><given-names>MS</given-names></string-name>, <string-name><surname>Ehre</surname><given-names>C</given-names></string-name>, <string-name><surname>Hill</surname><given-names>DB</given-names></string-name>, <string-name><surname>Wolfgang</surname><given-names>MC</given-names></string-name>, <string-name><surname>Kesimer</surname><given-names>M</given-names></string-name>, <string-name><surname>Ramsey</surname><given-names>KA</given-names></string-name>, <string-name><surname>Markovetz</surname><given-names>MR</given-names></string-name>, <string-name><surname>Garbarine</surname><given-names>IC</given-names></string-name>, <string-name><surname>Forest</surname><given-names>MG</given-names></string-name>, <string-name><surname>Seim</surname><given-names>I</given-names></string-name>, <string-name><surname>Zorn</surname><given-names>B</given-names></string-name>, <string-name><surname>Morrison</surname><given-names>CB</given-names></string-name>, <string-name><surname>Delion</surname><given-names>MF</given-names></string-name>, <string-name><surname>Thelin</surname><given-names>WR</given-names></string-name>, <string-name><surname>Villalon</surname><given-names>D</given-names></string-name>, <string-name><surname>Sabater</surname><given-names>JR</given-names></string-name>, <string-name><surname>Turkovic</surname><given-names>L</given-names></string-name>, <string-name><surname>Ranganathan</surname><given-names>S</given-names></string-name>, <string-name><surname>Stick</surname><given-names>SM</given-names></string-name>, <string-name><surname>Boucher</surname><given-names>RC</given-names></string-name></person-group>. <year>2019</year>. <article-title>Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis</article-title>. <source>Sci Transl Med</source><volume>11</volume>:<elocation-id>eaav3488</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.aav3488</pub-id>doi:<ext-link xlink:href="30944166" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30944166</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Durda-Masny</surname><given-names>M</given-names></string-name>, <string-name><surname>Goździk-Spychalska</surname><given-names>J</given-names></string-name>, <string-name><surname>John</surname><given-names>A</given-names></string-name>, <string-name><surname>Czaiński</surname><given-names>W</given-names></string-name>, <string-name><surname>Stróżewska</surname><given-names>W</given-names></string-name>, <string-name><surname>Pawłowska</surname><given-names>N</given-names></string-name>, <string-name><surname>Wlizło</surname><given-names>J</given-names></string-name>, <string-name><surname>Batura-Gabryel</surname><given-names>H</given-names></string-name>, <string-name><surname>Szwed</surname><given-names>A</given-names></string-name></person-group>. <year>2021</year>. <article-title>The determinants of survival among adults with cystic fibrosis-a cohort study</article-title>. <source>J Physiol Anthropol</source><volume>40</volume>:<fpage>19</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40101-021-00269-7</pub-id>doi:<ext-link xlink:href="34749804" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34749804</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bonyadi</surname><given-names>P</given-names></string-name>, <string-name><surname>Saleh</surname><given-names>NT</given-names></string-name>, <string-name><surname>Dehghani</surname><given-names>M</given-names></string-name>, <string-name><surname>Yamini</surname><given-names>M</given-names></string-name>, <string-name><surname>Amini</surname><given-names>K</given-names></string-name></person-group>. <year>2022</year>. <article-title>Prevalence of antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis infection: a systematic review and meta-analysis</article-title>. <source>Microb Pathog</source><volume>165</volume>:<fpage>105461</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.micpath.2022.105461</pub-id>doi:<ext-link xlink:href="35240288" ext-link-type="pmid"/><pub-id pub-id-type="pmid">35240288</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blanchard</surname><given-names>AC</given-names></string-name>, <string-name><surname>Waters</surname><given-names>VJ</given-names></string-name></person-group>. <year>2022</year>. <article-title>Opportunistic pathogens in cystic fibrosis: epidemiology and pathogenesis of lung infection</article-title>. <source>J Pediatric Infect Dis Soc</source><volume>11</volume>:<fpage>S3</fpage>–<lpage>S12</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jpids/piac052</pub-id>doi:<ext-link xlink:href="36069904" ext-link-type="pmid"/><pub-id pub-id-type="pmid">36069904</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gilpin</surname><given-names>D</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>LR</given-names></string-name>, <string-name><surname>Ceppe</surname><given-names>A</given-names></string-name>, <string-name><surname>Muhlebach</surname><given-names>MS</given-names></string-name></person-group>. <year>2021</year>. <article-title>Phenotypic characteristics of incident and chronic MRSA isolates in cystic fibrosis</article-title>. <source>J Cyst Fibros</source><volume>20</volume>:<fpage>692</fpage>–<lpage>698</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jcf.2021.05.015</pub-id>doi:<ext-link xlink:href="34103251" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34103251</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17</label>
      <mixed-citation publication-type="webpage"><article-title>Prevalence and antibiotic resistance of Stenotrophomonas maltophilia in respiratory tract samples: a 10-year epidemiological snapshot - PMC</article-title>. <year>2022</year>. <comment>Available from</comment>: <ext-link xlink:href="Https://Www.Ncbi.Nlm.NIH.Gov/Pmc/articles/Pmc6698998/" ext-link-type="uri">Https://Www.Ncbi.Nlm.NIH.Gov/Pmc/articles/Pmc6698998/</ext-link>. <comment>Retrieved</comment><date-in-citation>14 September 2022</date-in-citation>.</mixed-citation>
    </ref>
    <ref id="B18">
      <label>18</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>WX</given-names></string-name>, <string-name><surname>Lei</surname><given-names>X</given-names></string-name>, <string-name><surname>Ai</surname><given-names>HL</given-names></string-name>, <string-name><surname>Bai</surname><given-names>X</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>He</surname><given-names>J</given-names></string-name>, <string-name><surname>Li</surname><given-names>ZH</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>YS</given-names></string-name>, <string-name><surname>Feng</surname><given-names>T</given-names></string-name>, <string-name><surname>Liu</surname><given-names>JK</given-names></string-name></person-group>. <year>2019</year>. <article-title>Cytochalasans from the endophytic fungus xylaria cf. curta with resistance reversal activity against fluconazole-resistant Candida albicans</article-title>. <source>Org Lett</source><volume>21</volume>:<fpage>1108</fpage>–<lpage>1111</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.orglett.9b00015</pub-id>doi:<ext-link xlink:href="30681869" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30681869</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Risum</surname><given-names>M</given-names></string-name>, <string-name><surname>Hare</surname><given-names>RK</given-names></string-name>, <string-name><surname>Gertsen</surname><given-names>JB</given-names></string-name>, <string-name><surname>Kristensen</surname><given-names>L</given-names></string-name>, <string-name><surname>Johansen</surname><given-names>HK</given-names></string-name>, <string-name><surname>Helweg-Larsen</surname><given-names>J</given-names></string-name>, <string-name><surname>Abou-Chakra</surname><given-names>N</given-names></string-name>, <string-name><surname>Pressler</surname><given-names>T</given-names></string-name>, <string-name><surname>Skov</surname><given-names>M</given-names></string-name>, <string-name><surname>Jensen-Fangel</surname><given-names>S</given-names></string-name>, <string-name><surname>Arendrup</surname><given-names>MC</given-names></string-name></person-group>. <year>2020</year>. <article-title>Azole-resistant Aspergillus Fumigatus among Danish cystic fibrosis patients: Increasing prevalence and dominance of Tr34/L98H. frontiers in Microbiology</article-title>. <source>Front. Microbiol</source><volume>11</volume>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2020.01850</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Varela</surname><given-names>MC</given-names></string-name>, <string-name><surname>Roch</surname><given-names>M</given-names></string-name>, <string-name><surname>Taglialegna</surname><given-names>A</given-names></string-name>, <string-name><surname>Long</surname><given-names>SW</given-names></string-name>, <string-name><surname>Saavedra</surname><given-names>MO</given-names></string-name>, <string-name><surname>Rose</surname><given-names>WE</given-names></string-name>, <string-name><surname>Davis</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>LR</given-names></string-name>, <string-name><surname>Hernandez</surname><given-names>RE</given-names></string-name>, <string-name><surname>Rosato</surname><given-names>RR</given-names></string-name>, <string-name><surname>Rosato</surname><given-names>AE</given-names></string-name></person-group>. <year>2020</year>. <article-title>Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA</article-title>. <source>Commun Biol</source><volume>3</volume>:<fpage>599</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s42003-020-01313-5</pub-id>doi:<ext-link xlink:href="33093601" ext-link-type="pmid"/><pub-id pub-id-type="pmid">33093601</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scoffone</surname><given-names>VC</given-names></string-name>, <string-name><surname>Barbieri</surname><given-names>G</given-names></string-name>, <string-name><surname>Buroni</surname><given-names>S</given-names></string-name>, <string-name><surname>Scarselli</surname><given-names>M</given-names></string-name>, <string-name><surname>Pizza</surname><given-names>M</given-names></string-name>, <string-name><surname>Rappuoli</surname><given-names>R</given-names></string-name>, <string-name><surname>Riccardi</surname><given-names>G</given-names></string-name></person-group>. <year>2020</year>. <article-title>Vaccines to overcome antibiotic resistance: the challenge of Burkholderia cenocepacia</article-title>. <source>Trends Microbiol</source><volume>28</volume>:<fpage>315</fpage>–<lpage>326</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tim.2019.12.005</pub-id>doi:<ext-link xlink:href="31932141" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31932141</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Degiacomi</surname><given-names>G</given-names></string-name>, <string-name><surname>Sammartino</surname><given-names>JC</given-names></string-name>, <string-name><surname>Chiarelli</surname><given-names>LR</given-names></string-name>, <string-name><surname>Riabova</surname><given-names>O</given-names></string-name>, <string-name><surname>Makarov</surname><given-names>V</given-names></string-name>, <string-name><surname>Pasca</surname><given-names>MR</given-names></string-name></person-group>. <year>2019</year>. <article-title>Mycobacterium abscessus, an emerging and worrisome pathogen among cystic fibrosis patients</article-title>. <source>Int J Mol Sci</source><volume>20</volume>:<elocation-id>5868</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/ijms20235868</pub-id>doi:<ext-link xlink:href="31766758" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31766758</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Henrichfreise</surname><given-names>B</given-names></string-name>, <string-name><surname>Wiegand</surname><given-names>I</given-names></string-name>, <string-name><surname>Pfister</surname><given-names>W</given-names></string-name>, <string-name><surname>Wiedemann</surname><given-names>B</given-names></string-name></person-group>. <year>2007</year>. <article-title>Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation</article-title>. <source>Antimicrob Agents Chemother</source><volume>51</volume>:<fpage>4062</fpage>–<lpage>4070</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00148-07</pub-id>doi:<ext-link xlink:href="17876002" ext-link-type="pmid"/><pub-id pub-id-type="pmid">17876002</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ciofu</surname><given-names>O</given-names></string-name>, <string-name><surname>Tolker-Nielsen</surname><given-names>T</given-names></string-name></person-group>. <year>2019</year>. <article-title>Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents-how P. aeruginosa can escape antibiotics</article-title>. <source>Front Microbiol</source><volume>10</volume>:<fpage>913</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2019.00913</pub-id>doi:<ext-link xlink:href="31130925" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31130925</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25</label>
      <mixed-citation publication-type="webpage"><person-group person-group-type="author"><string-name><surname>Parry</surname><given-names>J</given-names></string-name></person-group>. <year>2022</year>. <article-title>New Yale center to advance Phage understanding, treatments, training, education</article-title>. <comment>Available from</comment>: <ext-link xlink:href="https://medicine.yale.edu/news-article/new-yale-center-to-advance-phage-understanding-treatments-training-education/" ext-link-type="uri">https://medicine.yale.edu/news-article/new-yale-center-to-advance-phage-understanding-treatments-training-education/</ext-link>. <comment>Retrieved</comment><date-in-citation>6 Dec 2022</date-in-citation>.</mixed-citation>
    </ref>
    <ref id="B26">
      <label>26</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chan</surname><given-names>BK</given-names></string-name>, <string-name><surname>Stanley</surname><given-names>G</given-names></string-name>, <string-name><surname>Modak</surname><given-names>M</given-names></string-name>, <string-name><surname>Koff</surname><given-names>JL</given-names></string-name>, <string-name><surname>Turner</surname><given-names>PE</given-names></string-name></person-group>. <year>2021</year>. <article-title>Bacteriophage therapy for infections in CF</article-title>. <source>Pediatr Pulmonol</source><volume>56</volume>:<fpage>S4</fpage>–<lpage>S9</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ppul.25190</pub-id>doi:<ext-link xlink:href="33434411" ext-link-type="pmid"/><pub-id pub-id-type="pmid">33434411</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koff</surname><given-names>J</given-names></string-name></person-group>. <year>2022</year>. <article-title>Cystic fibrosis bacterioPHage study at yale (CYPHY): a single-site, randomized, double-blind, placebo-controlled study of bacteriophage therapy YPT-01 for Pseudomonas aeruginosa infections in adults with cystic fibrosis</article-title>. <source>Clinical trial registration. clinicaltrials.gov</source></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johansen</surname><given-names>MD</given-names></string-name>, <string-name><surname>Alcaraz</surname><given-names>M</given-names></string-name>, <string-name><surname>Dedrick</surname><given-names>RM</given-names></string-name>, <string-name><surname>Roquet-Banères</surname><given-names>F</given-names></string-name>, <string-name><surname>Hamela</surname><given-names>C</given-names></string-name>, <string-name><surname>Hatfull</surname><given-names>GF</given-names></string-name>, <string-name><surname>Kremer</surname><given-names>L</given-names></string-name></person-group>. <year>2021</year>. <article-title>Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus</article-title>. <source>Dis Model Mech</source><volume>14</volume>:<elocation-id>dmm049159</elocation-id>. doi:<pub-id pub-id-type="doi">10.1242/dmm.049159</pub-id>doi:<ext-link xlink:href="34530447" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34530447</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lauman</surname><given-names>P</given-names></string-name>, <string-name><surname>Dennis</surname><given-names>JJ</given-names></string-name></person-group>. <year>2021</year>. <article-title>Advances in phage therapy: targeting the Burkholderia cepacia complex</article-title>. <source>Viruses</source><volume>13</volume>:<elocation-id>1331</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/v13071331</pub-id>doi:<ext-link xlink:href="34372537" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34372537</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reid</surname><given-names>G</given-names></string-name>, <string-name><surname>Kao</surname><given-names>SC</given-names></string-name>, <string-name><surname>Pavlakis</surname><given-names>N</given-names></string-name>, <string-name><surname>Brahmbhatt</surname><given-names>H</given-names></string-name>, <string-name><surname>MacDiarmid</surname><given-names>J</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>S</given-names></string-name>, <string-name><surname>Boyer</surname><given-names>M</given-names></string-name>, <string-name><surname>van Zandwijk</surname><given-names>N</given-names></string-name></person-group>. <year>2016</year>. <article-title>Clinical development of targomirs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer</article-title>. <source>Epigenomics</source><volume>8</volume>:<fpage>1079</fpage>–<lpage>1085</lpage>. doi:<pub-id pub-id-type="doi">10.2217/epi-2016-0035</pub-id>doi:<ext-link xlink:href="27185582" ext-link-type="pmid"/><pub-id pub-id-type="pmid">27185582</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Zandwijk</surname><given-names>N</given-names></string-name>, <string-name><surname>Pavlakis</surname><given-names>N</given-names></string-name>, <string-name><surname>Kao</surname><given-names>SC</given-names></string-name>, <string-name><surname>Linton</surname><given-names>A</given-names></string-name>, <string-name><surname>Boyer</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>S</given-names></string-name>, <string-name><surname>Huynh</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chrzanowska</surname><given-names>A</given-names></string-name>, <string-name><surname>Fulham</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Bailey</surname><given-names>DL</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>WA</given-names></string-name>, <string-name><surname>Kritharides</surname><given-names>L</given-names></string-name>, <string-name><surname>Ridley</surname><given-names>L</given-names></string-name>, <string-name><surname>Pattison</surname><given-names>ST</given-names></string-name>, <string-name><surname>MacDiarmid</surname><given-names>J</given-names></string-name>, <string-name><surname>Brahmbhatt</surname><given-names>H</given-names></string-name>, <string-name><surname>Reid</surname><given-names>G</given-names></string-name></person-group>. <year>2017</year>. <article-title>Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study</article-title>. <source>Lancet Oncol</source><volume>18</volume>:<fpage>1386</fpage>–<lpage>1396</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(17)30621-6</pub-id>doi:<ext-link xlink:href="28870611" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28870611</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reid</surname><given-names>G</given-names></string-name>, <string-name><surname>Pel</surname><given-names>ME</given-names></string-name>, <string-name><surname>Kirschner</surname><given-names>MB</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>YY</given-names></string-name>, <string-name><surname>Mugridge</surname><given-names>N</given-names></string-name>, <string-name><surname>Weiss</surname><given-names>J</given-names></string-name>, <string-name><surname>Williams</surname><given-names>M</given-names></string-name>, <string-name><surname>Wright</surname><given-names>C</given-names></string-name>, <string-name><surname>Edelman</surname><given-names>JJB</given-names></string-name>, <string-name><surname>Vallely</surname><given-names>MP</given-names></string-name>, <string-name><surname>McCaughan</surname><given-names>BC</given-names></string-name>, <string-name><surname>Klebe</surname><given-names>S</given-names></string-name>, <string-name><surname>Brahmbhatt</surname><given-names>H</given-names></string-name>, <string-name><surname>MacDiarmid</surname><given-names>JA</given-names></string-name>, <string-name><surname>van Zandwijk</surname><given-names>N</given-names></string-name></person-group>. <year>2013</year>. <article-title>Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma</article-title>. <source>Ann Oncol</source><volume>24</volume>:<fpage>3128</fpage>–<lpage>3135</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdt412</pub-id>doi:<ext-link xlink:href="24148817" ext-link-type="pmid"/><pub-id pub-id-type="pmid">24148817</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beg</surname><given-names>MS</given-names></string-name>, <string-name><surname>Brenner</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Sachdev</surname><given-names>J</given-names></string-name>, <string-name><surname>Borad</surname><given-names>M</given-names></string-name>, <string-name><surname>Kang</surname><given-names>Y-K</given-names></string-name>, <string-name><surname>Stoudemire</surname><given-names>J</given-names></string-name>, <string-name><surname>Smith</surname><given-names>S</given-names></string-name>, <string-name><surname>Bader</surname><given-names>AG</given-names></string-name>, <string-name><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name><surname>Hong</surname><given-names>DS</given-names></string-name></person-group>. <year>2017</year>. <article-title>Phase I study of Mrx34, a liposomal miR-34A mimic, administered twice weekly in patients with advanced solid tumors</article-title>. <source>Invest New Drugs</source><volume>35</volume>:<fpage>180</fpage>–<lpage>188</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10637-016-0407-y</pub-id>doi:<ext-link xlink:href="27917453" ext-link-type="pmid"/><pub-id pub-id-type="pmid">27917453</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Daige</surname><given-names>CL</given-names></string-name>, <string-name><surname>Wiggins</surname><given-names>JF</given-names></string-name>, <string-name><surname>Priddy</surname><given-names>L</given-names></string-name>, <string-name><surname>Nelligan-Davis</surname><given-names>T</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name><surname>Brown</surname><given-names>D</given-names></string-name></person-group>. <year>2014</year>. <article-title>Systemic delivery of a Mir34A mimic as a potential therapeutic for liver cancer</article-title>. <source>Mol Cancer Ther</source><volume>13</volume>:<fpage>2352</fpage>–<lpage>2360</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-14-0209</pub-id>doi:<ext-link xlink:href="25053820" ext-link-type="pmid"/><pub-id pub-id-type="pmid">25053820</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keskin</surname><given-names>S</given-names></string-name>, <string-name><surname>Brouwers</surname><given-names>CC</given-names></string-name>, <string-name><surname>Sogorb-Gonzalez</surname><given-names>M</given-names></string-name>, <string-name><surname>Martier</surname><given-names>R</given-names></string-name>, <string-name><surname>Depla</surname><given-names>JA</given-names></string-name>, <string-name><surname>Vallès</surname><given-names>A</given-names></string-name>, <string-name><surname>van Deventer</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Konstantinova</surname><given-names>P</given-names></string-name>, <string-name><surname>Evers</surname><given-names>MM</given-names></string-name></person-group>. <year>2019</year>. <article-title>Aav5-miHTT Lower huntingtin mRNA and protein without off-target effects in patient-derived neuronal cultures and astrocytes</article-title>. <source>Mol Ther Methods Clin Dev</source><volume>15</volume>:<fpage>275</fpage>–<lpage>284</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.omtm.2019.09.010</pub-id>doi:<ext-link xlink:href="31737741" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31737741</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miniarikova</surname><given-names>J</given-names></string-name>, <string-name><surname>Zanella</surname><given-names>I</given-names></string-name>, <string-name><surname>Huseinovic</surname><given-names>A</given-names></string-name>, <string-name><surname>van der Zon</surname><given-names>T</given-names></string-name>, <string-name><surname>Hanemaaijer</surname><given-names>E</given-names></string-name>, <string-name><surname>Martier</surname><given-names>R</given-names></string-name>, <string-name><surname>Koornneef</surname><given-names>A</given-names></string-name>, <string-name><surname>Southwell</surname><given-names>AL</given-names></string-name>, <string-name><surname>Hayden</surname><given-names>MR</given-names></string-name>, <string-name><surname>van Deventer</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Petry</surname><given-names>H</given-names></string-name>, <string-name><surname>Konstantinova</surname><given-names>P</given-names></string-name></person-group>. <year>2016</year>. <article-title>Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for huntington's disease</article-title>. <source>Mol Ther Nucleic Acids</source><volume>5</volume>:<elocation-id>e297</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/mtna.2016.7</pub-id>doi:<ext-link xlink:href="27003755" ext-link-type="pmid"/><pub-id pub-id-type="pmid">27003755</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gallant-Behm</surname><given-names>CL</given-names></string-name>, <string-name><surname>Piper</surname><given-names>J</given-names></string-name>, <string-name><surname>Lynch</surname><given-names>JM</given-names></string-name>, <string-name><surname>Seto</surname><given-names>AG</given-names></string-name>, <string-name><surname>Hong</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Mustoe</surname><given-names>TA</given-names></string-name>, <string-name><surname>Maari</surname><given-names>C</given-names></string-name>, <string-name><surname>Pestano</surname><given-names>LA</given-names></string-name>, <string-name><surname>Dalby</surname><given-names>CM</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>AL</given-names></string-name>, <string-name><surname>Rubin</surname><given-names>P</given-names></string-name>, <string-name><surname>Marshall</surname><given-names>WS</given-names></string-name></person-group>. <year>2019</year>. <article-title>A microrna-29 mimic (Remlarsen) represses extracellular matrix expression and fibroplasia in the skin</article-title>. <source>J Invest Dermatol</source><volume>139</volume>:<fpage>1073</fpage>–<lpage>1081</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jid.2018.11.007</pub-id>doi:<ext-link xlink:href="30472058" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30472058</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koeppen</surname><given-names>K</given-names></string-name>, <string-name><surname>Nymon</surname><given-names>A</given-names></string-name>, <string-name><surname>Barnaby</surname><given-names>R</given-names></string-name>, <string-name><surname>Bashor</surname><given-names>L</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name>, <string-name><surname>Liefeld</surname><given-names>AE</given-names></string-name>, <string-name><surname>Kolling</surname><given-names>FW</given-names></string-name>, <string-name><surname>LaCroix</surname><given-names>IS</given-names></string-name>, <string-name><surname>Gerber</surname><given-names>SA</given-names></string-name>, <string-name><surname>Hogan</surname><given-names>DA</given-names></string-name>, <string-name><surname>Kasetty</surname><given-names>S</given-names></string-name>, <string-name><surname>Nadell</surname><given-names>CD</given-names></string-name>, <string-name><surname>Stanton</surname><given-names>BA</given-names></string-name></person-group>. <year>2021</year>. <article-title>Let-7B-5P in vesicles secreted by human airway cells reduces biofilm formation and increases antibiotic sensitivity of P. aeruginosa</article-title>. <source>Proc Natl Acad Sci USA</source><volume>118</volume>:<elocation-id>e2105370118</elocation-id>. doi:<pub-id pub-id-type="doi">10.1073/pnas.2105370118</pub-id>doi:<ext-link xlink:href="34260396" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34260396</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Dean</surname><given-names>RA</given-names></string-name></person-group>. <year>2020</year>. <article-title>Movement of small Rnas in and between plants and fungi</article-title>. <source>Mol Plant Pathol</source><volume>21</volume>:<fpage>589</fpage>–<lpage>601</lpage>. doi:<pub-id pub-id-type="doi">10.1111/mpp.12911</pub-id>doi:<ext-link xlink:href="32027079" ext-link-type="pmid"/><pub-id pub-id-type="pmid">32027079</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cai</surname><given-names>Q</given-names></string-name>, <string-name><surname>Qiao</surname><given-names>L</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>He</surname><given-names>B</given-names></string-name>, <string-name><surname>Lin</surname><given-names>FM</given-names></string-name>, <string-name><surname>Palmquist</surname><given-names>J</given-names></string-name>, <string-name><surname>Huang</surname><given-names>SD</given-names></string-name>, <string-name><surname>Jin</surname><given-names>H</given-names></string-name></person-group>. <year>2018</year>. <article-title>Plants send small Rnas in extracellular vesicles to fungal pathogen to silence virulence genes</article-title>. <source>Science</source><volume>360</volume>:<fpage>1126</fpage>–<lpage>1129</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aar4142</pub-id>doi:<ext-link xlink:href="29773668" ext-link-type="pmid"/><pub-id pub-id-type="pmid">29773668</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nowara</surname><given-names>D</given-names></string-name>, <string-name><surname>Gay</surname><given-names>A</given-names></string-name>, <string-name><surname>Lacomme</surname><given-names>C</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>J</given-names></string-name>, <string-name><surname>Ridout</surname><given-names>C</given-names></string-name>, <string-name><surname>Douchkov</surname><given-names>D</given-names></string-name>, <string-name><surname>Hensel</surname><given-names>G</given-names></string-name>, <string-name><surname>Kumlehn</surname><given-names>J</given-names></string-name>, <string-name><surname>Schweizer</surname><given-names>P</given-names></string-name></person-group>. <year>2010</year>. <article-title>HIGS: host-induced gene silencing in the obligate biotrophic fungal pathogen Blumeria graminis</article-title>. <source>Plant Cell</source><volume>22</volume>:<fpage>3130</fpage>–<lpage>3141</lpage>. doi:<pub-id pub-id-type="doi">10.1105/tpc.110.077040</pub-id>doi:<ext-link xlink:href="20884801" ext-link-type="pmid"/><pub-id pub-id-type="pmid">20884801</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Dean</surname><given-names>RA</given-names></string-name></person-group>. <year>2022</year>. <article-title>Host induced gene silencing of Magnaporthe oryzae by targeting pathogenicity and development genes to control rice blast disease</article-title>. <source>Front Plant Sci</source><volume>13</volume>:<fpage>959641</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fpls.2022.959641</pub-id>doi:<ext-link xlink:href="36035704" ext-link-type="pmid"/><pub-id pub-id-type="pmid">36035704</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name><surname>da Cunha</surname><given-names>AP</given-names></string-name>, <string-name><surname>Rezende</surname><given-names>RM</given-names></string-name>, <string-name><surname>Cialic</surname><given-names>R</given-names></string-name>, <string-name><surname>Wei</surname><given-names>Z</given-names></string-name>, <string-name><surname>Bry</surname><given-names>L</given-names></string-name>, <string-name><surname>Comstock</surname><given-names>LE</given-names></string-name>, <string-name><surname>Gandhi</surname><given-names>R</given-names></string-name>, <string-name><surname>Weiner</surname><given-names>HL</given-names></string-name></person-group>. <year>2016</year>. <article-title>The host shapes the gut microbiota via fecal microrna</article-title>. <source>Cell Host Microbe</source><volume>19</volume>:<fpage>32</fpage>–<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2015.12.005</pub-id>doi:<ext-link xlink:href="26764595" ext-link-type="pmid"/><pub-id pub-id-type="pmid">26764595</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>T</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name><surname>Cai</surname><given-names>W</given-names></string-name>, <string-name><surname>Shi</surname><given-names>R</given-names></string-name>, <string-name><surname>Duan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>L</given-names></string-name>, <string-name><surname>Xing</surname><given-names>C</given-names></string-name></person-group>. <year>2022</year>. <article-title>Colon specific delivery of miR-155 inhibitor alleviates estrogen deficiency related phenotype via microbiota remodeling</article-title>. <source>Drug Deliv</source><volume>29</volume>:<fpage>2610</fpage>–<lpage>2620</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10717544.2022.2108163</pub-id>doi:<ext-link xlink:href="35938574" ext-link-type="pmid"/><pub-id pub-id-type="pmid">35938574</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Markelova</surname><given-names>N</given-names></string-name>, <string-name><surname>Glazunova</surname><given-names>O</given-names></string-name>, <string-name><surname>Alikina</surname><given-names>O</given-names></string-name>, <string-name><surname>Panyukov</surname><given-names>V</given-names></string-name>, <string-name><surname>Shavkunov</surname><given-names>K</given-names></string-name>, <string-name><surname>Ozoline</surname><given-names>O</given-names></string-name></person-group>. <year>2021</year>. <article-title>Suppression of Escherichia coli growth dynamics via Rnas secreted by competing bacteria</article-title>. <source>Frontiers in molecular BioSci</source><volume>8</volume>. doi:<pub-id pub-id-type="doi">10.3389/fmolb.2021.609979</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stanton</surname><given-names>BA</given-names></string-name></person-group>. <year>2021</year>. <article-title>Extracellular Vesicles and host–pathogen interactions: A review of inter-kingdom signaling by small Noncoding RNA</article-title>. <source>Genes (Basel)</source><volume>12</volume>:<elocation-id>1010</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/genes12071010</pub-id>doi:<ext-link xlink:href="34208860" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34208860</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koeppen</surname><given-names>K</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name>, <string-name><surname>Jarek</surname><given-names>M</given-names></string-name>, <string-name><surname>Scharfe</surname><given-names>M</given-names></string-name>, <string-name><surname>Gerber</surname><given-names>SA</given-names></string-name>, <string-name><surname>Mielcarz</surname><given-names>DW</given-names></string-name>, <string-name><surname>Demers</surname><given-names>EG</given-names></string-name>, <string-name><surname>Dolben</surname><given-names>EL</given-names></string-name>, <string-name><surname>Hammond</surname><given-names>JH</given-names></string-name>, <string-name><surname>Hogan</surname><given-names>DA</given-names></string-name>, <string-name><surname>Stanton</surname><given-names>BA</given-names></string-name></person-group>. <year>2016</year>. <article-title>A novel mechanism of host-pathogen interaction through sRNA in bacterial outer membrane Vesicles</article-title>. <source>PLoS Pathog</source><volume>12</volume>:<elocation-id>e1005672</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.ppat.1005672</pub-id>doi:<ext-link xlink:href="27295279" ext-link-type="pmid"/><pub-id pub-id-type="pmid">27295279</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Woith</surname><given-names>E</given-names></string-name>, <string-name><surname>Fuhrmann</surname><given-names>G</given-names></string-name>, <string-name><surname>Melzig</surname><given-names>MF</given-names></string-name></person-group>. <year>2019</year>. <article-title>Extracellular vesicles connecting kingdoms</article-title>. <source>Int J Mol Sci</source><volume>20</volume>:<elocation-id>5695</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/ijms20225695</pub-id>doi:<ext-link xlink:href="31739393" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31739393</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weiberg</surname><given-names>A</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Lin</surname><given-names>FM</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Kaloshian</surname><given-names>I</given-names></string-name>, <string-name><surname>Huang</surname><given-names>HD</given-names></string-name>, <string-name><surname>Jin</surname><given-names>H</given-names></string-name></person-group>. <year>2013</year>. <article-title>Fungal small Rnas suppress plant immunity by hijacking host RNA interference pathways</article-title>. <source>Science</source><volume>342</volume>:<fpage>118</fpage>–<lpage>123</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1239705</pub-id>doi:<ext-link xlink:href="24092744" ext-link-type="pmid"/><pub-id pub-id-type="pmid">24092744</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Weiberg</surname><given-names>A</given-names></string-name>, <string-name><surname>Dellota</surname><given-names>E</given-names></string-name>, <string-name><surname>Yamane</surname><given-names>D</given-names></string-name>, <string-name><surname>Jin</surname><given-names>H</given-names></string-name></person-group>. <year>2017</year>. <article-title>Botrytis small RNA BC-Sir37 suppresses plant defense genes by cross-kingdom Rnai</article-title>. <source>RNA Biol</source><volume>14</volume>:<fpage>421</fpage>–<lpage>428</lpage>. doi:<pub-id pub-id-type="doi">10.1080/15476286.2017.1291112</pub-id>doi:<ext-link xlink:href="28267415" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28267415</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Halder</surname><given-names>LD</given-names></string-name>, <string-name><surname>Babych</surname><given-names>S</given-names></string-name>, <string-name><surname>Palme</surname><given-names>DI</given-names></string-name>, <string-name><surname>Mansouri-Ghahnavieh</surname><given-names>E</given-names></string-name>, <string-name><surname>Ivanov</surname><given-names>L</given-names></string-name>, <string-name><surname>Ashonibare</surname><given-names>V</given-names></string-name>, <string-name><surname>Langenhorst</surname><given-names>D</given-names></string-name>, <string-name><surname>Prusty</surname><given-names>B</given-names></string-name>, <string-name><surname>Rambach</surname><given-names>G</given-names></string-name>, <string-name><surname>Wich</surname><given-names>M</given-names></string-name>, <string-name><surname>Trinks</surname><given-names>N</given-names></string-name>, <string-name><surname>Blango</surname><given-names>MG</given-names></string-name>, <string-name><surname>Kornitzer</surname><given-names>D</given-names></string-name>, <string-name><surname>Terpitz</surname><given-names>U</given-names></string-name>, <string-name><surname>Speth</surname><given-names>C</given-names></string-name>, <string-name><surname>Jungnickel</surname><given-names>B</given-names></string-name>, <string-name><surname>Beyersdorf</surname><given-names>N</given-names></string-name>, <string-name><surname>Zipfel</surname><given-names>PF</given-names></string-name>, <string-name><surname>Brakhage</surname><given-names>AA</given-names></string-name>, <string-name><surname>Skerka</surname><given-names>C</given-names></string-name></person-group>. <year>2021</year>. <article-title>Candida albicans induces cross-kingdom miRNA trafficking in human monocytes to promote fungal growth</article-title>. <source>mBio</source><volume>13</volume>:<elocation-id>e0356321</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/mbio.03563-21</pub-id>doi:<ext-link xlink:href="35132877" ext-link-type="pmid"/><pub-id pub-id-type="pmid">35132877</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Simons</surname><given-names>LE</given-names></string-name>, <string-name><surname>Hess</surname><given-names>CW</given-names></string-name>, <string-name><surname>Choate</surname><given-names>ES</given-names></string-name>, <string-name><surname>Van Orden</surname><given-names>AR</given-names></string-name>, <string-name><surname>Tremblay-McGaw</surname><given-names>AG</given-names></string-name>, <string-name><surname>Menendez</surname><given-names>M</given-names></string-name>, <string-name><surname>Boothroyd</surname><given-names>DB</given-names></string-name>, <string-name><surname>Parvathinathan</surname><given-names>G</given-names></string-name>, <string-name><surname>Griffin</surname><given-names>A</given-names></string-name>, <string-name><surname>Caruso</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Stinson</surname><given-names>J</given-names></string-name>, <string-name><surname>Weisman</surname><given-names>A</given-names></string-name>, <string-name><surname>Liu</surname><given-names>T</given-names></string-name>, <string-name><surname>Koeppen</surname><given-names>K</given-names></string-name></person-group>. <year>2022</year>. <article-title>Virtual reality-augmented physiotherapy for chronic pain in youth: protocol for a randomized controlled trial enhanced with a single-case experimental design</article-title>. <source>JMIR Res Protoc</source><volume>11</volume>:<elocation-id>e40705</elocation-id>. doi:<pub-id pub-id-type="doi">10.2196/40705</pub-id>doi:<ext-link xlink:href="36508251" ext-link-type="pmid"/><pub-id pub-id-type="pmid">36508251</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Teng</surname><given-names>G</given-names></string-name>, <string-name><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name><surname>Dai</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name><surname>Chu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name></person-group>. <year>2013</year>. <article-title>Let-7B is involved in the inflammation and immune responses associated with helicobacter pylori infection by targeting toll-like receptor 4</article-title>. <source>PLoS One</source><volume>8</volume>:<elocation-id>e56709</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0056709</pub-id>doi:<ext-link xlink:href="23437218" ext-link-type="pmid"/><pub-id pub-id-type="pmid">23437218</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mandolesi</surname><given-names>G</given-names></string-name>, <string-name><surname>Rizzo</surname><given-names>FR</given-names></string-name>, <string-name><surname>Balletta</surname><given-names>S</given-names></string-name>, <string-name><surname>Stampanoni Bassi</surname><given-names>M</given-names></string-name>, <string-name><surname>Gilio</surname><given-names>L</given-names></string-name>, <string-name><surname>Guadalupi</surname><given-names>L</given-names></string-name>, <string-name><surname>Nencini</surname><given-names>M</given-names></string-name>, <string-name><surname>Moscatelli</surname><given-names>A</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>CP</given-names></string-name>, <string-name><surname>Licursi</surname><given-names>V</given-names></string-name>, <string-name><surname>Dolcetti</surname><given-names>E</given-names></string-name>, <string-name><surname>Musella</surname><given-names>A</given-names></string-name>, <string-name><surname>Gentile</surname><given-names>A</given-names></string-name>, <string-name><surname>Fresegna</surname><given-names>D</given-names></string-name>, <string-name><surname>Bullitta</surname><given-names>S</given-names></string-name>, <string-name><surname>Caioli</surname><given-names>S</given-names></string-name>, <string-name><surname>Vanni</surname><given-names>V</given-names></string-name>, <string-name><surname>Sanna</surname><given-names>K</given-names></string-name>, <string-name><surname>Bruno</surname><given-names>A</given-names></string-name>, <string-name><surname>Buttari</surname><given-names>F</given-names></string-name>, <string-name><surname>Castelli</surname><given-names>C</given-names></string-name>, <string-name><surname>Presutti</surname><given-names>C</given-names></string-name>, <string-name><surname>De Santa</surname><given-names>F</given-names></string-name>, <string-name><surname>Finardi</surname><given-names>A</given-names></string-name>, <string-name><surname>Furlan</surname><given-names>R</given-names></string-name>, <string-name><surname>Centonze</surname><given-names>D</given-names></string-name>, <string-name><surname>De Vito</surname><given-names>F</given-names></string-name></person-group>. <year>2021</year>. <article-title>The microRNA Let-7B-5P is negatively associated with inflammation and disease severity in multiple sclerosis</article-title>. <source>Cells</source><volume>10</volume>:<elocation-id>330</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/cells10020330</pub-id>doi:<ext-link xlink:href="33562569" ext-link-type="pmid"/><pub-id pub-id-type="pmid">33562569</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lim</surname><given-names>LP</given-names></string-name>, <string-name><surname>Lau</surname><given-names>NC</given-names></string-name>, <string-name><surname>Garrett-Engele</surname><given-names>P</given-names></string-name>, <string-name><surname>Grimson</surname><given-names>A</given-names></string-name>, <string-name><surname>Schelter</surname><given-names>JM</given-names></string-name>, <string-name><surname>Castle</surname><given-names>J</given-names></string-name>, <string-name><surname>Bartel</surname><given-names>DP</given-names></string-name>, <string-name><surname>Linsley</surname><given-names>PS</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>JM</given-names></string-name></person-group>. <year>2005</year>. <article-title>Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs</article-title>. <source>Nature</source><volume>433</volume>:<fpage>769</fpage>–<lpage>773</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature03315</pub-id>doi:<ext-link xlink:href="15685193" ext-link-type="pmid"/><pub-id pub-id-type="pmid">15685193</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Friedman</surname><given-names>RC</given-names></string-name>, <string-name><surname>Farh</surname><given-names>KH</given-names></string-name>, <string-name><surname>Burge</surname><given-names>CB</given-names></string-name>, <string-name><surname>Bartel</surname><given-names>DP</given-names></string-name></person-group>. <year>2009</year>. <article-title>Most mammalian mRNAs are conserved targets of microRNAs</article-title>. <source>Genome Res</source><volume>19</volume>:<fpage>92</fpage>–<lpage>105</lpage>. doi:<pub-id pub-id-type="doi">10.1101/gr.082701.108</pub-id>doi:<ext-link xlink:href="18955434" ext-link-type="pmid"/><pub-id pub-id-type="pmid">18955434</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <label>57</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rooda</surname><given-names>I</given-names></string-name>, <string-name><surname>Hensen</surname><given-names>K</given-names></string-name>, <string-name><surname>Kaselt</surname><given-names>B</given-names></string-name>, <string-name><surname>Kasvandik</surname><given-names>S</given-names></string-name>, <string-name><surname>Pook</surname><given-names>M</given-names></string-name>, <string-name><surname>Kurg</surname><given-names>A</given-names></string-name>, <string-name><surname>Salumets</surname><given-names>A</given-names></string-name>, <string-name><surname>Velthut-Meikas</surname><given-names>A</given-names></string-name></person-group>. <year>2020</year>. <article-title>Target prediction and validation of microRNAs expressed from FSHR and aromatase genes in human ovarian granulosa cells</article-title>. <source>Sci Rep</source><volume>10</volume>:<fpage>2300</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-020-59186-x</pub-id>doi:<ext-link xlink:href="32042028" ext-link-type="pmid"/><pub-id pub-id-type="pmid">32042028</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <label>58</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Busch</surname><given-names>A</given-names></string-name>, <string-name><surname>Richter</surname><given-names>AS</given-names></string-name>, <string-name><surname>Backofen</surname><given-names>R</given-names></string-name></person-group>. <year>2008</year>. <article-title>Intarna: efficient prediction of bacterial sRNA targets incorporating target site accessibility and seed regions</article-title>. <source>Bioinformatics</source><volume>24</volume>:<fpage>2849</fpage>–<lpage>2856</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btn544</pub-id>doi:<ext-link xlink:href="18940824" ext-link-type="pmid"/><pub-id pub-id-type="pmid">18940824</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <label>59</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Azeredo</surname><given-names>J</given-names></string-name>, <string-name><surname>Azevedo</surname><given-names>NF</given-names></string-name>, <string-name><surname>Briandet</surname><given-names>R</given-names></string-name>, <string-name><surname>Cerca</surname><given-names>N</given-names></string-name>, <string-name><surname>Coenye</surname><given-names>T</given-names></string-name>, <string-name><surname>Costa</surname><given-names>AR</given-names></string-name>, <string-name><surname>Desvaux</surname><given-names>M</given-names></string-name>, <string-name><surname>Di Bonaventura</surname><given-names>G</given-names></string-name>, <string-name><surname>Hébraud</surname><given-names>M</given-names></string-name>, <string-name><surname>Jaglic</surname><given-names>Z</given-names></string-name>, <string-name><surname>Kačániová</surname><given-names>M</given-names></string-name>, <string-name><surname>Knøchel</surname><given-names>S</given-names></string-name>, <string-name><surname>Lourenço</surname><given-names>A</given-names></string-name>, <string-name><surname>Mergulhão</surname><given-names>F</given-names></string-name>, <string-name><surname>Meyer</surname><given-names>RL</given-names></string-name>, <string-name><surname>Nychas</surname><given-names>G</given-names></string-name>, <string-name><surname>Simões</surname><given-names>M</given-names></string-name>, <string-name><surname>Tresse</surname><given-names>O</given-names></string-name>, <string-name><surname>Sternberg</surname><given-names>C</given-names></string-name></person-group>. <year>2017</year>. <article-title>Critical review on biofilm methods</article-title>. <source>Crit Rev Microbiol</source><volume>43</volume>:<fpage>313</fpage>–<lpage>351</lpage>. doi:<pub-id pub-id-type="doi">10.1080/1040841X.2016.1208146</pub-id>doi:<ext-link xlink:href="27868469" ext-link-type="pmid"/><pub-id pub-id-type="pmid">27868469</pub-id></mixed-citation>
    </ref>
    <ref id="B60">
      <label>60</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wainwright</surname><given-names>CE</given-names></string-name>, <string-name><surname>Quittner</surname><given-names>AL</given-names></string-name>, <string-name><surname>Geller</surname><given-names>DE</given-names></string-name>, <string-name><surname>Nakamura</surname><given-names>C</given-names></string-name>, <string-name><surname>Wooldridge</surname><given-names>JL</given-names></string-name>, <string-name><surname>Gibson</surname><given-names>RL</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>S</given-names></string-name>, <string-name><surname>Montgomery</surname><given-names>AB</given-names></string-name></person-group>. <year>2011</year>. <article-title>Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa</article-title>. <source>J Cyst Fibros</source><volume>10</volume>:<fpage>234</fpage>–<lpage>242</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jcf.2011.02.007</pub-id>doi:<ext-link xlink:href="21441078" ext-link-type="pmid"/><pub-id pub-id-type="pmid">21441078</pub-id></mixed-citation>
    </ref>
    <ref id="B61">
      <label>61</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bahamondez-Canas</surname><given-names>TF</given-names></string-name>, <string-name><surname>Heersema</surname><given-names>LA</given-names></string-name>, <string-name><surname>Smyth</surname><given-names>HDC</given-names></string-name></person-group>. <year>2019</year>. <article-title>Current status of in vitro models and assays for susceptibility testing for wound biofilm infections</article-title>. <source>Biomedicines</source><volume>7</volume>:<elocation-id>34</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/biomedicines7020034</pub-id>doi:<ext-link xlink:href="31052271" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31052271</pub-id></mixed-citation>
    </ref>
    <ref id="B62">
      <label>62</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Festini</surname><given-names>F</given-names></string-name>, <string-name><surname>Buzzetti</surname><given-names>R</given-names></string-name>, <string-name><surname>Bassi</surname><given-names>C</given-names></string-name>, <string-name><surname>Braggion</surname><given-names>C</given-names></string-name>, <string-name><surname>Salvatore</surname><given-names>D</given-names></string-name>, <string-name><surname>Taccetti</surname><given-names>G</given-names></string-name>, <string-name><surname>Mastella</surname><given-names>G</given-names></string-name></person-group>. <year>2006</year>. <article-title>Isolation measures for prevention of infection with respiratory pathogens in cystic fibrosis: a systematic review</article-title>. <source>J Hosp Infect</source><volume>64</volume>:<fpage>1</fpage>–<lpage>6</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jhin.2006.02.021</pub-id>doi:<ext-link xlink:href="16835001" ext-link-type="pmid"/><pub-id pub-id-type="pmid">16835001</pub-id></mixed-citation>
    </ref>
    <ref id="B63">
      <label>63</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Magalhães</surname><given-names>AP</given-names></string-name>, <string-name><surname>Lopes</surname><given-names>SP</given-names></string-name>, <string-name><surname>Pereira</surname><given-names>MO</given-names></string-name></person-group>. <year>2016</year>. <article-title>Insights into cystic fibrosis polymicrobial consortia: the role of species interactions in biofilm development, phenotype, and response to in-use antibiotics</article-title>. <source>Front Microbiol</source><volume>7</volume>:<fpage>2146</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2016.02146</pub-id>doi:<ext-link xlink:href="28133457" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28133457</pub-id></mixed-citation>
    </ref>
    <ref id="B64">
      <label>64</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stuart</surname><given-names>B</given-names></string-name>, <string-name><surname>Lin</surname><given-names>JH</given-names></string-name>, <string-name><surname>Mogayzel</surname><given-names>PJ</given-names></string-name></person-group>. <year>2010</year>. <article-title>Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis</article-title>. <source>Paediatr Respir Rev</source><volume>11</volume>:<fpage>177</fpage>–<lpage>184</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.prrv.2010.05.003</pub-id>doi:<ext-link xlink:href="20692633" ext-link-type="pmid"/><pub-id pub-id-type="pmid">20692633</pub-id></mixed-citation>
    </ref>
    <ref id="B65">
      <label>65</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krause</surname><given-names>KM</given-names></string-name>, <string-name><surname>Haglund</surname><given-names>CM</given-names></string-name>, <string-name><surname>Hebner</surname><given-names>C</given-names></string-name>, <string-name><surname>Serio</surname><given-names>AW</given-names></string-name>, <string-name><surname>Lee</surname><given-names>G</given-names></string-name>, <string-name><surname>Nieto</surname><given-names>V</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>F</given-names></string-name>, <string-name><surname>Kane</surname><given-names>TR</given-names></string-name>, <string-name><surname>Machajewski</surname><given-names>TD</given-names></string-name>, <string-name><surname>Hildebrandt</surname><given-names>D</given-names></string-name>, <string-name><surname>Pillar</surname><given-names>C</given-names></string-name>, <string-name><surname>Thwaites</surname><given-names>M</given-names></string-name>, <string-name><surname>Hall</surname><given-names>D</given-names></string-name>, <string-name><surname>Miesel</surname><given-names>L</given-names></string-name>, <string-name><surname>Hackel</surname><given-names>M</given-names></string-name>, <string-name><surname>Burek</surname><given-names>A</given-names></string-name>, <string-name><surname>Andrews</surname><given-names>LD</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>E</given-names></string-name>, <string-name><surname>Swem</surname><given-names>L</given-names></string-name>, <string-name><surname>Jubb</surname><given-names>A</given-names></string-name>, <string-name><surname>Cirz</surname><given-names>RT</given-names></string-name></person-group>. <year>2019</year>. <article-title>Potent Lpxc inhibitors with in Vitro activity against multidrug-resistant Pseudomonas aeruginosa</article-title>. <source>Antimicrob Agents Chemother</source><volume>63</volume>:<elocation-id>e00977-19</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00977-19</pub-id>doi:<ext-link xlink:href="31451507" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31451507</pub-id></mixed-citation>
    </ref>
    <ref id="B66">
      <label>66</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yan</surname><given-names>TH</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>C</given-names></string-name>, <string-name><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name><surname>Li</surname><given-names>WH</given-names></string-name></person-group>. <year>2018</year>. <article-title>Mir-877-5p suppresses cell growth, migration and invasion by targeting cyclin dependent kinase 14 and predicts prognosis in hepatocellular carcinoma</article-title>. <source>Eur Rev Med Pharmacol Sci</source><volume>22</volume>:<fpage>3038</fpage>–<lpage>3046</lpage>. doi:<pub-id pub-id-type="doi">10.26355/eurrev_201805_15061</pub-id>doi:<ext-link xlink:href="29863248" ext-link-type="pmid"/><pub-id pub-id-type="pmid">29863248</pub-id></mixed-citation>
    </ref>
    <ref id="B67">
      <label>67</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name><surname>Diao</surname><given-names>H</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name><surname>Guan</surname><given-names>F</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H</given-names></string-name></person-group>. <year>2021</year>. <article-title>microRNA-877-5p exerts tumor-suppressive functions in prostate cancer through repressing transcription of forkhead box M1</article-title>. <source>Bioengineered</source><volume>12</volume>:<fpage>9094</fpage>–<lpage>9102</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21655979.2021.1989969</pub-id>doi:<ext-link xlink:href="34654353" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34654353</pub-id></mixed-citation>
    </ref>
    <ref id="B68">
      <label>68</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Cao</surname><given-names>L</given-names></string-name>, <string-name><surname>Yin</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L</given-names></string-name></person-group>. <year>2022</year>. <article-title>Microrna-877-5p inhibits cell progression by targeting Foxm1 in lung cancer</article-title>. <source>Can Respir J</source><volume>2022</volume>:<fpage>4256172</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2022/4256172</pub-id>doi:<ext-link xlink:href="35756697" ext-link-type="pmid"/><pub-id pub-id-type="pmid">35756697</pub-id></mixed-citation>
    </ref>
    <ref id="B69">
      <label>69</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name><surname>Yu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Tang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Wei</surname><given-names>W</given-names></string-name>, <string-name><surname>Xie</surname><given-names>D</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Y</given-names></string-name>, <string-name><surname>Xiao</surname><given-names>Q</given-names></string-name></person-group>. <year>2020</year>. <article-title>miR-877-5p suppresses gastric cancer cell proliferation through targeting Foxm1</article-title>. <source>Onco Targets Ther</source><volume>13</volume>:<fpage>4731</fpage>–<lpage>4742</lpage>. doi:<pub-id pub-id-type="doi">10.2147/OTT.S251916</pub-id>doi:<ext-link xlink:href="32547102" ext-link-type="pmid"/><pub-id pub-id-type="pmid">32547102</pub-id></mixed-citation>
    </ref>
    <ref id="B70">
      <label>70</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>K</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Tian</surname><given-names>S</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>J</given-names></string-name>, <string-name><surname>Zou</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>F</given-names></string-name></person-group>. <year>2021</year>. <article-title>Microrna-877-5p alleviates ARDS via enhancing Pi3K/AKT path by targeting Cdkn1B both in vivo and in vitro</article-title>. <source>Int Immunopharmacol</source><volume>95</volume>:<fpage>107530</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.intimp.2021.107530</pub-id>doi:<ext-link xlink:href="33735715" ext-link-type="pmid"/><pub-id pub-id-type="pmid">33735715</pub-id></mixed-citation>
    </ref>
    <ref id="B71">
      <label>71</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cigana</surname><given-names>C</given-names></string-name>, <string-name><surname>Bianconi</surname><given-names>I</given-names></string-name>, <string-name><surname>Baldan</surname><given-names>R</given-names></string-name>, <string-name><surname>De Simone</surname><given-names>M</given-names></string-name>, <string-name><surname>Riva</surname><given-names>C</given-names></string-name>, <string-name><surname>Sipione</surname><given-names>B</given-names></string-name>, <string-name><surname>Rossi</surname><given-names>G</given-names></string-name>, <string-name><surname>Cirillo</surname><given-names>DM</given-names></string-name>, <string-name><surname>Bragonzi</surname><given-names>A</given-names></string-name></person-group>. <year>2018</year>. <article-title>Staphylococcus aureus impacts Pseudomonas aeruginosa chronic respiratory disease in murine models</article-title>. <source>J Infect Dis</source><volume>217</volume>:<fpage>933</fpage>–<lpage>942</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jix621</pub-id>doi:<ext-link xlink:href="29216403" ext-link-type="pmid"/><pub-id pub-id-type="pmid">29216403</pub-id></mixed-citation>
    </ref>
    <ref id="B72">
      <label>72</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jean-Pierre</surname><given-names>F</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name>, <string-name><surname>Schultz</surname><given-names>D</given-names></string-name>, <string-name><surname>Hogan</surname><given-names>DA</given-names></string-name>, <string-name><surname>Groleau</surname><given-names>MC</given-names></string-name>, <string-name><surname>Déziel</surname><given-names>E</given-names></string-name>, <string-name><surname>O’Toole</surname><given-names>GA</given-names></string-name></person-group>. <year>2023</year>. <article-title>Community composition shapes microbial-specific phenotypes in a cystic fibrosis polymicrobial model system</article-title>. <source>Elife</source><volume>12</volume>:<elocation-id>e81604</elocation-id>. doi:<pub-id pub-id-type="doi">10.7554/eLife.81604</pub-id>doi:<ext-link xlink:href="36661299" ext-link-type="pmid"/><pub-id pub-id-type="pmid">36661299</pub-id></mixed-citation>
    </ref>
    <ref id="B73">
      <label>73</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Durda-Masny</surname><given-names>M</given-names></string-name>, <string-name><surname>Goździk-Spychalska</surname><given-names>J</given-names></string-name>, <string-name><surname>John</surname><given-names>A</given-names></string-name>, <string-name><surname>Czaiński</surname><given-names>W</given-names></string-name>, <string-name><surname>Stróżewska</surname><given-names>W</given-names></string-name>, <string-name><surname>Pawłowska</surname><given-names>N</given-names></string-name>, <string-name><surname>Wlizło</surname><given-names>J</given-names></string-name>, <string-name><surname>Batura-Gabryel</surname><given-names>H</given-names></string-name>, <string-name><surname>Szwed</surname><given-names>A</given-names></string-name></person-group>. <year>2021</year>. <article-title>The determinants of survival among adults with cystic fibrosis-a cohort study</article-title>. <source>J Physiol Anthropol</source><volume>40</volume>:<fpage>19</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40101-021-00269-7</pub-id>doi:<ext-link xlink:href="34749804" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34749804</pub-id></mixed-citation>
    </ref>
    <ref id="B74">
      <label>74</label>
      <mixed-citation publication-type="report"><year>2021</year>. <source>CF Patient Registry Annual Data Report</source></mixed-citation>
    </ref>
    <ref id="B75">
      <label>75</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zemanick</surname><given-names>ET</given-names></string-name>, <string-name><surname>Harris</surname><given-names>JK</given-names></string-name>, <string-name><surname>Wagner</surname><given-names>BD</given-names></string-name>, <string-name><surname>Robertson</surname><given-names>CE</given-names></string-name>, <string-name><surname>Sagel</surname><given-names>SD</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Accurso</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Laguna</surname><given-names>TA</given-names></string-name></person-group>. <year>2013</year>. <article-title>Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations</article-title>. <source>PLoS One</source><volume>8</volume>:<elocation-id>e62917</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0062917</pub-id>doi:<ext-link xlink:href="23646159" ext-link-type="pmid"/><pub-id pub-id-type="pmid">23646159</pub-id></mixed-citation>
    </ref>
    <ref id="B76">
      <label>76</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wexler</surname><given-names>AG</given-names></string-name>, <string-name><surname>Goodman</surname><given-names>AL</given-names></string-name></person-group>. <year>2017</year>. <article-title>An insider's perspective: bacteroides as a window into the microbiome</article-title>. <source>Nat Microbiol</source><volume>2</volume>:<fpage>17026</fpage>. doi:<pub-id pub-id-type="doi">10.1038/nmicrobiol.2017.26</pub-id>doi:<ext-link xlink:href="28440278" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28440278</pub-id></mixed-citation>
    </ref>
    <ref id="B77">
      <label>77</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wexler</surname><given-names>HM</given-names></string-name></person-group><year>2007</year>. <article-title>Bacteroides: the good, the bad, and the nitty-gritty</article-title>. <source>Clin Microbiol Rev</source><volume>20</volume>:<fpage>593</fpage>–<lpage>621</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CMR.00008-07</pub-id>doi:<ext-link xlink:href="17934076" ext-link-type="pmid"/><pub-id pub-id-type="pmid">17934076</pub-id></mixed-citation>
    </ref>
    <ref id="B78">
      <label>78</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sears</surname><given-names>CL</given-names></string-name>, <string-name><surname>Geis</surname><given-names>AL</given-names></string-name>, <string-name><surname>Housseau</surname><given-names>F</given-names></string-name></person-group>. <year>2014</year>. <article-title>Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis</article-title>. <source>J Clin Invest</source><volume>124</volume>:<fpage>4166</fpage>–<lpage>4172</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI72334</pub-id>doi:<ext-link xlink:href="25105360" ext-link-type="pmid"/><pub-id pub-id-type="pmid">25105360</pub-id></mixed-citation>
    </ref>
    <ref id="B79">
      <label>79</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hayden</surname><given-names>HS</given-names></string-name>, <string-name><surname>Eng</surname><given-names>A</given-names></string-name>, <string-name><surname>Pope</surname><given-names>CE</given-names></string-name>, <string-name><surname>Brittnacher</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Vo</surname><given-names>AT</given-names></string-name>, <string-name><surname>Weiss</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Hager</surname><given-names>KR</given-names></string-name>, <string-name><surname>Martin</surname><given-names>BD</given-names></string-name>, <string-name><surname>Leung</surname><given-names>DH</given-names></string-name>, <string-name><surname>Heltshe</surname><given-names>SL</given-names></string-name>, <string-name><surname>Borenstein</surname><given-names>E</given-names></string-name>, <string-name><surname>Miller</surname><given-names>SI</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>LR</given-names></string-name></person-group>. <year>2020</year>. <article-title>Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure</article-title>. <source>Nat Med</source><volume>26</volume>:<fpage>215</fpage>–<lpage>221</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-019-0714-x</pub-id>doi:<ext-link xlink:href="31959989" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31959989</pub-id></mixed-citation>
    </ref>
    <ref id="B80">
      <label>80</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rogers</surname><given-names>GB</given-names></string-name>, <string-name><surname>Narkewicz</surname><given-names>MR</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>LR</given-names></string-name></person-group>. <year>2016</year>. <article-title>The CF gastrointestinal microbiome: structure and clinical impact</article-title>. <source>Pediatr Pulmonol</source><volume>51</volume>:<fpage>S35</fpage>–<lpage>S44</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ppul.23544</pub-id>doi:<ext-link xlink:href="27662102" ext-link-type="pmid"/><pub-id pub-id-type="pmid">27662102</pub-id></mixed-citation>
    </ref>
    <ref id="B81">
      <label>81</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pukatzki</surname><given-names>S</given-names></string-name>, <string-name><surname>Ma</surname><given-names>AT</given-names></string-name>, <string-name><surname>Revel</surname><given-names>AT</given-names></string-name>, <string-name><surname>Sturtevant</surname><given-names>D</given-names></string-name>, <string-name><surname>Mekalanos</surname><given-names>JJ</given-names></string-name></person-group>. <year>2007</year>. <article-title>Type VI secretion system translocates a Phage tail spike-like protein into target cells where it cross-links actin</article-title>. <source>Proc Natl Acad Sci USA</source><volume>104</volume>:<fpage>15508</fpage>–<lpage>15513</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0706532104</pub-id>doi:<ext-link xlink:href="17873062" ext-link-type="pmid"/><pub-id pub-id-type="pmid">17873062</pub-id></mixed-citation>
    </ref>
    <ref id="B82">
      <label>82</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mougous</surname><given-names>JD</given-names></string-name>, <string-name><surname>Cuff</surname><given-names>ME</given-names></string-name>, <string-name><surname>Raunser</surname><given-names>S</given-names></string-name>, <string-name><surname>Shen</surname><given-names>A</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>M</given-names></string-name>, <string-name><surname>Gifford</surname><given-names>CA</given-names></string-name>, <string-name><surname>Goodman</surname><given-names>AL</given-names></string-name>, <string-name><surname>Joachimiak</surname><given-names>G</given-names></string-name>, <string-name><surname>Ordoñez</surname><given-names>CL</given-names></string-name>, <string-name><surname>Lory</surname><given-names>S</given-names></string-name>, <string-name><surname>Walz</surname><given-names>T</given-names></string-name>, <string-name><surname>Joachimiak</surname><given-names>A</given-names></string-name>, <string-name><surname>Mekalanos</surname><given-names>JJ</given-names></string-name></person-group>. <year>2006</year>. <article-title>A virulence locus of Pseudomonas aeruginosa encodes a protein secretion apparatus</article-title>. <source>Science</source><volume>312</volume>:<fpage>1526</fpage>–<lpage>1530</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1128393</pub-id>doi:<ext-link xlink:href="16763151" ext-link-type="pmid"/><pub-id pub-id-type="pmid">16763151</pub-id></mixed-citation>
    </ref>
    <ref id="B83">
      <label>83</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Russell</surname><given-names>AB</given-names></string-name>, <string-name><surname>Wexler</surname><given-names>AG</given-names></string-name>, <string-name><surname>Harding</surname><given-names>BN</given-names></string-name>, <string-name><surname>Whitney</surname><given-names>JC</given-names></string-name>, <string-name><surname>Bohn</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Goo</surname><given-names>YA</given-names></string-name>, <string-name><surname>Tran</surname><given-names>BQ</given-names></string-name>, <string-name><surname>Barry</surname><given-names>NA</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>H</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>SB</given-names></string-name>, <string-name><surname>Chou</surname><given-names>S</given-names></string-name>, <string-name><surname>Gonen</surname><given-names>T</given-names></string-name>, <string-name><surname>Goodlett</surname><given-names>DR</given-names></string-name>, <string-name><surname>Goodman</surname><given-names>AL</given-names></string-name>, <string-name><surname>Mougous</surname><given-names>JD</given-names></string-name></person-group>. <year>2014</year>. <article-title>A type VI secretion-related pathway in bacteroidetes mediates Interbacterial antagonism</article-title>. <source>Cell Host Microbe</source><volume>16</volume>:<fpage>227</fpage>–<lpage>236</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2014.07.007</pub-id>doi:<ext-link xlink:href="25070807" ext-link-type="pmid"/><pub-id pub-id-type="pmid">25070807</pub-id></mixed-citation>
    </ref>
    <ref id="B84">
      <label>84</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hood</surname><given-names>RD</given-names></string-name>, <string-name><surname>Singh</surname><given-names>P</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>F</given-names></string-name>, <string-name><surname>Güvener</surname><given-names>T</given-names></string-name>, <string-name><surname>Carl</surname><given-names>MA</given-names></string-name>, <string-name><surname>Trinidad</surname><given-names>RRS</given-names></string-name>, <string-name><surname>Silverman</surname><given-names>JM</given-names></string-name>, <string-name><surname>Ohlson</surname><given-names>BB</given-names></string-name>, <string-name><surname>Hicks</surname><given-names>KG</given-names></string-name>, <string-name><surname>Plemel</surname><given-names>RL</given-names></string-name>, <string-name><surname>Li</surname><given-names>M</given-names></string-name>, <string-name><surname>Schwarz</surname><given-names>S</given-names></string-name>, <string-name><surname>Wang</surname><given-names>WY</given-names></string-name>, <string-name><surname>Merz</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Goodlett</surname><given-names>DR</given-names></string-name>, <string-name><surname>Mougous</surname><given-names>JD</given-names></string-name></person-group>. <year>2010</year>. <article-title>A type VI secretion system of Pseudomonas aeruginosa targets a toxin to bacteria</article-title>. <source>Cell Host Microbe</source><volume>7</volume>:<fpage>25</fpage>–<lpage>37</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2009.12.007</pub-id>doi:<ext-link xlink:href="20114026" ext-link-type="pmid"/><pub-id pub-id-type="pmid">20114026</pub-id></mixed-citation>
    </ref>
    <ref id="B85">
      <label>85</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Russell</surname><given-names>AB</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>SB</given-names></string-name>, <string-name><surname>Mougous</surname><given-names>JD</given-names></string-name></person-group>. <year>2014</year>. <article-title>Type VI secretion system effectors: poisons with a purpose</article-title>. <source>Nat Rev Microbiol</source><volume>12</volume>:<fpage>137</fpage>–<lpage>148</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrmicro3185</pub-id>doi:<ext-link xlink:href="24384601" ext-link-type="pmid"/><pub-id pub-id-type="pmid">24384601</pub-id></mixed-citation>
    </ref>
    <ref id="B86">
      <label>86</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cherrak</surname><given-names>Y</given-names></string-name>, <string-name><surname>Flaugnatti</surname><given-names>N</given-names></string-name>, <string-name><surname>Durand</surname><given-names>E</given-names></string-name>, <string-name><surname>Journet</surname><given-names>L</given-names></string-name>, <string-name><surname>Cascales</surname><given-names>E</given-names></string-name></person-group>. <year>2019</year>. <article-title>Structure and activity of the type VI secretion system</article-title>. <source>Microbiol Spectr</source><volume>7</volume>. doi:<pub-id pub-id-type="doi">10.1128/microbiolspec.PSIB-0031-2019</pub-id>doi:<ext-link xlink:href="31298206" ext-link-type="pmid"/></mixed-citation>
    </ref>
    <ref id="B87">
      <label>87</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cherrak</surname><given-names>Y</given-names></string-name>, <string-name><surname>Rapisarda</surname><given-names>C</given-names></string-name>, <string-name><surname>Pellarin</surname><given-names>R</given-names></string-name>, <string-name><surname>Bouvier</surname><given-names>G</given-names></string-name>, <string-name><surname>Bardiaux</surname><given-names>B</given-names></string-name>, <string-name><surname>Allain</surname><given-names>F</given-names></string-name>, <string-name><surname>Malosse</surname><given-names>C</given-names></string-name>, <string-name><surname>Rey</surname><given-names>M</given-names></string-name>, <string-name><surname>Chamot-Rooke</surname><given-names>J</given-names></string-name>, <string-name><surname>Cascales</surname><given-names>E</given-names></string-name>, <string-name><surname>Fronzes</surname><given-names>R</given-names></string-name>, <string-name><surname>Durand</surname><given-names>E</given-names></string-name></person-group>. <year>2018</year>. <article-title>Biogenesis and structure of a type VI secretion baseplate</article-title>. <source>Nat Microbiol</source><volume>3</volume>:<fpage>1404</fpage>–<lpage>1416</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41564-018-0260-1</pub-id>doi:<ext-link xlink:href="30323254" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30323254</pub-id></mixed-citation>
    </ref>
    <ref id="B88">
      <label>88</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Verster</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Ross</surname><given-names>BD</given-names></string-name>, <string-name><surname>Radey</surname><given-names>MC</given-names></string-name>, <string-name><surname>Bao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Goodman</surname><given-names>AL</given-names></string-name>, <string-name><surname>Mougous</surname><given-names>JD</given-names></string-name>, <string-name><surname>Borenstein</surname><given-names>E</given-names></string-name></person-group>. <year>2017</year>. <article-title>The landscape of type VI secretion across human gut microbiomes reveals its role in community composition</article-title>. <source>Cell Host Microbe</source><volume>22</volume>:<fpage>411</fpage>–<lpage>419</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2017.08.010</pub-id>doi:<ext-link xlink:href="28910638" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28910638</pub-id></mixed-citation>
    </ref>
    <ref id="B89">
      <label>89</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ross</surname><given-names>BD</given-names></string-name>, <string-name><surname>Verster</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Radey</surname><given-names>MC</given-names></string-name>, <string-name><surname>Schmidtke</surname><given-names>DT</given-names></string-name>, <string-name><surname>Pope</surname><given-names>CE</given-names></string-name>, <string-name><surname>Hoffman</surname><given-names>LR</given-names></string-name>, <string-name><surname>Hajjar</surname><given-names>AM</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>SB</given-names></string-name>, <string-name><surname>Borenstein</surname><given-names>E</given-names></string-name>, <string-name><surname>Mougous</surname><given-names>JD</given-names></string-name></person-group>. <year>2019</year>. <article-title>Human gut bacteria contain acquired Interbacterial defence systems</article-title>. <source>Nature</source><volume>575</volume>:<fpage>224</fpage>–<lpage>228</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-019-1708-z</pub-id>doi:<ext-link xlink:href="31666699" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31666699</pub-id></mixed-citation>
    </ref>
    <ref id="B90">
      <label>90</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>SM</given-names></string-name>, <string-name><surname>Donaldson</surname><given-names>GP</given-names></string-name>, <string-name><surname>Mikulski</surname><given-names>Z</given-names></string-name>, <string-name><surname>Boyajian</surname><given-names>S</given-names></string-name>, <string-name><surname>Ley</surname><given-names>K</given-names></string-name>, <string-name><surname>Mazmanian</surname><given-names>SK</given-names></string-name></person-group>. <year>2013</year>. <article-title>Bacterial colonization factors control specificity and stability of the gut microbiota</article-title>. <source>Nature</source><volume>501</volume>:<fpage>426</fpage>–<lpage>429</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature12447</pub-id>doi:<ext-link xlink:href="23955152" ext-link-type="pmid"/><pub-id pub-id-type="pmid">23955152</pub-id></mixed-citation>
    </ref>
    <ref id="B91">
      <label>91</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dejea</surname><given-names>CM</given-names></string-name>, <string-name><surname>Fathi</surname><given-names>P</given-names></string-name>, <string-name><surname>Craig</surname><given-names>JM</given-names></string-name>, <string-name><surname>Boleij</surname><given-names>A</given-names></string-name>, <string-name><surname>Taddese</surname><given-names>R</given-names></string-name>, <string-name><surname>Geis</surname><given-names>AL</given-names></string-name>, <string-name><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name><surname>DeStefano Shields</surname><given-names>CE</given-names></string-name>, <string-name><surname>Hechenbleikner</surname><given-names>EM</given-names></string-name>, <string-name><surname>Huso</surname><given-names>DL</given-names></string-name>, <string-name><surname>Anders</surname><given-names>RA</given-names></string-name>, <string-name><surname>Giardiello</surname><given-names>FM</given-names></string-name>, <string-name><surname>Wick</surname><given-names>EC</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name><surname>Wu</surname><given-names>S</given-names></string-name>, <string-name><surname>Pardoll</surname><given-names>DM</given-names></string-name>, <string-name><surname>Housseau</surname><given-names>F</given-names></string-name>, <string-name><surname>Sears</surname><given-names>CL</given-names></string-name></person-group>. <year>2018</year>. <article-title>Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria</article-title>. <source>Science</source><volume>359</volume>:<fpage>592</fpage>–<lpage>597</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aah3648</pub-id>doi:<ext-link xlink:href="29420293" ext-link-type="pmid"/><pub-id pub-id-type="pmid">29420293</pub-id></mixed-citation>
    </ref>
    <ref id="B92">
      <label>92</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>W</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name></person-group>. <year>2019</year>. <article-title>Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data</article-title>. <source>Genome Biol</source><volume>20</volume>:<elocation-id>18</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s13059-019-1629-z</pub-id>doi:<ext-link xlink:href="30670076" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30670076</pub-id></mixed-citation>
    </ref>
    <ref id="B93">
      <label>93</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name></person-group>. <year>2020</year>. <article-title>miRDB: An online database for prediction of functional microRNA targets</article-title>. <source>Nucleic Acids Res</source><volume>48</volume>:<fpage>D127</fpage>–<lpage>D131</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkz757</pub-id>doi:<ext-link xlink:href="31504780" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31504780</pub-id></mixed-citation>
    </ref>
    <ref id="B94">
      <label>94</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bertucci</surname><given-names>A</given-names></string-name>, <string-name><surname>Prasetyanto</surname><given-names>EA</given-names></string-name>, <string-name><surname>Septiadi</surname><given-names>D</given-names></string-name>, <string-name><surname>Manicardi</surname><given-names>A</given-names></string-name>, <string-name><surname>Brognara</surname><given-names>E</given-names></string-name>, <string-name><surname>Gambari</surname><given-names>R</given-names></string-name>, <string-name><surname>Corradini</surname><given-names>R</given-names></string-name>, <string-name><surname>De Cola</surname><given-names>L</given-names></string-name></person-group>. <year>2015</year>. <article-title>Combined delivery of Temozolomide and anti-Mir221 PNA using Mesoporous silica nanoparticles induces apoptosis in resistant glioma cells</article-title>. <source>Small</source><volume>11</volume>:<fpage>5687</fpage>–<lpage>5695</lpage>. doi:<pub-id pub-id-type="doi">10.1002/smll.201500540</pub-id>doi:<ext-link xlink:href="26395266" ext-link-type="pmid"/><pub-id pub-id-type="pmid">26395266</pub-id></mixed-citation>
    </ref>
    <ref id="B95">
      <label>95</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Neill</surname><given-names>CP</given-names></string-name>, <string-name><surname>Dwyer</surname><given-names>RM</given-names></string-name></person-group>. <year>2020</year>. <article-title>Nanoparticle-based delivery of tumor suppressor microRNA for cancer therapy</article-title>. <source>Cells</source><volume>9</volume>:<elocation-id>521</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/cells9020521</pub-id>doi:<ext-link xlink:href="32102476" ext-link-type="pmid"/><pub-id pub-id-type="pmid">32102476</pub-id></mixed-citation>
    </ref>
    <ref id="B96">
      <label>96</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Yoo</surname><given-names>JY</given-names></string-name>, <string-name><surname>Shu</surname><given-names>D</given-names></string-name>, <string-name><surname>Li</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Yu</surname><given-names>JG</given-names></string-name>, <string-name><surname>Jaime-Ramirez</surname><given-names>AC</given-names></string-name>, <string-name><surname>Acunzo</surname><given-names>M</given-names></string-name>, <string-name><surname>Romano</surname><given-names>G</given-names></string-name>, <string-name><surname>Cui</surname><given-names>R</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H-L</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Z</given-names></string-name>, <string-name><surname>Old</surname><given-names>M</given-names></string-name>, <string-name><surname>Kaur</surname><given-names>B</given-names></string-name>, <string-name><surname>Guo</surname><given-names>P</given-names></string-name>, <string-name><surname>Croce</surname><given-names>CM</given-names></string-name></person-group>. <year>2017</year>. <article-title>RNA nanoparticle-based targeted therapy for glioblastoma through inhibition of Oncogenic miR-21</article-title>. <source>Mol Ther</source><volume>25</volume>:<fpage>1544</fpage>–<lpage>1555</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymthe.2016.11.016</pub-id>doi:<ext-link xlink:href="28109960" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28109960</pub-id></mixed-citation>
    </ref>
    <ref id="B97">
      <label>97</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goss</surname><given-names>CH</given-names></string-name>, <string-name><surname>Muhlebach</surname><given-names>MS</given-names></string-name></person-group>. <year>2011</year>. <article-title>Review: Staphylococcus aureus and MRSA in cystic fibrosis</article-title>. <source>J Cyst Fibros</source><volume>10</volume>:<fpage>298</fpage>–<lpage>306</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jcf.2011.06.002</pub-id>doi:<ext-link xlink:href="21719362" ext-link-type="pmid"/><pub-id pub-id-type="pmid">21719362</pub-id></mixed-citation>
    </ref>
    <ref id="B98">
      <label>98</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Skov</surname><given-names>RL</given-names></string-name>, <string-name><surname>Jensen</surname><given-names>KS</given-names></string-name></person-group>. <year>2009</year>. <article-title>Community-associated Meticillin-resistant Staphylococcus aureus as a cause of hospital-acquired infections</article-title>. <source>J Hosp Infect</source><volume>73</volume>:<fpage>364</fpage>–<lpage>370</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jhin.2009.07.004</pub-id>doi:<ext-link xlink:href="19786313" ext-link-type="pmid"/><pub-id pub-id-type="pmid">19786313</pub-id></mixed-citation>
    </ref>
    <ref id="B99">
      <label>99</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>Z</given-names></string-name></person-group>. <year>2011</year>. <part-title>The guideline of the design and validation of Mirna mimics</part-title>, <comment>p</comment><fpage>211</fpage>–<lpage>223</lpage>. In <person-group person-group-type="editor"><string-name><surname>Wu</surname><given-names>W</given-names></string-name></person-group> (ed), <source>Microrna and cancer: Methods and protocols. Humana press</source>. <publisher-name>Humana Press</publisher-name>, <publisher-loc>Totowa</publisher-loc>.</mixed-citation>
    </ref>
    <ref id="B100">
      <label>100</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Younger</surname><given-names>ST</given-names></string-name>, <string-name><surname>Corey</surname><given-names>DR</given-names></string-name></person-group>. <year>2011</year>. <article-title>Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters</article-title>. <source>Nucleic Acids Res</source><volume>39</volume>:<fpage>5682</fpage>–<lpage>5691</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkr155</pub-id>doi:<ext-link xlink:href="21427083" ext-link-type="pmid"/><pub-id pub-id-type="pmid">21427083</pub-id></mixed-citation>
    </ref>
    <ref id="B101">
      <label>101</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hart</surname><given-names>M</given-names></string-name>, <string-name><surname>Nickl</surname><given-names>L</given-names></string-name>, <string-name><surname>Walch-Rueckheim</surname><given-names>B</given-names></string-name>, <string-name><surname>Krammes</surname><given-names>L</given-names></string-name>, <string-name><surname>Rheinheimer</surname><given-names>S</given-names></string-name>, <string-name><surname>Diener</surname><given-names>C</given-names></string-name>, <string-name><surname>Taenzer</surname><given-names>T</given-names></string-name>, <string-name><surname>Kehl</surname><given-names>T</given-names></string-name>, <string-name><surname>Sester</surname><given-names>M</given-names></string-name>, <string-name><surname>Lenhof</surname><given-names>HP</given-names></string-name>, <string-name><surname>Keller</surname><given-names>A</given-names></string-name>, <string-name><surname>Meese</surname><given-names>E</given-names></string-name></person-group>. <year>2020</year>. <article-title>Wrinkle in the plan: Mir-34A-5P impacts Chemokine signaling by Modulating Cxcl10/Cxcl11/Cxcr3-axis in Cd4+, Cd8+ T cells, and M1 Macrophages</article-title>. <source>J Immunother cancer</source><volume>8</volume>:<elocation-id>e001617</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/jitc-2020-001617</pub-id>doi:<ext-link xlink:href="33229509" ext-link-type="pmid"/><pub-id pub-id-type="pmid">33229509</pub-id></mixed-citation>
    </ref>
    <ref id="B102">
      <label>102</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Segal</surname><given-names>M</given-names></string-name>, <string-name><surname>Slack</surname><given-names>FJ</given-names></string-name></person-group>. <year>2020</year>. <article-title>Challenges identifying efficacious miRNA Therapeutics for cancer</article-title>. <source>Expert Opin Drug Discov</source><volume>15</volume>:<fpage>987</fpage>–<lpage>992</lpage>. doi:<pub-id pub-id-type="doi">10.1080/17460441.2020.1765770</pub-id>doi:<ext-link xlink:href="32421364" ext-link-type="pmid"/><pub-id pub-id-type="pmid">32421364</pub-id></mixed-citation>
    </ref>
    <ref id="B103">
      <label>103</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Richards</surname><given-names>AM</given-names></string-name></person-group>. <year>2021</year>. <article-title>Effective tools for RNA-derived Therapeutics: SiRNA interference or miRNA Mimicry</article-title>. <source>Theranostics</source><volume>11</volume>:<fpage>8771</fpage>–<lpage>8796</lpage>. doi:<pub-id pub-id-type="doi">10.7150/thno.62642</pub-id>doi:<ext-link xlink:href="34522211" ext-link-type="pmid"/><pub-id pub-id-type="pmid">34522211</pub-id></mixed-citation>
    </ref>
    <ref id="B104">
      <label>104</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huckaby</surname><given-names>JT</given-names></string-name>, <string-name><surname>Lai</surname><given-names>SK</given-names></string-name></person-group>. <year>2018</year>. <article-title>Pegylation for enhancing nanoparticle diffusion in mucus</article-title>. <source>Adv Drug Deliv Rev</source><volume>124</volume>:<fpage>125</fpage>–<lpage>139</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.addr.2017.08.010</pub-id>doi:<ext-link xlink:href="28882703" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28882703</pub-id></mixed-citation>
    </ref>
    <ref id="B105">
      <label>105</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schuster</surname><given-names>BS</given-names></string-name>, <string-name><surname>Suk</surname><given-names>JS</given-names></string-name>, <string-name><surname>Woodworth</surname><given-names>GF</given-names></string-name>, <string-name><surname>Hanes</surname><given-names>J</given-names></string-name></person-group>. <year>2013</year>. <article-title>Nanoparticle diffusion in respiratory mucus from humans without lung disease</article-title>. <source>Biomaterials</source><volume>34</volume>:<fpage>3439</fpage>–<lpage>3446</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.01.064</pub-id>doi:<ext-link xlink:href="23384790" ext-link-type="pmid"/><pub-id pub-id-type="pmid">23384790</pub-id></mixed-citation>
    </ref>
    <ref id="B106">
      <label>106</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Crater</surname><given-names>JS</given-names></string-name>, <string-name><surname>Carrier</surname><given-names>RL</given-names></string-name></person-group>. <year>2010</year>. <article-title>Barrier properties of gastrointestinal mucus to nanoparticle transport</article-title>. <source>Macromol Biosci</source><volume>10</volume>:<fpage>1473</fpage>–<lpage>1483</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mabi.201000137</pub-id>doi:<ext-link xlink:href="20857389" ext-link-type="pmid"/><pub-id pub-id-type="pmid">20857389</pub-id></mixed-citation>
    </ref>
    <ref id="B107">
      <label>107</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yeh</surname><given-names>Y-C</given-names></string-name>, <string-name><surname>Huang</surname><given-names>T-H</given-names></string-name>, <string-name><surname>Yang</surname><given-names>S-C</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C-C</given-names></string-name>, <string-name><surname>Fang</surname><given-names>J-Y</given-names></string-name></person-group>. <year>2020</year>. <article-title>Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances</article-title>. <source>Front Chem</source><volume>8</volume>:<fpage>286</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fchem.2020.00286</pub-id>doi:<ext-link xlink:href="32391321" ext-link-type="pmid"/><pub-id pub-id-type="pmid">32391321</pub-id></mixed-citation>
    </ref>
    <ref id="B108">
      <label>108</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koeppen</surname><given-names>K</given-names></string-name>, <string-name><surname>Stanton</surname><given-names>BA</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name></person-group>. <year>2017</year>. <article-title>Scangeo: parallel mining of high-throughput gene expression data</article-title>. <source>Bioinformatics</source><volume>33</volume>:<fpage>3500</fpage>–<lpage>3501</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btx452</pub-id>doi:<ext-link xlink:href="29036513" ext-link-type="pmid"/><pub-id pub-id-type="pmid">29036513</pub-id></mixed-citation>
    </ref>
    <ref id="B109">
      <label>109</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name><surname>Koeppen</surname><given-names>K</given-names></string-name>, <string-name><surname>Holden</surname><given-names>VI</given-names></string-name>, <string-name><surname>Neff</surname><given-names>SL</given-names></string-name>, <string-name><surname>Cengher</surname><given-names>L</given-names></string-name>, <string-name><surname>Demers</surname><given-names>EG</given-names></string-name>, <string-name><surname>Mould</surname><given-names>DL</given-names></string-name>, <string-name><surname>Stanton</surname><given-names>BA</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name></person-group>. <year>2021</year>. <article-title>GAUGE-Annotated microbial Transcriptomic data facilitate parallel mining and high-throughput Reanalysis to form data-driven hypotheses</article-title>. <source>mSystems</source><volume>6</volume>:<elocation-id>e01305-20</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/mSystems.01305-20</pub-id>doi:<ext-link xlink:href="33758032" ext-link-type="pmid"/><pub-id pub-id-type="pmid">33758032</pub-id></mixed-citation>
    </ref>
    <ref id="B110">
      <label>110</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neff</surname><given-names>SL</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name>, <string-name><surname>Puerner</surname><given-names>C</given-names></string-name>, <string-name><surname>Cengher</surname><given-names>L</given-names></string-name>, <string-name><surname>Doing</surname><given-names>G</given-names></string-name>, <string-name><surname>Lee</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Koeppen</surname><given-names>K</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>AL</given-names></string-name>, <string-name><surname>Hogan</surname><given-names>DA</given-names></string-name>, <string-name><surname>Cramer</surname><given-names>RA</given-names></string-name>, <string-name><surname>Stanton</surname><given-names>BA</given-names></string-name></person-group>. <year>2022</year>. <article-title>CF-Seq, an accessible web application for rapid re-analysis of cystic fibrosis pathogen RNA sequencing studies</article-title>. <source>Sci Data</source><volume>9</volume>:<fpage>343</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41597-022-01431-1</pub-id>doi:<ext-link xlink:href="35710652" ext-link-type="pmid"/><pub-id pub-id-type="pmid">35710652</pub-id></mixed-citation>
    </ref>
    <ref id="B111">
      <label>111</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koeppen</surname><given-names>K</given-names></string-name>, <string-name><surname>Hampton</surname><given-names>TH</given-names></string-name>, <string-name><surname>Neff</surname><given-names>SL</given-names></string-name>, <string-name><surname>Stanton</surname><given-names>BA</given-names></string-name></person-group>. <year>2022</year>. <article-title>ESKAPE act plus: Pathway activation analysis for bacterial pathogens</article-title>. <source>mSystems</source><volume>7</volume>:<elocation-id>e0046822</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/msystems.00468-22</pub-id>doi:<ext-link xlink:href="36259735" ext-link-type="pmid"/><pub-id pub-id-type="pmid">36259735</pub-id></mixed-citation>
    </ref>
    <ref id="B112">
      <label>112</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Furuno</surname><given-names>M</given-names></string-name>, <string-name><surname>Kasukawa</surname><given-names>T</given-names></string-name>, <string-name><surname>Saito</surname><given-names>R</given-names></string-name>, <string-name><surname>Adachi</surname><given-names>J</given-names></string-name>, <string-name><surname>Suzuki</surname><given-names>H</given-names></string-name>, <string-name><surname>Baldarelli</surname><given-names>R</given-names></string-name>, <string-name><surname>Hayashizaki</surname><given-names>Y</given-names></string-name>, <string-name><surname>Okazaki</surname><given-names>Y</given-names></string-name></person-group>. <year>2003</year>. <article-title>CDS annotation in full-length cDNA sequence</article-title>. <source>Genome Res</source><volume>13</volume>:<fpage>1478</fpage>–<lpage>1487</lpage>. doi:<pub-id pub-id-type="doi">10.1101/gr.1060303</pub-id>doi:<ext-link xlink:href="12819146" ext-link-type="pmid"/><pub-id pub-id-type="pmid">12819146</pub-id></mixed-citation>
    </ref>
    <ref id="B113">
      <label>113</label>
      <mixed-citation publication-type="journal">. <article-title>What are UniProtKB’s criteria for defining a CDS as a protein?</article-title>
<source>| UniProt help | UniProt</source>. <ext-link xlink:href="https://www.uniprot.org/help/cds_protein_definition" ext-link-type="uri">https://www.uniprot.org/help/cds_protein_definition</ext-link>. <date-in-citation>Retrieved 9 December 2022</date-in-citation>.</mixed-citation>
    </ref>
    <ref id="B114">
      <label>114</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chipman</surname><given-names>LB</given-names></string-name>, <string-name><surname>Pasquinelli</surname><given-names>AE</given-names></string-name></person-group>. <year>2019</year>. <article-title>miRNA targeting: Growing beyond the seed</article-title>. <source>Trends Genet</source><volume>35</volume>:<fpage>215</fpage>–<lpage>222</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tig.2018.12.005</pub-id>doi:<ext-link xlink:href="30638669" ext-link-type="pmid"/><pub-id pub-id-type="pmid">30638669</pub-id></mixed-citation>
    </ref>
    <ref id="B115">
      <label>115</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schnall-Levin</surname><given-names>M</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Perrimon</surname><given-names>N</given-names></string-name>, <string-name><surname>Berger</surname><given-names>B</given-names></string-name></person-group>. <year>2010</year>. <article-title>Conserved microRNA targeting in Drosophila is as widespread in coding regions as in 3'Utrs</article-title>. <source>Proc Natl Acad Sci USA</source><volume>107</volume>:<fpage>15751</fpage>–<lpage>15756</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1006172107</pub-id>doi:<ext-link xlink:href="20729470" ext-link-type="pmid"/><pub-id pub-id-type="pmid">20729470</pub-id></mixed-citation>
    </ref>
    <ref id="B116">
      <label>116</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fromm</surname><given-names>B</given-names></string-name>, <string-name><surname>Domanska</surname><given-names>D</given-names></string-name>, <string-name><surname>Høye</surname><given-names>E</given-names></string-name>, <string-name><surname>Ovchinnikov</surname><given-names>V</given-names></string-name>, <string-name><surname>Kang</surname><given-names>W</given-names></string-name>, <string-name><surname>Aparicio-Puerta</surname><given-names>E</given-names></string-name>, <string-name><surname>Johansen</surname><given-names>M</given-names></string-name>, <string-name><surname>Flatmark</surname><given-names>K</given-names></string-name>, <string-name><surname>Mathelier</surname><given-names>A</given-names></string-name>, <string-name><surname>Hovig</surname><given-names>E</given-names></string-name>, <string-name><surname>Hackenberg</surname><given-names>M</given-names></string-name>, <string-name><surname>Friedländer</surname><given-names>MR</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>KJ</given-names></string-name></person-group>. <year>2020</year>. <article-title>Mirgenedb 2.0: The Metazoan microRNA complement</article-title>. <source>Nucleic Acids Res</source><volume>48</volume>:<elocation-id>D1172</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkz1016</pub-id>doi:<ext-link xlink:href="31642479" ext-link-type="pmid"/><pub-id pub-id-type="pmid">31642479</pub-id></mixed-citation>
    </ref>
    <ref id="B117">
      <label>117</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mann</surname><given-names>M</given-names></string-name>, <string-name><surname>Wright</surname><given-names>PR</given-names></string-name>, <string-name><surname>Backofen</surname><given-names>R</given-names></string-name></person-group>. <year>2017</year>. <article-title>Intarna 2.0: Enhanced and Customizable prediction of RNA-RNA interactions</article-title>. <source>Nucleic Acids Res</source><volume>45</volume>:<fpage>W435</fpage>–<lpage>W439</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkx279</pub-id>doi:<ext-link xlink:href="28472523" ext-link-type="pmid"/><pub-id pub-id-type="pmid">28472523</pub-id></mixed-citation>
    </ref>
    <ref id="B118">
      <label>118</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krüger</surname><given-names>J</given-names></string-name>, <string-name><surname>Rehmsmeier</surname><given-names>M</given-names></string-name></person-group>. <year>2006</year>. <article-title>Rnahybrid: Microrna target prediction easy, fast and flexible</article-title>. <source>Nucleic Acids Res</source><volume>34</volume>:<fpage>W451</fpage>–<lpage>4</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkl243</pub-id>doi:<ext-link xlink:href="16845047" ext-link-type="pmid"/><pub-id pub-id-type="pmid">16845047</pub-id></mixed-citation>
    </ref>
    <ref id="B119">
      <label>119</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tafer</surname><given-names>H</given-names></string-name>, <string-name><surname>Hofacker</surname><given-names>IL</given-names></string-name></person-group>. <year>2008</year>. <article-title>Rnaplex: A fast tool for RNA-RNA interaction search</article-title>. <source>Bioinformatics</source><volume>24</volume>:<fpage>2657</fpage>–<lpage>2663</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btn193</pub-id>doi:<ext-link xlink:href="18434344" ext-link-type="pmid"/><pub-id pub-id-type="pmid">18434344</pub-id></mixed-citation>
    </ref>
    <ref id="B120">
      <label>120</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Wickham</surname><given-names>H</given-names></string-name></person-group><year>2022</year>. <part-title>Stringr: Simple</part-title>. <source>Consistent Wrappers for Common String Operations</source></mixed-citation>
    </ref>
    <ref id="B121">
      <label>121</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Uni Prot Consortium</collab></person-group>. <year>2023</year>. <article-title>Uniprot: The universal protein Knowledgebase in 2023</article-title>. <source>Nucleic Acids Res</source><volume>51</volume>:<fpage>D523</fpage>–<lpage>D531</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkac1052</pub-id>doi:<ext-link xlink:href="36408920" ext-link-type="pmid"/><pub-id pub-id-type="pmid">36408920</pub-id></mixed-citation>
    </ref>
    <ref id="B122">
      <label>122</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Geistlinger</surname><given-names>L</given-names></string-name>, <string-name><surname>Csaba</surname><given-names>G</given-names></string-name>, <string-name><surname>Zimmer</surname><given-names>R</given-names></string-name></person-group>. <year>2016</year>. <article-title>Bioconductor's Enrichmentbrowser: Seamless navigation through combined results of Set- &amp; network-based enrichment analysis</article-title>. <source>BMC Bioinformatics</source><volume>17</volume>:<elocation-id>45</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s12859-016-0884-1</pub-id>doi:<ext-link xlink:href="26791995" ext-link-type="pmid"/><pub-id pub-id-type="pmid">26791995</pub-id></mixed-citation>
    </ref>
    <ref id="B123">
      <label>123</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>R Core Team</collab></person-group>. <year>2021</year>. <source>R: a language and environment for statistical computing</source>:<elocation-id>Vienna, Austria</elocation-id>.</mixed-citation>
    </ref>
    <ref id="B124">
      <label>124</label>
      <mixed-citation publication-type="book">. <person-group person-group-type="author"><collab>RStudio Team</collab></person-group>. <year>2020</year>. <source>RStudio: Integrated Development for R Studio</source>. <publisher-name>PBC</publisher-name>, <publisher-loc>Boston, MA</publisher-loc>.</mixed-citation>
    </ref>
    <ref id="B125">
      <label>125</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Chang</surname><given-names>W</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>J</given-names></string-name>, <string-name><surname>Allaire</surname><given-names>J</given-names></string-name>, <string-name><surname>Sievert</surname><given-names>C</given-names></string-name>, <string-name><surname>Schloerke</surname><given-names>B</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Y</given-names></string-name>, <string-name><surname>Allen</surname><given-names>J</given-names></string-name>, <string-name><surname>McPherson</surname><given-names>J</given-names></string-name>, <string-name><surname>Dipert</surname><given-names>A</given-names></string-name>, <string-name><surname>Borges</surname><given-names>B</given-names></string-name></person-group>. <year>2022</year>. <source>Shiny: Web application framework for R</source></mixed-citation>
    </ref>
    <ref id="B126">
      <label>126</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Chang</surname><given-names>W</given-names></string-name>, <string-name><surname>Borges Ribeiro</surname><given-names>B</given-names></string-name></person-group>. <year>2021</year>. <source>Shinydashboard: Create Dashboards with shiny</source></mixed-citation>
    </ref>
    <ref id="B127">
      <label>127</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Attali</surname><given-names>D</given-names></string-name></person-group>. <year>2021</year>. <source>Shinyjs: easily improve the user experience of your shiny apps in seconds</source></mixed-citation>
    </ref>
    <ref id="B128">
      <label>128</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Bailey</surname><given-names>E</given-names></string-name></person-group>. <year>2022</year>. <source>shinyBS: twitter bootstrap components for shiny</source></mixed-citation>
    </ref>
    <ref id="B129">
      <label>129</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><given-names>Y</given-names><surname>Xie</surname></string-name>, <string-name><given-names>J</given-names><surname>Cheng</surname></string-name>, <string-name><given-names>X</given-names><surname>Tan</surname></string-name></person-group>. <year>2022</year>. <source>DT: a wrapper of the javascript library datatables</source></mixed-citation>
    </ref>
    <ref id="B130">
      <label>130</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Sali</surname><given-names>A</given-names></string-name></person-group>. <year>2020</year>. <article-title>“Shinycssloaders: Add loading Animations to a “shiny” output while it’s Recalculating”</article-title></mixed-citation>
    </ref>
    <ref id="B131">
      <label>131</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Sievert</surname><given-names>C</given-names></string-name></person-group>. <year>2020</year>. <source>Interactive web-based data visualization with R, Plotly, and shiny</source></mixed-citation>
    </ref>
    <ref id="B132">
      <label>132</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Wilkinson</surname><given-names>S</given-names></string-name></person-group><year>2018</year>. <article-title>Kmer: an R package for fast alignment-free clustering of biological sequences</article-title></mixed-citation>
    </ref>
    <ref id="B133">
      <label>133</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>Ripley</surname><given-names>B</given-names></string-name>, <string-name><surname>Venables</surname><given-names>B</given-names></string-name>, <string-name><surname>Bates</surname><given-names>DM</given-names></string-name></person-group>. <year>1998</year>. <article-title>(Partial port, ca 1998) AG (partial port, firth D. 2023. mass: support functions and datasets for venables and ripley’s MASS</article-title>:<fpage>3</fpage>–<lpage>60</lpage>.</mixed-citation>
    </ref>
  </ref-list>
</back>
